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DNA damaging agents are commonly used in the clinic for the treatment of cancer. In 
particular, the DNA alkylating agent, temozolomide, is the primary chemotherapeutic option for 
the treatment of glioblastoma, a particularly aggressive form of brain cancer. Temozolomide 
produces three main DNA lesions: O6-methylguanine, N7-methylguanine and N3-
methyladenine.  Most of the clinical toxicity is a result of the O6-methylguanine lesion, which 
activates the mismatch repair pathway and results in apoptosis. The N7-methylguanine and N3-
methyladenine lesions are effectively repaired by the base excision repair pathway (BER) and 
hence the toxicity of these lesions is minimal. Resistance to O6-methylguanine mediated cell 
death is prevalent, particularly in recurrent glioblastomas, at which point treatment options are 
limited. We have previously shown that targeting of the BER pathway through genetic means or 
small molecules (resulting in BER failure) can produce tumor cell death independent of the O6-
methylguanine lesion. This dissertation addresses the critical questions of the mechanisms by 
which BER failure results in tumor cell death and investigates new combinational therapy 
options to enhance tumor cell death by BER failure. Cell death after BER failure results from 
accumulation of repair intermediates and hyperactivation of PARP1. I have shown PARP1 
hyperactivation results in cellular loss of NAD+ and ATP. In particular, nuclear PARP activation 
results in a severe block to glycolysis and a defect in mitochondrial respiratory capacity. These 
metabolic defects result in subcellular ATP loss from the mitochondria as well as from the 
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nuclear and cytosolic compartments. This suggests that targeting both BER and cellular energetic 
pathways would enhance N7-methylguanine and N3-methyladenine mediated toxicity. To this 
end I have shown that dual targeting of BER (inhibition by methoxyamine) and NAD+ 
biosynthesis (inhibition by FK866) in combination with TMZ results in enhanced tumor cell 
death and is capable of overcoming resistance to the O6-methylguanine lesion. This opens the 
possibility for further pre-clinical testing using xenograft models, as well as, potential synthetic 
lethal interactions for the treatment of glioblastomas deficient in an alternate arm of NAD+ 
biosynthesis. 
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1.0  INTRODUCTION 
1.1 GLIOBLASTOMA  
1.1.1 Glioblastoma physical and genetic characteristics 
Malignant glioma is a particularly devastating disease with limited treatment options. While rare, 
occurring in 5/100,000 people, malignant glioma is  the most commonly occuring primary brain 
tumor (1, 2). Research into the pathophysiology of the disease is particularly intense due to the 
poor prognosis of these tumors. Malignant gliomas occur most frequently in white males and are 
typically diagnosed in middle age to old age (1). The majority of malignant gliomas are not 
inherited. Only 5% of cases have a family history, and these patients are generally  from families 
with genetic cancer predisposition syndromes such as Li-Fraumeni  syndrome (1). Malignant 
gliomas can be categorized into glioblastomas (70%), anaplastic astrocytomas (15%) and 
anaplastic oligodenrogliomas/anaplastic oligoastrocytomas (10%) (1). Of these, glioblastomas 
are considered WHO grade IV and have by far the worst prognosis with a median survival time 
of 14.6 months under optimal treatment and a 2-year survival rate of 26.5%. Anaplastic glioma 
patients have a better outcome with a median survival of 2 to 5 years (1). Glioblastomas can 
either be primary glioblastomas or secondary tumors that progress from lower grade anaplastic 
astrocytomas to glioblastomas over a period of years. These two sub-types present different 
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genetic profiles, and while primary glioblastomas occur in older patients (median age of 
diagnosis is 64 years), secondary glioblastomas generally present at a younger age (median age 
of 45) after progression from a lower grade tumor to a glioblastoma over a period of 4-5 years (1, 
4).  
The most common mutation in primary glioblastomas (occurring in 60-80% of tumors)  
is loss of heterozygozity in chromosome 10 resulting in inactivation of phosphatase and tensin 
homolog (PTEN) (4). Another genetic marker of primary glioblastoma is amplification of 
epidermal growth factor receptor (EGFR) (occurring in 40-50% of tumors), and of this subset, 
50% express a constitutively active variant of EGFR (1, 4).  Targeting of receptor tyrosine kinase 
signaling cascades in tumors overexpressing EGFR has been aggressively pursued as a potential 
treatment option for primary glioblastomas as has targeting of the AKT and mTOR pathways, 
however inhibitors of tyrosine kinase signaling have had little success to date (4).  
Secondary glioblastomas commonly have p53 mutations and abnormal platelet derived 
growth factor receptor (PDGFR) expression (1, 4). Very recently, large-scale analysis of 
malignant gliomas has identified mutations in isocytrate dehyrogenase 1 and 2 (IDH1/2) that  are 
largely seen in secondary glioblastomas versus primary glioblastomas (5, 6). IDH1 and IDH2 
under normal conditions generate α-ketogluterate. The IDH1 and IDH2 mutations result in an 
altered active site and generation of an alternative tumor specific product, 2-hydroxy-gluterate 
(2-HG), generated from α-ketogluterate (7). 2-HG seems to have an impact on tumor cell 
epigenetics, and the discovery of a tumor specific metabolite has sparked an intense interest in 
studying and manipulating 2-HG and IDH mutations for the treatment of glioblastoma (7).  
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1.1.2 Treatment of GBM 
Current standard treatment for GBM includes maximal debulking surgery whenever possible.  
GBMs are diffuse tumors and infiltrate into normal tissue, making surgery difficult or in some 
cases impossible. Surgical reduction is followed by fractionated radiation up to 60 Gy and 
concurrent and adjuvant chemotherapy with the DNA alkylating drug, temozolomide (Temodar) 
(1, 8). Radiation therapy has been used in the treatment of glioblastoma for the last 30 years and 
increases median survival from 3-4 months without radiation to 7-12 months with radiation 
treatment (1). Prior to adding temozolomide to the treatment regimen the most common 
chemotherapy for glioblastoma were nitrosoureas (e.g., carmustine). However, they provided 
only a small survival benefit of a 5% increase in two-year survival based on meta-analysis of 12 
randomized trials (8). The monofunctional alkylating agent, temozolomide, showed promise as a 
monotherapy in malignant gliomas and malignant metastatic melanoma (2). A multicenter 
randomized phase III trial involving 573 patients published by Strupp et. al. in 2005 showed 
radiotherapy with concomitant and adjuvant temozolomide provided significant improvement in 
patient outcome for newly diagnosed glioblastomas. Temozolomide, in addition to standard 
treatment of surgery and radiation, enhanced median survival from 12.1 months to 14.6 months 
and two-year survival from 10.4% to 26.5% adding an additional 1.9 months of progression-free 
survival (8). The survival benefit extended to the 5-year follow up and provided critical 
information about which patients might most benefit from temozolomide treatment (9). Current 
standard chemotherapy for glioblastoma is now either temozolomide or carmustine wafers 
implanted into the resected tumor bed (1). Carmustine wafers are polymer wafers allowing 
delivery of chemotherapy directly to the site of the tumor without systemic treatment (1).  
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The most difficult aspect in the treatment of glioblastoma is the eventual recurrence of 
the tumor, even in cases of optimal treatment. 80-90% of tumors recur within 2 cm of the 
original tumor, and almost all recurrent glioblastomas no longer respond to chemotherapy (1, 4). 
The benefits of surgery and radiation for recurrent tumors remains controversial (1). Recurrent 
tumors are largely temozolomide resistant, with only a 5.4% response rate (10). There are 
currently very few alternate chemotherapy treatment options for patients with recurrent disease. 
1.2 DNA ALKYLATING AGENTS AS CHEMOTHERAPY  
1.2.1 Temozolomide 
Temozolomide is a 194 dalton monofunctional alkylating agent of the imidazotetrazine class 
generated in a laboratory at Aston University in 1984 (11). Temozolomide, unlike the other 
clinically useful imidazotetrazine, 5-(3,3-dimethyltriazeno)imidazol-4-carboxamide (DTIC), 
does not require metabolism by the liver or any enzyme for activation, but rather breaks down 
spontaneously at biological pH to form 5-(3-metyltriazene-1-yl)-imidazole-4-carboxamide 
(MTIC). MTIC breaks down spontaneously into 5-aminoimidazole-4-carboxamide (AIC) and the 
reactive methyldiazonium cation responsible for DNA methylation (2, 11). Temozolomide has 
100% bioavailability after oral dosing; the low pH of the stomach prevents the spontaneous 
breakdown to MTIC, and temozolomide is easily absorbed by the intestinal tract (11). This 
results in peak plasma concentration within 30-90 minutes of administration (11). The lipophilic 
characteristic of the drug allows it to easily cross the blood-brain barrier where it accumulates to 
30-40% of the peak plasma concentration (11). Temozolomide (TMZ) and other monofunctional 
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alkylating agents such as the commonly used laboratory agents methyl methanesulfonate (MMS) 
and methyl-N’-nitro-N-nitrosoguanidine (MNNG), create a spectrum of DNA base lesions: 
primarily O6-methylguanine, N7-methylguanine and N3-methyladenine (2, 12). The percentage 
of each lesion formed is in Table 1 below for comparison (2, 12). 
 
Table 1. Breakdown of methyl adducts formed by monofunctional alkylating agents 
 O6-methylguanine N7-methylguanine N3-methyladenine 
TMZ 5% 70% 9.2% 
MMS 10.4% 81% 0.3% 
MNNG 12% 67% 7% 
 
 The N7-methylguanine and N3-methyladenine adducts are substrates for the base 
excision repair pathway (BER) via methylpurine DNA glycosylase recognition of the lesion and 
subsequent removal and repair (11, 13). This rapid repair of adducts by BER limits any potential 
toxicity of the adducts, specifically the N3-methyladenine, which is believed to act as a toxic 
block to replication (14). The O6-methylguanine lesion produces most of the TMZ, MMS and 
MNNG associated toxicity in the presence of an intact BER pathway (11). O6-methylguanine, if 
not removed by the suicide repair protein O6-methylguanine-DNA methyltransferase (MGMT), 
is either paired correctly with cytosine or can be mispaired with thymine, creating a mispair 
recognized by the mismatch repair (MMR) complex. However, MMR does not remove the 
damaged base but rather the mispaired thymine, resulting in multiple futile cycles of MMR (11). 
This can induce apoptosis through two separate proposed mechanisms: 1) repeated rounds of 
futile repair result in persistent strand breaks that become double strand breaks upon multiple 
rounds of replication. 2) hMutsα (heterodimer of MSH6 and MSH2)  recruits 
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hMutLα (heterodimer of MLH1 and PMS1), ATRIP and ATR resulting in DNA damage 
signaling, cell cycle arrest and apoptosis (15, 16). Temozolomide’s dose limiting toxicity is 
mediated by thrombocytopenia (2).  
1.2.2 Modes of O6-methylguanine resistance  
The other significant challenge in the treatment of glioblastoma is either endogenous or acquired 
resistance to O6-methylguanine induced cell death. While BER function results in tolerance of 
80% of the lesions induced by TMZ, MGMT expression can confer resistance to the O6-
methylguanine lesion through direct repair of the lesion (17). Forty-five percent of glioblastomas 
have a methylated MGMT promoter, resulting in repression of MGMT expression and sensitivity 
to TMZ, leaving 55% of glioblastomas at least partially resistant to O6-methyguanine mediated 
cell death (1). The data generated by the 5-year follow up of the multi-site phase III trial for 
radiotherapy with concomitant and adjuvant temozolomide revealed that patients with MGMT 
methylation did significantly better in terms of survival in both groups treated with radiotherapy 
alone or combination treatment (9). In patients receiving combined radiotherapy and TMZ, those 
with unmethylated MGMT survived a median of 12.6 months versus those with methylated 
MGMT who survived a median of 23.4 months. Of all the subgroups in the study (degree of 
resection, age, MGMT methylation status), MGMT gene methylation was the strongest predictor 
of outcome (9).  
In addition to MGMT promoter methylation and expression, the functionality of the 
MMR pathway represents another possible mechanism for TMZ resistance. Mutations in 
mismatch repair genes result in failure to recognize the O6-methylguanine lesion and to signal for 
apoptosis (18). Recent studies performing large scale sequencing of tumor genomes have 
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identified mutations in MMR genes in recurrent tumors specifically after temozolomide 
treatment. In particular, they identified mutations in MSH6 (19, 20). Since the MMR pathway is 
further down in the cell death pathway initiated by O6-methylguanine than MGMT-mediated 
repair of the lesion, MMR mutations can confer TMZ resistance independent of MGMT status 
(2). Even patients with favorable MGMT promoter methylation may still present as TMZ 
resistant due to MMR mutations. 
1.2.3 MGMT inhibition in combination with TMZ 
Given the strong negative correlation between MGMT expression and extended survival after 
TMZ treatment, there was a strong effort put into developing ways to prevent MGMT activity in 
combination with TMZ and other DNA alkylators such as carmustine. O6-benzylguanine (O6-
BG) and O6-(4-bromothenyl) guanine (PaTrin) are small molecules that compete for MGMT 
binding with the O6-methylguanine lesion (11). While O6-BG and PaTrin were effective in 
promoting TMZ and carmustine sensitivity in pre-clinical studies, their efficacy was limited by 
dose limiting myelosuppression, and they ultimately yielded no advantageous effect over TMZ 
treatment alone (21). Another strategy for overcoming TMZ resistance by MGMT expression is 
to deplete MGMT by combining alkylating agents or using an alternate dosing schedule of TMZ, 
in which TMZ dosing was either extended or compressed to deliver cumulatively higher amounts 
of TMZ than the standard dosing schedule of 200 mg/m2/d for 5 days. The compressed schedule, 
in which patients with metastatic melanoma received 200mg/m2 every 4 hours for 16 hours, 
resulted in no significant enhancement in TMZ antitumor activity but significant hematological 
side effects (17). A number of extended schedules are being tested for ways to minimize 
hematological side effects and maximize MGMT depletion. 
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1.3 BASE EXCISION REPAIR AND TEMOZOLOMIDE 
1.3.1 Base excision repair of alkylated bases 
Base excision repair is the pathway responsible for removing and repairing small single base 
lesions such as oxidized bases, methylated bases, uracil, 8-oxoG and spontaneous abasic sites 
(22). BER can proceed through short patch repair, removing a single base or through long patch 
repair, in which a larger section of DNA is removed (22). Repair of N7-methylguanine and N3-
methyladenine generated by TMZ proceeds primarily through short patch repair. BER can be 
broken down into the steps of: lesion recognition and removal, strand scission, gap tailoring, 
DNA synthesis and ligation (22). Damage specific glycosylases facilitate the detection and 
removal of DNA base lesions. Alkylated bases are recognized and removed by the 
monofunctional glycosylase, methylpurine DNA glycosylase (MPG), which utilizes a base 
flipping mechanism to interrogate DNA for alkylation lesions (23). The abasic site formed by 
MPG removal of the damaged base is recognized by APE1, which cleaves the DNA backbone to 
produce a 3’OH end and a 5’dexoyribose phosphate (5’dRP) repair intermediate (22). It is 
widely accepted that PARP1 plays a critical role in BER by recognizing the single strand DNA 
break and generating poly(ADP)ribose that recruits the rest of the BER complex, such as 
XRCC1/LigIII and DNA Polymerase ß (Polß) (24). The 5’dRP repair intermediate must be 
removed for further repair of the DNA. This is executed by the 5’dRP lyase activity of the X 
family polymerase, Polß (22, 25). Polß is primarily a dedicated BER polymerase, and while other 
DNA polymerases such as Pol lambda and Pol iota have 5’dRP lyase activity, they are unable to 
complement phenotypes generated by Polß deficiency, such as alkylation hypersensitivity (13, 
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26, 27). Polß polymerase activity fills in the now tailored DNA gap, and XRCC1/LigIII ligates 
the DNA nick to complete repair (22). A summary of the BER pathway is presented in Figure 1. 
 
Figure 1. Model of the BER Pathway 
1.3.2 BER inhibitors 
Given that over 80% of the lesions formed by TMZ and other monofunctional alkylating agents 
such as MMS or MNNG are repaired by BER, inhibiting the BER pathway is another potential 
strategy for enhancing TMZ toxicity and overcoming O6-methylguanine resistance due to either 
MGMT expression or MMR defects. Inhibitors to several proteins critical to BER have been 
developed. Inhibitors of APE1 such as lucanthone and CRT0044867, can sensitize cells to TMZ 
(28, 29). The rationale and development of inhibitors to Polß or PARP1 will be explored further 
below. Another BER inhibitor of note is Methoxyamine (TRC102), which does not inhibit a 
BER protein directly but binds to the aldehydic form of the abasic site formed by the 
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glycosylase-mediated removal of the damaged base and blocks further processing of the lesion 
by APE1. Methoxyamine has been investigated in combination with alkylating agents in pre-
clinical settings for the treatment of cancer with promising results (30-32). Currently Dr. Gerson 
at Case Western Reserve is conducting a phase I clinical trial to determine the pharmacokinetic 
profile and safety of methoxyamine in combination with temozolomide in a variety of cancers 
(lung, breast, pancreatic skin adnexal) (33). The preliminary report shows the combinations are 
well tolerated, and that a one hour intravenous infusion results in reduction in detectable AP sites 
(as predicted by MX binding) and an increase in DNA strand breaks (33). 
1.3.3 Role of Polß and BER failure 
The protein Polß is of particular interest in attempts to inhibit BER and enhance toxicity to TMZ. 
Polß is a 39 kDa protein with an 8 kDa 5’dRP lyase domain and a 31 kDa polymerase domain 
(34, 35). Polß plays two critical roles, the removal of the 5’dRP repair intermediate via its 5’dRP 
lyase activity and DNA synthesis via its polymerase activity (26). Polß knockout in mice results 
in death shortly after birth making in vivo studies of Polß function difficult, but Polß knockout 
mice can be used to generate Polß knockout MEFs (36). Polß knockout MEFS exhibited 
hypersensitivity to the alkylating agent MMS, confirming the critical role of Polß in repair of 
alkylated bases (36). Interestingly, it is not the lack of polymerase function of Polß that results in 
this hypersensitivity. Complementation of the KO MEFs with polymerase domain mutants 
R283A and D256A, affecting nucleotide incorporation and discrimination or polymerase 
activity, respectively, were able to completely recover the Polß KO phenotype similar to WT 
Polß, indicating no role of polymerase activity in the hypersensitivity to alkylating agents (26). 
Alternatively, mutations in the 8kDa 5’dRP lyase domain, K35A, K68A and K72A, all resulting 
  11 
in loss of 5’dRP lyase activity, were not able to complement the Polß KO phenotype, indicating 
that inability to perform removal of the 5’dRP lesion results in hypersensitivity to alkylating 
agents (26). To further strengthen this report, complementation with the 31kDa domain of Polß, 
lacking the 5’dRP lyase domain, did not rescue the Polß KO MEF sensitivity to MMS, whereas 
complementation with the 8 kDa 5’dRP lyase domain alone completely reverted Polß KO cells to 
the WT phenotype (26). 
The ability of repair intermediates to elicit sensitivity to alkylating agents is dependent on 
initiation of repair by MPG (37). The unrepaired alkylated bases appear to be non-toxic, whereas 
incomplete repair results in cell death. Sensitivity to MMS in Polß KO cells is independent of 
p53 signaling, but repair intermediates may be shuttled into the alternate repair pathway of 
homologous recombination (HR) (38). Polß KO cells treated with MMS showed an increase in 
sister chromatid exchange suggesting repair intermediates eventually form double strand breaks 
that can be repaired by HR (38). This ability of MPG expression and Polß 5’dRP lyase activity to 
generate toxic repair intermediates and enhance sensitivity to alkylating agents has profound 
implications on inhibiting BER to enhance toxicity of the TMZ lesions N7-methylguanine and 
N3-methyladinine and strongly suggests that Polß inhibitors could be effective in combination 
with TMZ. Polß inhibitors that prevent Polß lyase activity would be especially desirable for 
enhancing accumulation of toxic 5’dRP repair intermediates. There are a number of reported 
Polß inhibitors that exhibit inhibition of 5’dRP lyase activity; although in many cases the 
specificity and selectivity of these for Polß versus other polymerases or other cellular enzymes is 
largely untested (39). Wilson and Hecht have begun to address this through targeted NMR, 
biochemical and cell biology approaches and have determined a number of lead compounds that 
are 5’dRP lyase inhibitors. They tested each inhibitor in combination with MMS in WT and Polß 
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KO MEFs in order to rule out off target effects. From these efforts pamoic acid has been 
identified as the most promising lead compound, and studies with this class of inhibitors are 
ongoing (39, 40).  
1.4 ROLE OF PARP IN DNA DAMAGE  
1.4.1 PARP in DNA damage response 
The poly(ADP-ribose) polymerase (PARP) or ADP-ribosyltransferase (ART) family of proteins 
catalyze the formation of mono (ADP-ribose) or poly(ADP-ribose) (PAR) from NAD+ onto the 
glutamine and aspartate residues of proteins (41).  PAR is formed by the glycosidic linkage of 
ADP-ribose monomers and can form linear or branched chains up to 200 units long (41). 
Whether chain length or branching determines the specific functions and consequences of PAR 
polymers as either free polymer or protein modification is yet to be determined. PARP1, PARP2 
and PARP3 are among the poly(ADP-ribose) polymerases. PARP1 and PARP2 have been 
implicated in response to DNA damage through participation in BER. PARP1 is the primary 
PARP family member implicated in repair. PARP1 is the most abundant of the PARP family 
members with approximately 1x106 molecules per cell (41). Its involvement in the DNA damage 
response was first documented in 1980 when Durkacz et. al. found that PARP inhibition resulted 
in  delayed rate of repair and increased cell death following treatment with DNA damaging agent 
dimethyl sulphate (DMS). PARP1 is activated up to 500 fold higher than basal levels by DNA 
strand breaks (41). Activation occurs when PARP1 zinc finger motifs recognize the altered DNA 
structure of a DNA nick or break. PARP1 binds to the strand break as a homodimer, stimulating 
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PARP1 catalytic activity (41). Once activated, PARP1 then poly(ADP) ribosylates a number of 
proteins including histones, topoisomerases, transcription factors and other nuclear proteins (42). 
However, the primary target of poly(ADP) ribosylation is PARP1 itself on glutamine residues in 
its BCRT domain (the primary domain associated with PARP protein- protein interaction) (41, 
42). PARP1 activity has been linked to BER repair capacity through a number of studies. PARP1 
binds to repair proteins, such as XRCC1, and auto-modification enhances XRCC1 recruitment to 
damage sites (24,43). Inhibition of PARP in conjunction with DNA damage increases 
cytotoxicity in vivo and in clonogenic cell culture assays, presumably through an increase in 
unrepaired single strand breaks being converted into double strand breaks. PARP1 knockout 
mice are viable with no visible phenotype, but show increased sensitivity to whole body 
irradiation or high dose DNA damaging agents such as MNU or MNNG (44).  
While PARP1 plays a critical role in facilitating DNA repair by BER, PARP1 activity 
can also mediate cell death following excessive DNA damage. PARP1 hyperactivation has been 
observed after high doses of alkylation damage or excitoxicity by NMDA receptors after 
ischemic stroke, traumatic brain injury or MPTP induced Parkinson’s disease (41). PARP family 
members utilize NAD+ to catalyze poly(ADP-ribose) polymer formation. Excessive activation of 
PARP after ischemia or alkylation damage has been shown to reduce NAD+ levels to 10-20% of 
original levels. NAD+ and NADH are  required cofactors for ATP generating processes, and 
resynthesis of NAD+ consumed by PARP requires between 2-4 molecules of ATP depending on 
which arm of the NAD+ salvage pathway is used (45). ATP depletion follows NAD+ depletion 
resulting in eventual necrotic cell death. Alternatively, the Dawson’s have set forth a model in 
which PARP hyperactivation induced cell death after ischemia or MNNG treatment is dependent 
on the PAR polymer itself, with long complex PAR polymers causing the most toxicity (42). 
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PAR mediated cell death activates a signaling cascade resulting in apoptosis inducing factor 
(AIF) release from the mitochondria to the nucleus and an AIF dependent caspase independent 
form of cell death, termed “Parthanatos” (46, 47). Inhibition of PARP1 after ischemic stroke or 
mycocardial infarction is protective of the necrotic cell death typically seen after insult (48). 
PARP2 has been linked to DNA damage repair more recently. Ame et. al. demonstrated 
PARP2 can also be stimulated by DNA damage (49); although PARP2 activation only accounts 
for 10% of PARP activity in the cell, whereas PARP1 accounts for 85% of PARP activity. 
PARP2 binds to XRCC1, Polß and DNA ligaseIII (50). PARP2 knockout mice are also viable 
with no phenotype except for increased sensitivity to high levels of DNA damage, although to a 
lesser degree than PARP1 knockout mice (49). 
  PARP3, whos function was previously unknown, has recently been implicated in two 
separate reports as a double strand break repair protein. Rulten et. al. reported that PARP3 has 
ADP-ribosylation activity that is stimulated by DNA double strand breaks versus the single 
strand  break stimulation of  PARP1 or PARP2. PARP3 modifies histone H1 and PARP3 itself 
resulting in the recruitment of aprataxin-and-PNK-like factor 1 (APLF1). APLF1 then recruits 
and retains XRCC4-ligaseIV that is responsible for the final step of non-homologous end joining 
(51). While PARP3 influences the kinetics of DSB repair, it is not essential since simply 
overexpressing XRCC4-ligaseIV can overcome a depletion of PARP3 (51). Boehler et. al. 
simultaneously reported that PARP3 played an important role not only in double strand break 
repair, but also in maintenance of the mitotic spindle and telomeres, through association with 
NuMA and tankyrase1 respectively (52). 
PAR polymers formed by PARP family members are catabolized primarily by the protein 
poly(ADP-ribose) glycohydrolase (PARG). PARG breaks the glycosidic bond between PAR 
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monomers resulting in release of free ADP-ribose (45). PARG expression has been linked to 
both repair capacity and PARP1 hyperactivation induced cell death. PARG knockout in mice 
results in embryonic lethality and the accumulation of PAR polymers during development and 
apoptosis (41). Lower levels of PARG worsen cell death after ischemic brain injury (42). 
Interestingly overexpression of a cytosolic version of PARG can rescue ischemic cell death and 
prevent AIF release, supporting a cytosolic role of PAR, despite most studies showing primarily 
nuclear localization of PARP and PAR after DNA damage (42). PARG has also been shown to 
associate with XRCC1 (53). After auto-ribosylation, the highly negative charge of the PAR 
polymers forces PARP1 off of the DNA. Removal of the PAR from PARP1 by PARG allows 
PARP1 to be recycled back onto sites of DNA damage, thus making PARG a critical member of 
the BER repair complex (41).  
1.4.2 PARP inhibitors 
There are currently a large number of clinical and experimental PARP inhibitors being used 
within the clinic and laboratory. Most PARP inhibitors are specific for PARP1 and PARP2, 
although some effect on PARP3 has also been seen at higher doses (54). Inhibition of PARP has 
been shown to rescue necrosis after PARP hyperactivation, and PARP inhibitors have shown to 
be potentially beneficial for the treatment of ischemia reperfusion injury after stroke or 
mycocardial infarction (37, 55, 56). Perhaps PARP inhibitors are most exciting at the moment 
for their ability to treat BRCA1 or BRCA2 deficient breast cancers as a monotherapy. BRCA1 
and BRCA2 are critical proteins in homologous recombination. Mutation of BRCA1 and 
BRCA2 are hereditary and lead to genomic instability and a greatly increased risk for breast and 
ovarian cancers (57). It was shown that inhibition of PARP is synthetically lethal with BRCA1/2 
  16 
mutations resulting in apoptotic cell death, presumably through inhibition of the BER pathway 
resulting in increased double strand breaks that can no longer be repaired by homologous 
recombination due to the cancer specific defect in BRAC1/2 (57-59).  
Given the critical role of PARP1 and PARP2 in BER, there is intense interest in 
combining TMZ with PARP inhibitors in the clinic. The Abbott Labs PARP inhibitor, ABT-888, 
has been shown to enhance the efficacy of multiple DNA damaging agents, including TMZ, in a 
number of xenograft and preclinical models, including lung, pancreatic, breast, ovarian and 
prostate (60).  A note of particular interest was that the PARP inhibitor-TMZ combination was 
able to overcome TMZ resistance due to tolerance of the O6-methylguanine lesion. This supports 
the idea of enhancing the toxicity of BER substrates, N7-methylguanine and N3-methyladenine, 
through BER inhibition (60). In this case BER inhibition via PARP inhibition results in 
unrepaired single strand breaks, conversion of those single strand breaks to double strand breaks 
upon replication and apoptosis.   
1.5 HYPOTHESIS 
Over 80% of the lesions created by TMZ are BER substrates, which are efficiently repaired by 
tumor cells. Previous studies by the Sobol lab and others have identified Polß as a critical step in 
BER repair of TMZ induced lesions. It has been shown that genetic depletion of Polß results in 
BER failure, accumulation of 5’dRP repair intermediates and hypersensitivity of tumor cells to 
TMZ. However, the mechanism of 5’dRP cell death is still unknown.  
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Hypothesis: The base excision repair pathway functionally interacts with cellular energetic 
pathways such as NAD+ biosynthesis, glycolysis and oxidative phosphorylation through PARP 
activation. A drug combination that targets both BER and NAD+ biosynthesis would enhance 
response to TMZ in resistant glioblastoma tumors. 
 
This thesis addresses the mechanism behind 5’dRP mediated cell death, linking BER to cellular 
energetic pathways. These studies further expand the mechanistic link between BER failure and 
PARP hyperactivation to investigate the subcellular kinetics of energy depletion and the effects 
on cellular metabolic processes. Based on the mechanistic studies, this thesis puts forth a novel 
dual targeting strategy, inhibiting both BER and NAD+ biosynthetic pathways, for the treatment 
of glioblastomas with multiple modes of O6-methylguanine resistance.  
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2.0  MATERIALS AND METHODS 
2.1.1 Chemicals and reagents 
Alpha EMEM was from MediaTech (Manassas, VA). MEM, heat-inactivated fetal bovine serum 
(FBS), L-glutamine, antibiotic/antimycotic, and geneticin were from InVitrogen (Carlsbad, CA). 
Gentamycin was from Sigma (St. Louis, MO). Temozolomide (NSC# 362856; IUPAC name: 3-
methyl-2-oxo-1, 3, 4, 5, 8-pentazabicyclo[4.3.0]nona-4,6,8-triene-7-carboxamide; CAS number: 
856622-93-1) (61) was obtained from the National Cancer Institute Developmental Therapeutics 
Program and Sigma (St. Louis, MO). A temozolomide (TMZ) stock solution was prepared in 
DMSO at 100 mM. FK866 (NIMH #F-901; IUPAC name: (E)-[4-(1-Benzyoylpiperidin-4-
yl)butly]-3-(pyridin-3-yl)acrylamide; CAS number: 201034-75-5) was obtained from the 
National Institute of Mental Health Chemical Synthesis and Drug Supply Program (Bethesda, 
MD). FK866 was dissolved in DMSO to prepare a stock solution at a concentration of 1mM and 
stored at -20˚C. Methyl methanesulfonate (MMS) and methoxyamine hydrochloride (MX) were 
from Sigma (St. Louis, MO). Puromycin, Gentamicin and Neomycin were purchased from 
Clontech Laboratories, Irvine Scientific and InVitrogen, respectively. PJ34 was purchased from 
Calbiochem. ß-nicotinamide mononucleotide (NMN) was obtained from Sigma (cat# N3501) 
and Nicotinic Acid (NA) was obtained from Fisher (cat# AC12829). 
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2.1.2 Cell culture and cell line development 
All cells were cultured at 5% CO2 and 37°C. LN428 glioblastoma cells (a generous gift from Dr. 
Ian Pollock, University of Pittsburgh) and derived cell lines were cultured in Alpha EMEM 
supplemented with 10% heat inactivated FBS, L-glutamine, antibiotic/antimytotic and 
gentamycin (62, 63). The LN428/MPG cells (over-expressing methylpurine DNA glycosylase; 
MPG) were supplemented with 6 mg/mL G418. LN428/MPG cell lines with stable knockdown 
of PARP1, PARP2, MLH1, MSH2 and MSH6 were generated via lentiviral transduction of 
shRNA as previously described (37) and cultured in growth media with 6 mg/mL G418 and 1.0 
µg/mL puromycin. Knockdown of the target gene was assessed by reverse transcription PCR 
(RT-PCR). The T98G glioblasoma cell line was purchased from American Type Culture 
Collection and cultured in MEM supplemented with 10% heat inactivated FBS, non-essential 
amino acids, sodium pyruvate and antibiotic/antimytotic (64). Both cell lines were tested for 
cross species contamination and authenticated by RADIL cell check services as of 11/16/2010. 
The genetic profiles provided by RADIL were checked against the ATCC STR loci database to 
confirm the identity of the T98G cell line, and to ensure that the LN428 genetic profile was 
unique from any ATCC banked cell line. 
2.1.3 Short term cytotoxicity assay 
Glioma cells were seeded 24 hours prior to treatment at 2000 cells/well in 96-well plates. For 
FK866 pre-treatment experiments, cells were treated with the indicated dose of FK866 or media 
control for 24 hours. Media was then removed and cells were treated with the indicated dose of 
MMS for 1 hour. Cells were then washed with media and allowed to recover for 48 hours, at 
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which point cell survival was assayed utilizing the MTS assay (Promega). For PJ34, cells were 
pre-exposed to the inhibitor for 30 minutes and were then treated with TMZ in the presence of 
the inhibitor for 48 hours. For NA and NMN, cells were pre-exposed to each for 24 hours 
(concentrations as indicated in the legend) and were then treated with TMZ (1.0 mM) in the 
presence of NA or NMN for 48 hours prior to assaying for cell survival.  Results shown are the 
average of three independent experiments and reported as percent survival of MMS treated cells 
compared to control wells. 
2.1.4 PAR lysate collection, Western blot and PAR ELISA 
For whole cell extracts used in poly(ADP-ribose) (PAR) formation assays, 3 × 106 cells were 
seeded into a 100 mm cell culture dish 24 hours before drug treatment. Cells were either treated 
with TMZ only or pre-exposed to a PARP inhibitor (PJ34) followed by PARP inhibitor plus 
TMZ treatment. For the FK866 experiments cells were seeded at 1.5 x 106 24 hours prior to 
treatment, cells were then incubated in the presence of FK866 (10 nM) or DMSO for 24 hours 
followed by treatment with MMS. After treatment, cells were washed twice with cold PBS, 
collected and lysed with 400 µL of 2 × Laemmli buffer (2% SDS, 20% Glycerol, 62.5 mM Tris-
HCl pH6.8, 0.01% Bromophenol Blue). Samples were boiled for 8 min and extract from 
approximately 1.5 × 105 cells were loaded each lane on a 4-12% pre-cast NuPAGE Tris-Glycine 
gel (InVitrogen) for immunoblot assay (used in Chapter 3). Alternatively, cells were treated as 
above and lysed in modified Laemmli buffer containing 1% SDS in the absence of bromophenol 
blue. Protein content was quantified using the DC protein assay (Bio-Rad). 30 micrograms of 
protein was loaded for analysis (used in Chapter 5).  
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 The following primary antibodies were used for immunoblot analysis: anti-PCNA (Santa 
Cruz); anti-poly(ADP-ribse) (PAR) (Clone 10H, kindly provided by M. Ziegler) and anti-
poly(ADP-ribose) polymerase-1 (PARP1) (BD Pharmingen). 
 
Quantitative PAR assay 
Cells were seeded at 3 x 106 cells per 100 mm dish 24 hours prior to treatment. Cells were then 
treated with media (control) or MMS for the indicated time. Cells were immediately lysed in 
modified Laemmli buffer containing 1% SDS in the absence of bromophenol blue. Protein 
content was quantified using the DC protein assay (Bio-Rad). PAR content was quantified using 
a colorimetric PAR ELISA kit (Trevigen). Briefly, strip wells were coated with PAR capture 
antibody 24 hours prior to assay. PAR lyastes, generated as specified above, were incubated with 
5µg total protein per well at room temperature (2 hr), followed by washing and incubation with 
PAR detection antibody. A secondary antibody to the PAR detection antibody was incubated for 
1 hour at room temperature, and signal was generated using horseradish peroxidase to generate a 
luminescent signal. Signal was determined using a Molecular Devices VersaMax™ tuneable 
plate reader.  
2.1.5 AIF immunofluorescence and confocal microscopy 
Cells were cultured on glass coverslips for 24 hours prior to treatment with MMS or media 
control. One-hour post treatment cells were washed and allowed to recover in media for 5 hours. 
Cells were then fixed with 4% paraformaldehyde for 20 minutes, permeabilized with 0.5% 
Triton X-100 for 15 minutes, and blocked with 2% BSA for 1 hour, all at room temperature. AIF 
was detected by incubating 1 hour at room temperature with an anti-AIF antibody (Santa Cruz) 
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at 1:100 dilution, followed by goat anti-mouse Alexa 488 secondary antibody (Molecular 
Probes) at 1:500, Alexa 647 phalloidin actin stain at 1:250 (Molecular Probes), and 5 µM 
DRAQ5 nuclear stain for 1 hour at room temperature. Slides were mounted and imaged on the 
Olympus fluoview 500 confocal microscope. 
2.1.6 NAD+ and ATP measurement 
NAD+ Measurement 
Cells were seeded 24 hours prior to treatment. One-hour post treatment with MMS or 24 hours 
post FK866 treatment cells were trypsinized, counted and 1x105 cells were pelleted. NAD+ 
lysates were prepared and NAD+ measurements obtained using the EnzychromTM NAD+/NADH 
assay kit (BioAssay Systems). Absorbance was determined using a Molecular Devices 
VersaMax™ tuneable plate reader. 
 
ATP measurements 
Cells were seeded in black 96-well plates (Perkin Elmer) 24 hours prior to treatment. One-hour 
post treatment with MMS cells were washed and allowed to recover in normal media for one 
hour before analysis. For experiments with methoxyamine or FK866, treatments were performed 
as described in the short-term cyototoxicity experiments. Cells were then lysed and ATP content 
measured by luminescent output using the ATP-lite assay kit (PerkinElmer). Luminescent 
readings were performed using a BioTek Synergy™ 2 Multi-Mode microplate reader. 
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2.1.7 Long term cytotoxicity Assay 
Long-term cytotoxicity assay in modified LN428 cell lines  
For long-term survival assays with FK866 pre-treatment, cells were seeded at 80,000 cells/well 
in 6-well plates 24 hours prior to treatment. Cells were treated with FK866 or media control for 
24 hours. Cells were then trypsinized and plated into 60 mm dishes with or without FK866 and 
were allowed to attach for 6 hours prior to replacing media with TMZ containing media. All 
doses were done in triplicate 60 mm dishes. Cells were allowed to grow for 10-12 days in the 
presence of TMZ. Cells were then trypsinized and counted using a CASY automated cell 
counter. All experiments were performed in triplicate. Long-term survival experiments 
combining FK866 with MX pre-treatment were performed as above, but after the 6-hour 
attachment, cells were treated for 30 minutes with 10 mM MX that was diluted to 5 mM upon 
addition of TMZ. Cells were allowed to grow for 10-12 days in the presence of MX and TMZ 
prior to counting. 
 
Long-term cytotoxicity assay in T98G cells 
T98G cells (1,150) were seeded in 60mm dishes and allowed to adhere for 24 hours. Cells were 
then treated with FK866 or media control for 24 hours, followed by MX pre-treatment or media 
control as described above. Cells were treated with TMZ either alone or as a co-treatment with 
MX for 6 hours, at which time the drug treatments were removed and replaced with normal 
culture media. Cells were allowed to grow for an additional 7 days and were assayed for cell 
survival as described above. All doses were performed in triplicate.  
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2.1.8 Subcellular ATP analysis 
ATeam FRET probes were designed by Hiromi Imamura et. al. to measure subcellular ATP 
through FRET by linking mVenus and mseCFP to the ε subunit of the Bacillus subtilis F0F1-ATP 
synthase (65). ATeam version 1.03 targeted to the mitochondria, cytoplasm or nucleus were 
obtained from Hiromi Imamura at the Institute of Scientific and Industrial Research, Osaka 
University Japan. ATeam 1.03 has a Kd for ATP of 3.3mM, has no change in fluorescence 
between pH 7.1-8.5 and has a Kon and Koff of 1.7x10-2 and 9.8x10-2 s-1. Subcellular FRET probes 
were able to detect differential depletion of ATP in the cytoplasm and mitochondria after 
treatment with 2-DG and potassium cyanide respectively (65).  
For experiments determining loss of subcellular ATP after alkylation damage, cells were 
seeded in 35mm glass bottom MatTek dishes 24 hours prior to transfection. Cells were 
transfected with Fugene transfection reagent according to the manufacturer. After culturing the 
cells for 48-72 hours, media was replaced with phenol red free imaging media and analyzed by 
epifluorescent microscopy with measurements taken every minute with 400ms to 800ms 
exposure and 2x2 binning. A ten-minute baseline was taken before adding MNNG to a final 
concentration of 5µM. Change in FRET ratio was measured for one hour until a change in the 
FRET ratio in LN428/MPG cells had plateaued. FRET ratio was calculated by subtracting 
background values from CFP and mVenus signals. FRET ratios were generated by dividing 
background corrected CFP/YFP. Ratios for each subcellular measurement were normalized by 
dividing by the ratio at time point 0. Traces are the average of all normalized FRET traces +/- 
standard error. 
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2.1.9 Metabolic flux measurement 
To measure metabolic flux in real time the Seahorse Extracellular Flux Analyzer (Seahorse 
biosciences) was utilized. Cells were plated at a density of 40,000 cells per well in the 
specialized Seahorse plates (well area is equivalent to that of a 96 well plate) in normal culture 
media. Pretreatment with PJ34 or FK866 was performed as described in the short-term 
cytotoxicity experiments. One hour prior to the experiment media was replaced with un-buffered 
DMEM, un-buffered DMEM with MNNG or un-buffered DMEM with inhibitor alone or 
inhibitor plus MNNG. Cells were incubated in un-buffered media and drug combinations for 1 
hour at 37°C and 0% CO2. The Seahorse cartridge containing probes for oxygen and pH was 
loaded with the metabolic inhibitors oligomycin, carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone (FCCP), 2-deoxyglucose and rotenone into injection ports A-
D respectively to inject at final concentrations of 1 µM oligomycin, 300 nM FCCP, 100 mM 2-
DG and 1 µM rotenone. The protocol was set up as illustrated below, with a baseline 
measurement of 4 points, followed by injection of port A, 3 measurements, injection of port B, 
etc. to produce a general metabolic profile for oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR). 
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Figure 2. Illustration of metabolic profiles generated by Seahorse Extracellular Flux Analyzer 
 General metabolic profile for T98G glioblastoma cell line seeded at 40,000 cells per well. 
 
Each data point is from the average of 5 separate wells to form technical replicates for each 
treatment group. Each experiment was run in independent duplicates. The OCR and ECAR 
metabolic profiles of the two independent trials were averaged and the standard error of the mean 
for each measurement was calculated. The following measurements were calculated from OCR 
and ECAR profiles. 
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Table 2. Calculation of metabolic parameters from Seahorse data 
Non-mitochondrial respiration Average of OCR points 14-16 (post rotenone measurements) 
Basal OCR Average of OCR points 1-4 (baseline OCR) minus Non-
mitochondrial respiration 
Proton Leak Average of OCR points 5-6 (post oligomycin measurements) 
minus non-mitochondrial respiration 
ATP-coupled OCR Basal OCR minus Proton leak 
Total mitochondrial reserve 
capacity 
Average of OCR points 11-13 (post 2-DG measurement) 
minus non-mitochondrial respiration 
Basal glycolytic rate Average of ECAR points 1-4 (baseline ECAR) 
Oligomycin induced glycolytic 
rate 
Average of ECAR points 5-6 (post oligomycin measurement)  
 
2.1.10 Statistical Analysis 
All data is shown as a mean +/- standard error from 3 independent experiments unless otherwise 
indicated. Student’s t-test was used for comparisons between two groups. For multiple 
comparisons, one-way ANOVA followed by post-hoc test with Bonferroni correction was used. 
Statistical analysis was performed using GraphPad PRISM. 
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3.0  BIOENERGETIC METABOLITES REGULATE BASE EXCISION 
REPAIR DEPENDENT CELL DEATH IN RESPONSE TO DNA DAMAGE 
3.1 INTRODUCTION 
Efficacy of chemotherapy or radiation treatment is intimately dependent on DNA repair 
capacity (18). Robust repair of therapeutically induced DNA damage can provide significant 
resistance whereas tumor-specific defects in DNA repair or inhibition of specific DNA repair 
proteins can provide therapeutic advantage (66). In particular, inhibiting base excision repair 
(BER) can be an effective means to improve response to temozolomide (TMZ), radiation, 
bleomycin and cisplatin, among other treatments (22, 36, 67-72). As with most DNA repair 
pathways, BER is a multi-step mechanism comprised of more than 20 proteins, depending on the 
initial base lesion (22). However, inhibiting each step in the BER pathway will have different 
outcomes. DNA glycosylase inhibition or loss blocks BER initiation, leading to the accumulation 
of both cytotoxic (67) and mutagenic base lesions (68), the latter contributing to cellular 
dysfunction. In this regard, the preferred option is the inhibition of BER after repair initiation, 
promoting the accumulation of cytotoxic BER intermediates such as abasic sites and DNA 
single-strand breaks by inhibiting abasic site repair with methoxyamine, inhibiting the BER 
enzyme poly(ADP-ribose)polymerase-1 (PARP1) or by loss or inhibition of DNA polymerase ß 
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(Polß) (36, 66, 69). We refer to inhibition of the intermediate steps in BER as the induction of 
“BER failure”, since repair is initiated yet is unable to be completed. 
Importantly, understanding the mechanisms that are responsible for the increase in cell 
death due to BER inhibition or BER failure is critical in tailoring treatment, as well as designing 
rational adjuvant or combination treatments that may further increase overall response. For 
example, inhibiting PARP1 has proven effective in improving TMZ induced cell death (70). 
Inhibition of PARP1 results in the accumulation of replication-mediated DNA double-strand 
breaks (DSBs) and the onset of apoptosis (71, 72). This detailed understanding of the mechanism 
of cell death induced by combining a DNA damaging agent (TMZ) and a PARP1 inhibitor 
suggests that PARP1 inhibition would be effective against many tumors but may be ineffective 
against tumors that are resistant to apoptosis (73). Further, cell death induced by PARP1 
inhibition suggested a requirement for homologous recombination (HR) in the cellular response 
to the accumulated DSBs, prompting pre-clinical and clinical trials of PARP1 inhibitors in the 
treatment of HR defective tumors (66).  
 There are several BER proteins essential for the repair of TMZ-induced DNA lesions. 
Using a mouse embryonic fibroblast (MEF) cell model, we have shown that loss of Polß can 
significantly improve the cytotoxic effect of TMZ (13), suggesting that inhibition of Polß may 
improve response to TMZ in human tumor cells. TMZ is currently used in the treatment of 
glioblastoma (17) and it is therefore critical to evaluate the role of Polß in glioma cell response to 
TMZ treatment. No previous studies have investigated the role of Polß in the response of human 
glioma tumor cells to TMZ. Further, there is no mechanistic explanation for the increase in 
alkylation-induced cell death observed in cells that are deficient in Polß beyond the evidence that 
cell death in mouse cells is the result of accumulation of un-repaired BER intermediates (13, 36).  
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Acute alkylation damage has been suggested to induce cell death by multiple 
mechanisms, including necrosis (74), caspase-3 and caspase-9 activation and the onset of 
apoptosis (75), apoptosis inducing factor (AIF) translocation from the mitochondria to the 
nucleus (46, 76, 77), ADP-ribose induced activation of the Ca2+ channel TRPM2 or AMP-
mediated inhibition of ATP transport (78-80).  In most, if not all cases, cell death has been 
attributed to the direct action of either poly(ADP-ribose) (PAR) formed by PARP1 activation or 
PAR catabolites that accumulate after PAR degradation by the catabolic enzyme poly(ADP-
ribose) glycohydrolase (PARG). Polß deficient mouse cells are hypersensitive to the cell killing 
effects of alkylating agents due to failure to repair the 5’dRP BER intermediate (26). However, 
the exact downstream signaling events and mechanism of cytotoxicity specifically induced by 
the un-repaired 5’dRP lesion remains unclear. Previous studies in mouse cells have not been 
conclusive. One report suggested that the absence of Polß led to damage-induced cell death via 
apoptosis (81) whereas a later study proposed a necrotic form of cell death for both wild-type 
and Polß deficient cells (82), similar to what has been proposed as a general mechanism of 
alkylation-induced cell death in mouse fibroblasts (74). However, this latter study required the 
use of apoptosis-deficient cells to observe necrotic cell death (74). None of these previous 
studies have identified a mechanism of cell death specific to Polβ deficiency and BER failure or 
a failure to repair the cytotoxic BER intermediate 5’dRP. 
The studies described herein were designed to specifically define the mechanism of cell 
death in human tumor cells resulting from failure to repair the BER intermediate 5’dRP due to 
‘inhibition of’ or a ‘deficiency in’ Polß (BER failure). We have hypothesized that PARP1 
functions in BER as both a complex coordinator and as a molecular repair sensor. As a BER 
molecular sensor, we suggest that PARP1 facilitates cell death in response to incomplete BER or 
  31 
BER failure. In support of this hypothesis, we show that a specific BER intermediate, a single-
strand DNA strand break containing a 3’OH and 5’dRP, is an in vivo substrate in human cells 
that activates PARP1 in the context of BER and that elevated cytotoxicity observed in Polß 
deficient human cells is controlled by the activation of PARP1. Further, we provide clear 
evidence that following “BER failure” human cells die independent of RIP1 activation or AIF 
translocation, thus ruling out PAR as the cell death signal that is initiated upon BER failure. 
Further, we show that the observed cell death in Polß deficient cells is un-related to the 
accumulation of PAR catabolites such as ADP-ribose or AMP yet is dependent on NAD+ 
metabolite bioavailability or the bioenergetic capacity of the cell. 
This study provides mechanistic insight into why Polß deficiency leads to cell death, 
defines the mode of death and offers a mechanistic link between BER failure and energy 
metabolism - the novel finding that DNA damage-induced cytotoxicity mediated via BER 
inhibition is primarily dependent on cellular metabolite bioavailability. Finally, we offer a 
mechanistic justification for the elevated alkylation-induced cytotoxicity of Polß deficient cells, 
suggesting a linkage between DNA repair, cell survival and cellular bioenergetics. 
3.2 RESULTS 
Hyperactivation of PARP due to Polß deficiency and failure to repair the base 
excision repair intermediate 5’deoxyribose phosphate 
BER is a finely tuned process that requires balanced expression of several proteins to 
avoid accumulation of mutatgenic or cytotoxic repair intermediates (22). To understand how 
alterations in BER enzyme activity in human tumor cells leads to DNA damage-induced cell 
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sensitivity, we developed human glioma (LN428) cell lines with a functional deficiency in Polß 
by increasing expression of MPG and depleting the cell of Polß by stable, lentiviral-mediated 
expression of shRNA. As we have reported, human cells with elevated expression of MPG are 
sensitive to alkylation damage due to a deficiency in Polß (83), a phenotype that is enhanced by 
Polß knockdown (Polß-KD). Conversely, re-expression of Polß eliminated the alkylation 
hypersensitive phenotype (Appendix A; Supplementary Fig S1 and S2). These cells 
(LN428/MPG and LN428/MPG/Polß-KD cells) are therefore functionally deficient in Polß and 
were utilized to determine the mechanism that mediates the enhanced DNA damage-induced cell 
death resulting from Polß deficiency. This allows for a model system in which events related to 
incomplete BER can be dissected from other alkylation damage events such as effects on 
translation (84). In addition, by utilizing relatively low doses of alkylating agent that produce an 
effect only in the LN428/MPG or LN428/MPG/Polß-KD cell line we can eliminate effects from 
other alkylation events such as the formation of DNA double-strand breaks or protein alkylation 
(85). For example, LN428/MPG cells are hypersensitive to the alkylating agent MMS at doses as 
low as 0.5 mM, a dose that has no cytotoxic effect on the parental LN428 cell line (Figure 3A). 
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Figure 3. Functional Polß deficiency results in sensitivity to alkylating agents and PARP activation 
(A) Cell viability of LN428 or LN428/MPG cells after 1 h MMS treatment, as measured by an MTS assay 48 hours 
after exposure. Plots show the % viable cells as compared to untreated (control) cells. Means are calculated from 
quadruplicate values in each experiment. Results indicate the mean ± S.E. of three independent experiments. 
(B) PAR generation in LN428 or LN428/MPG cells before or after 15 minute MMS exposure (1.5 mM), as 
measured by quantitative ELISA (see Materials & Methods). Results indicate the mean ± S.E. of three independent 
experiments 
 
The DNA binding and signaling molecules PARP1 and PARP2 have each been 
implicated in BER (22). PARP1 facilitates BER complex formation and it has been postulated 
that local, strand-break induced activation of PARP1 and the resultant synthesis of PAR mediates 
recruitment of the BER proteins XRCC1 and Polß to stimulate DNA repair (86). We therefore 
have hypothesized that in cells that fail to complete BER (e.g., when 5’dRP lesions are not 
repaired; herein referred to as ‘BER Failure’), PARP1 is hyper-activated and functions as a 
DNA damage signaling protein that triggers cell death. To determine whether PARP is activated 
by the BER intermediate (5’dRP) in vivo, we exposed the control (LN428) and corresponding 
BER defective cells (Polß deficient LN428/MPG and LN428/MPG/Polß-KD cells) to TMZ for 
up to 90 minutes. Whole cell extracts were probed by immunoblot for PAR accumulation 
following TMZ exposure (Appendix A; Fig 1A). The level of PAR accumulation was shown to 
correlate with the extent of the BER defect. PARP activation was elevated in the LN428/MPG 
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cells (an intermediate level of sensitivity), with the highest level of PAR observed 30 minutes 
following exposure to TMZ whereas essentially no PARP activation was observed in the LN428 
cells. In the more sensitive cell line (LN428/MPG/Polß-KD), PARP activation was more robust 
and rapid as compared to that of the LN428/MPG cell line, as PAR reached its highest level at 15 
minutes after exposure to TMZ (Appendix A; Fig 1A). This is further demonstrated utilizing a 
quantitative ELISA method, where we find that PAR generation is 10-fold higher in 
LN428/MPG cells treated with an MMS dose of 1.5 mM at the 15 minute time point compared to 
LN428 cells under the same conditions (Figure 3B). Comparable results were also observed in a 
Polß defective breast cancer cell line where elevated TMZ-induced PARP activation is restricted 
to the cells with Polß deficiency (Appendix A; Supplementary Fig. S2B and C) (37). 
Conversely, exposure to etoposide resulted in a low level of PARP activation at all time points 
for all three cell lines LN428, LN428/MPG and LN428/MPG/Polß-KD (Appendix A; 
Supplementary Fig S2D). Thus, PARP activation is elevated in BER defective (Polß deficient) 
cells following alkylation damage. 
Since the combination of alkylating agent treatment and Polß deficiency triggers PARP 
activation, we next validated the significance and specificity of this finding by re-expression of 
Polß in the LN428/MPG and LN428/MPG/Polß-KD cells. We find that the BER deficient 
phenotype (increased cellular sensitivity to alkylating agents) observed in both the LN428/MPG 
and LN428/MPG/ Polß-KD cells was reversed by complementation (expression) of FLAG- Polß 
(WT) (Appendix A; Fig. 1B, Supplementary Fig S1E) (37). Similarly, we find that 
complementation with FLAG- Polß (WT) but not with the Polß 5’dRP lyase mutant eliminated 
the TMZ-induced activation of PARP observed in BER defective cells (Appendix A; Fig. 1B 
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and C) (37). These data therefore suggests that the Polß specific BER intermediate (5’dRP 
lesion) triggers rapid and robust PARP1 activation in vivo, triggering the onset of cytotoxicity. 
The correlation between PARP activation and alkylation sensitivity prompted us to 
determine if inhibition of PARP reverses the cellular hypersensitivity of Polß deficient human 
tumor cells. We inhibited activation of PARP by pre- and co-treatment with the PARP1/PARP2 
inhibitors PJ34 or DR2313. Inhibition of PARP by PJ34 significantly reduced the level of TMZ-
induced PARP activation in the Polß deficient cells (LN428/MPG) (Appendix A; Fig 2A) (37). 
We next assayed if PARP inhibition can rescue the alkylation-sensitive phenotype of 
LN428/MPG cells, as determined by an MTS assay 48 hours after TMZ exposure. Most 
importantly, we find that PARP inhibition by either PJ34 or DR2313 treatment converted the 
LN428/MPG cells from a sensitive phenotype to a resistant phenotype (Appendix A; Fig. 2B, 
Supplementary Fig. S3A) (37). Rescue by PARP inhibition was also observed in Polß deficient 
MDA-MB-231 cells (Appendix A; Supplementary Fig. S3B) (37). This resistant phenotype is 
confined to short-term survival assays. Upon several rounds of replication PARP inhibition 
potentiates TMZ cell killing measured by a long-term survival assay, presumably through BER 
failure induced single-strand breaks leading to the formation of DNA double-strand breaks and 
the onset of apoptosis (87). Regardless, these studies support our hypothesis that PARP 
hyperactivation mediates the alkylation sensitive phenotype of Polß deficient cells.  
  
Un-repaired base excision repair intermediates (5’dRP lesions) trigger cell death via 
energy depletion in the absence of PAR or PAR-catabolite mediated signaling 
A number of different mechanisms have been attributed to PARP1 activation-induced 
cell death. We first evaluated the involvement of caspase-dependent cell death in control cells as 
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compared to the corresponding Polß deficient cells following TMZ treatment (Appendix A; 
Supplementary Fig. S4A and B) (37). These experiments rule out a caspase-dependent 
response due to BER failure, in-line with our previous report (83). Although it has been 
demonstrated that an autophagic-response contributes to TMZ-induced cell death in some cells 
(88), TMZ hypersensitivity of Polß deficient cells is not affected by the autophagy inhibitor 3-
MA (Appendix A; Supplementary Fig S4C) (37). In support of this observation, we did not 
observe increased LC3 puncta in BER defective cells following TMZ exposure (83). 
A major mechanism that has been attributed to PARP-activation induced cell death is 
direct PAR signaling to the mitochondria where PAR mediates translocation of apoptosis 
inducing factor (AIF) from the mitochondria to the nucleus to induce caspase-independent cell 
death (46, 76, 89) via a mechanism that requires receptor (TNFRSF)-interacting serine-threonine 
kinase 1 (RIP1) activation (90) (Figure 4).  
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Figure 4. Model of possible mechanisms of cell death after PARP hyperactivation. 
 
RIP1 can be inhibited by necrostatins, small molecule inhibitors shown to inhibit cell death (91, 
92). Therefore, we investigated the role of RIP1 in the PARP-mediated cell death we observed 
by inhibiting RIP1 with Necrostatin-1 (92) and evaluating the impact of RIP1 inhibition on DNA 
damage-induced cell survival in both control and Polß deficient cells (Appendix A; 
Supplementary Fig. S5) (37). However, inhibition of RIP1 did not prevent cell death in either 
the parental or Polß deficient cells, suggesting but not proving that AIF translocation may not be 
related to the observed cell death.  
We therefore next evaluated the sub-cellular localization of AIF in control and Polß 
deficient cells following exposure to the alkylating agents MMS or TMZ as compared to vehicle 
(media) by immunoflourescent staining and confocal microscopy (Figure 5) or by sub-cellular 
fractionation and immunoblot analysis (Appendix A; Supplementary Fig. S6). In-line with the 
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RIP1 inhibition data above, alkylating agent treatment of Polß deficient cells did not alter the 
sub-cellular localization of AIF (Figure 5).  
 
 
Figure 5. Subcellular localization of AIF before and after alkylation treatment. 
Absence of mitochondria to nucleus translocation of AIF due to BER failure as determined by confocal microscopy. 
BER deficient cells (LN428/MPG) were treated with media (left panel) or 1.5 mM MMS (right panel) for 1 hour and 
then washed and allowed to recover in media for 5 hours prior to fixation and staining for AIF (green), actin (red) 
and nucleus (blue). 
 
All the detectable AIF was localized to the mitochondria in both cell lines regardless of agent or 
time of exposure (up to 12 hours), thus ruling out PAR as a cell death signal upon BER failure. 
In the absence of a PAR-mediated cell death process (AIF translocation), it is possible 
that cell death is initiated via the rapid breakdown of PAR (Appendix A; Fig. 1A) by the 
catabolic enzyme PARG and the accumulation of the PAR catabolites ADP-ribose, ribose-5-
phosphate and/or AMP (Figure 4) (84). ADP-ribose acts as a second messenger to activate the 
cation channel TRPM2 to trigger Ca2+ influx, resulting in cell death (78, 79) or inhibits ABC 
transporters (93) whereas elevated AMP can block ATP transport, leading to ATP depletion and 
cell death (80). To investigate the possibility that PAR catabolites contribute to PARP-mediated 
cell death in Polß deficient cells, we first blocked Ca2+ influx with BAPTA-AM, shown recently 
by Boothman and colleagues to abrogate PARP1-activation induced cell death (94, 95). Unlike 
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that observed following DNA damage from reactive oxygen species (ROS) or oxidative stress, 
BAPTA-AM did not prevent the elevated damage-induced cell death in Polß deficient cells 
(Appendix A; Supplementary Fig. S7) (37). However, as there may be multiple mechanisms of 
PAR-catabolite-induced cell death, we next knocked-down expression of PARG by stable-
transduction of both cell lines with a lentivirus expressing shRNA specific to PARG. Expression 
of PARG mRNA is reduced to 35% as compared to the GFP-control cells when determined by 
qRT-PCR. Importantly, we found no evidence for PAR degrading activity in the cells with stable 
depletion of PARG (Figure 6; left panel). When exposed to an alkylating agent, BER deficient 
PARG-KD cells accumulate significant levels of PAR with no evidence for PAR degradation 
(Figure 6; left panel lanes 2-4). This is in contrast to the presence of PARG, when the PAR 
molecule is degraded within 60-90 minutes (Appendix A; Fig.1, lanes 7-12). These data 
demonstrate that these PARG-KD cells do not degrade PAR and hence do not accumulate PAR-
catabolites, providing an opportunity to determine if PAR catabolites contribute to cell death in 
these cells. As shown in Figure 6 (right panel), PARG-KD did not rescue or reverse the enhanced 
damage-induced cell death phenotype of Polß deficient (LN428/MPG) cells. In fact, PARG-KD 
cells (black bars) were more sensitive to the cell killing effect of the alkylating agent TMZ as 
compared to the PARG expressing cells (open bars) (Figure 6, right panel).  
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Figure 6. PARG knockdown does not rescue BER failure induced cell death. 
PARG KD prevented degradation of DNA damage-induced PAR. (Left Panel) Immunoblot of PAR to determine the 
degradation of PAR in LN428/MPG/PARG-KD cells following treatment with 1.5 mM TMZ. Compare to Appendix 
A Figure 1A lanes 7-12.  PCNA protein expression level was shown as a loading control. (Right Panel) Preventing 
generation of PAR catabolites from degradation of PAR via PARG KD enhances TMZ-induced cytotoxicity. LN428 
and LN428/MPG cells with (black solid bars) or without (white empty bars) PARG KD were exposed to TMZ (1 
mM) or vehicle control (DMSO) for 48 hours. Viable cells are reported as percentage relative to vehicle control 
treated cells (% control). Results indicate the mean ± S.E. of three independent experiments. 
*This figure contributed by Dr. Jiang-bo Tang as part of co-author manuscript (37)  
 
 
The inability of necrostatins to abrogate the response and the lack of PAR-mediated AIF 
translocation strongly suggests that PAR is not acting as a signaling molecule to induce cell 
death, as has been suggested (42, 96). Further, the inability of BAPTA-AM and most 
importantly, PARG-KD, to reverse the alkylation-sensitive phenotype of Polß deficient cells also 
suggests that the observed cell death is un-related to the accumulation of PAR catabolites such as 
ADP-ribose or AMP. Finally, one of the hallmarks of caspase-independent cell death is secretion 
of HMGB1 into the extracellular space (97, 98). A significant level of HMGB1 was secreted into 
the culture media following exposure of the BER defective cells (LN428/MPG) to TMZ as 
compared to that of the control LN428 cells (Appendix A; Fig. 3D). HMGB1 release was 
mediated through PARP activation, likely due to PARP1 modification (98), as PARP inhibition 
greatly reduced the release of HMGB1 (Appendix A; Fig. 3D).  It is unclear how or if HMGB1 
release due to failed BER is related to the recently reported role of HMGB1 in BER (99).  
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An alternate process of cell death due to PARP1 activation was originally proposed by 
Berger to involve energy (NAD+ and ATP) depletion (100, 101), in support of an earlier 
observation by Jacobson and colleagues demonstrating a decrease in NAD+ concurrent with an 
increase in PAR synthesis (102). We therefore measured NAD+ and ATP levels in the control 
(LN428) and Polß deficient (LN428/MPG and LN428/MPG/Polß-KD) cells before and after 
exposure to MMS or TMZ. In line with the cytotoxicity and PARP1 activation results described 
above, exposure of Polß deficient cells to MMS or TMZ led to a rapid and drastic depletion of 
both NAD+ and ATP whereas the NAD+ and ATP levels in the control cells were not affected 
(Figure 7A). We next measured the impact of alkylation damage on the corresponding cells 
depleted of PARG (PARG-KD). If PAR catabolites trigger cell death, we would expect that 
NAD+ and ATP loss would be attenuated in PARG-KD cells. However, exposure of Polß 
deficient PARG-KD cells to TMZ led to enhanced depletion of both NAD+ and ATP (Figure 
7B). The absence of PAR or PAR-catabolite mediated cell death together with the specific loss 
of NAD+ and ATP even when the formation of PAR-catabolites are prevented, suggests that the 
BER failure response is linked to the cellular bioenergetic capacity of the cell. 
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Figure 7. BER failure results in energetic depletion that is not rescued by PARG knockdown. 
(A) Alkylation damage promotes NAD+ and ATP depletion in BER defective cells. NAD+ content (left panel): Cells 
were treated with media (white bars) or 0.5 mM MMS (black bars) for 1 hour prior to collection for NAD+ content 
analysis via enzymatic assay as described in the Materials and Methods section. ATP content (right panel): Cells 
were treated with media (white bars), 0.5 mM MMS (grey bars) or 1.5 mM MMS (black bars) for one hour. ATP 
content was measured after 1-hour recovery in normal media via the luminescence ATP assay described in the 
Materials and Methods section. NAD+ levels or ATP levels shown are the average of three independent experiments 
and are reported as percent control of the untreated control cell line.  
(B) PARG-KD does not rescue alkylation damage induced NAD+ and ATP depletion in BER defective cells. NAD+ 
content (left panel): PARG-KD cell lines were treated with media (white bars) or 0.5 TMZ (black bars) for one hour 
prior to collection for NAD+ content analysis as described in the Materials and Methods section. ATP content (right 
panel): PARG-KD cells were treated with media (white bars), 0.5 mM TMZ (dotted bars), 1.0 mM TMZ (grey bars) 
or 1.5 mM TMZ (black bars) for one hour. ATP content was measured after 1-hour recovery in normal media via the 
luminescence ATP assay described in the Materials and Methods section. NAD+ levels or ATP levels shown are the 
average of three independent experiments and are reported as percent control of the untreated control cell line.  
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For this paradigm to hold, we hypothesized that the availability of bioenergetic 
metabolites would impact the survival of Polß deficient cells exposed to an alkylating agent.  In-
line with this hypothesis, we find that supplementation of the cells with either ß-nicotinamide 
mononucleotide (NMN) (103) or nicotinic acid (NA) reversed the DNA damage-induced 
phenotype, rendering the Polß deficient cells (black bars) completely (NMN) or 80% (NA) 
resistant to the cell killing effects of the alkylating agent, as compared to the BER proficient cells 
(open bars) (Figure 8).  
                                   
Figure 8. NAD+ precursors rescue BER failure induced cell death. 
Bioenergetic metabolites rescue Polß deficient cells from DNA damage-induced cell death. LN428 and 
LN428/MPG cells were pre-treated with NMN, NA or vehicle control (media) for 24 hours and were then exposed 
to TMZ (1 mM) in the presence or absence of NMN or NA for 48 hours. Viable cells were measured as in Figure 1B 
and were reported as percentage relative to vehicle control treated cells (% control). Results indicate the mean ± S.E. 
of three independent experiments. 
*This figure contributed by Dr. Jiang-bo Tang as part of co-author manuscript (37)  
 
Conversely, we anticipated that the hypersensitive phenotype of Polß deficient cells would be 
exacerbated by a reduction in the cellular level of NAD+ and related bioenergetic metabolites. 
We therefore evaluated the impact of transient NAD+ depletion on the observed “BER Failure” 
response by pre-treating cells with FK866, a highly specific non-competitive small molecule 
inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), a critical enzyme in the NAD+ 
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biosynthetic salvage pathway that catalyzes the synthesis of NMN (104). Most importantly, the 
sensitivity of control cells to alkylation damage was not altered by FK866 treatment. However, 
the BER deficient cells are 9-fold more sensitive to MMS following a non-toxic (10 nM) 
treatment with FK866, as compared to the untreated cells  (Figure 9A) even though PAR 
synthesis after the combined FK866 + MMS treatment is attenuated (Figure 9B). 
 
 
Figure 9. Enhancement of BER failure induced cell death by NAD+ biosynthesis inhibition. 
(A) NAD+ biosynthesis inhibition augments BER failure-induced cell death. Cells were pretreated for 24 hours with 
a non-toxic 10nM dose of FK866 (black bars) or DMSO (white bars). Cells were then exposed to media control or 
MMS (0.5 mM) for 1 hour. Results indicate the mean ± S.E. of three independent experiments. 
(B) FK866 prevents BER failure induced PAR synthesis. Cells were pretreated with FK866 (10nM) or DMSO 
control for 24 hours prior to exposure to MMS (1.5mM). PAR synthesis at multiple time points post exposure was 
measured via immunoblot. PARP1 immunoblot is provided as loading control.  
 
These results support our overall hypothesis that the BER failure phenotype of Polß deficient 
cells is mediated by BER intermediate (5’dRP) induced PARP1 activation and induction of 
caspase-independent cell death that is uniquely dependent on the availability of bioenergetic 
metabolites such as NMN and NAD+. 
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3.3 DISCUSSION 
The requirement for BER in general and Polß more specifically in the repair of genomic 
DNA base damage, (13, 36), elevates the significance of characterizing the mechanism 
responsible for Polß deficiency-induced cell death [e.g., a failure to complete repair of the BER 
intermediate 5’dRP in the absence of Polß]. As evidenced recently by the development of 
clinically significant PARP1 inhibitors, identifying BER proteins critical for response to DNA 
damaging agents (e.g., chemotherapy) can have broad human health implications. Equally 
important is a clear understanding of the mechanism(s) that contribute to the enhanced cell death 
observed upon DNA repair inhibition. For example, PARP1 inhibition triggers apoptosis via the 
accumulation of DSBs (71, 72) and a requirement for homologous recombination proteins such 
as BRCA1 and BRCA2 (66). To this end, we have developed a unique series of genetically 
modified human tumor cell lines as models of Polß deficiency that accumulate the cytotoxic 
BER intermediate 5’dRP following exposure to alkylating agents (TMZ, MMS and MNNG). By 
directly comparing BER (Polß deficient) defective and BER competent isogenic human cell 
lines, the cellular, biochemical and signaling responses to DNA base damage can be defined as 
either global (non-specific) or BER (Polß) specific effects, the latter resulting from a cellular 
response to the inability to complete BER, referred to herein as “BER Failure”. We have then 
utilized this system to define the mechanism of cell death resulting from Polß loss/inhibition or 
BER failure and propose and test paradigms to enhance the cell death response.  
From these studies, we find that the un-repaired BER intermediates that accumulate upon 
DNA damaging agent exposure when Polß is deficient will activate PARP1, leading to a rapid 
onset of PARP1-dependent, caspase-independent cell death with little or no role for a caspase-
dependent or autophagy-dependent process in the response. It remains to be determined if the 
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BER failure-induced cell death observed herein is dependent on ERK1/2–mediated PARP1 
phosphorylation (105), SIRT1-regulated deacetylation of PARP1 (106) or if the observed 
PARP1-induced cell death requires BAX, Calpain and JNK activation (107). Coincident with 
damage-induced necrosis in Polß deficient cells is PARP1-dependent HMGB1 secretion (98), a 
hallmark of caspase-independent cell death and inflammation signaling. HMGB1 functions in the 
extra-cellular space as a robust RAGE ligand and inflammatory cytokine or damage-associated 
molecular pattern molecule (97), suggesting that BER failure and the resulting PARP1 activation 
may trigger an inflammatory response in tissues with a BER imbalance such as ulcerative colitis 
(108). 
There are multiple PARP1-activation induced cell death mechanisms, as outlined in the 
diagram shown in Figure 4. In one, it is suggested that PAR, the product of PARP1 activation, is 
a cell death molecule. In this process, PAR initiates the translocation of AIF from the 
mitochondria to the nucleus by a RIP1-dependent mechanism (46, 76, 89, 90). Uniquely, PAR 
generated due to BER failure does not appear to trigger cell death via RIP1 activation nor does 
PAR function as a signal to initiate AIF translocation. PARP1 is involved in many DNA repair 
processes including homologous recombination (HR) and non-homologous end joining (NHEJ) 
in response to DSBs and has a role in telomere maintenance (45, 109). The question remains if 
PAR generated via BER failure is of a unique chemical make-up as compared to PAR generated 
from DSB-induced PARP1 activation. One possible explanation for the absence of a role for AIF 
in this study is the concentration of DNA damaging agents used. In this report, we have used 
TMZ or MMS at a maximum concentration of 1.5 mM or MNNG at a concentration of 5 µM, 
resulting in 90-95% cell death in the BER deficient cells with little or no cell death in the control 
cells. Many reports of PAR-induced AIF translocation include MNNG concentrations of 100 and 
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500 µM (107, 110, 111). Such high concentrations of DNA damaging gents (e.g., MNNG at 20x 
and 100x that used herein) have the potential to directly induce DNA DSBs, create 
overwhelming levels of both nuclear and mitochondrial genome damage (112) as well as the 
possibility of direct protein alkylation. Regardless, it is clear that the cell death initiated by BER 
failure is independent of RIP1 activation and AIF translocation, thus ruling out PAR as the cell 
death signal that is initiated upon BER failure. 
One explanation for the absence of PAR-mediated cell death is the rapid catabolism of 
PAR by PARG (84). In this study, we find that PAR synthesized due to PARP activation is 
degraded within 90 minutes. As summarized in Figure 4, the breakdown products of PAR (PAR 
catabolites) are also likely mediators of cell death, including ADP-ribose (activator of the Ca2+ 
channel TRPM2) and AMP (inhibitor of ATP transport) (78-80). However, PARG knockdown 
did not reverse the DNA damage-sensitive phenotype of Polß deficient cells (Figure 6), 
suggesting that damage-dependent cell death in Polß deficient cells is not initiated by PAR 
catabolites. Conversely, it was suggested that the PAR catabolite AMP may provide a protective 
phenotype by activation of AMPK, induction of autophagy and enhanced ATP synthesis 
following ROS-induced DNA damage and PARP1 activation (113). However, this report has 
since been withdrawn. Although loss of AMPK activation and induction of autophagy upon 
PARG-KD could explain, in part, the enhanced cell death observed in the PARG-KD cells 
(Figure 6), we suggest this is unlikely, since in this study, autophagy is not involved and the 
activation of AMPK, if any, does not appear to overcome the damage-induced cell death 
phenotype resulting from BER failure in the PARG proficient cells. In all, these studies imply 
that the alkylation-sensitive phenotype of Polß deficient cells is un-related to the accumulation of 
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PAR catabolites such as ADP-ribose or AMP and is likely wholly dependent on the metabolite 
bioavailability or bioenergetic capacity of the cell.  
 The over-riding response to the loss of Polß and an inability to complete BER (BER 
failure) is energy failure or depletion of bioenergetic metabolites with no evidence for cell death 
triggered by PAR or the PAR catabolites ADP-ribose or AMP. The energy collapse or depletion 
of NAD+ and ATP due to BER failure is offset by elevated levels of NMN (103) and is 
negatively affected by NAD+ biosynthesis inhibition (FK866). This suggest  FK866 (APO866) 
and related NAD+ biosynthesis inhibitors might be combined with TMZ and BER inhibitors to 
improve TMZ response. This also suggests any stress on or defects in the NAD+ biosynthesis 
pathway such as over-activation of SIRT1 (114) or attenuating defects in NAMPT, NMNAT1 or 
related NAD+ biosynthetic enzymes (115) may have significant effects on cell survival following 
BER failure.  
Similar phenotypes (stress-induced PARP1 activation and cell survival dependent on 
NAD+ metabolites) have been observed in diverse human cell types and mammalian organ 
systems, stressing the significance of these findings. PARP1 activation and the resulting “NAD+ 
depletion”-mediated or ATP-depletion mediated cell death plays a critical role in tissue injury 
from cerebral and myocardial ischemia (116-119). Analogous to the studies described herein, 
cellular protection from cerebral ischemia is provided by NAD+ metabolite supplementation 
(120, 121). Similarly, streptozotocin-induced diabetes results from PARP1 activation, energy 
imbalance and cell death dependent on the BER enzyme MPG (122-125). Most importantly, 
cellular NAD+ metabolism plays an essential role in pancreatic ß-cell viability and insulin 
secretion (126). With the observation that BER failure triggers NAD+ depletion, it is interesting 
to speculate if overall BER capacity controls susceptibility to ischemia or streptozotocin-induced 
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and age-related diabetes onset via neuronal or ß-cell death from loss of bioenergetic metabolites 
subsequent to BER failure. The onset of these physiologically significant outcomes (stroke, 
neurodegeneration, ischemia, diabetes) involves PARP1 activation, NAD+ depletion and cell 
death, similar to that reported here. Although a portion of the environmental and endogenous 
stressors that induce these phenotypes via PARP1 activation will directly induce DNA single-
strand breaks, it is reasonable to presume that a significant proportion of cell death related to 
stroke, retinal degeneration, ischemia and diabetes may initiate from genomic DNA base 
damage, requiring repair by the BER machinery. As such, the failure to repair the DNA damage 
and the resulting accumulation of DNA repair intermediates (BER failure) may be the trigger of 
PARP1 activation and cell death.  
In summary, these studies suggest that PARP1 functions as a BER molecular sensor 
protein to induce caspase-independent cell death following BER failure and provides 
mechanistic insight into why Polß deficiency leads to cell death. Further, we show that the 
observed DNA damage dependent cell death in Polß deficient cells is un-related to the 
accumulation of PAR catabolites such as ADP-ribose or AMP yet is dependent on NAD+ 
metabolite bioavailability or bioenergetic capacity of the cell, suggesting a linkage between 
DNA repair capacity, cell survival and cellular bioenergetic metabolites. Finally, these studies 
have potentially important implications for therapeutic development as it relates to a 
chemotherapy-induced synthetic lethality approach to cancer therapy involving the combination 
of a chemotherapeutic DNA damaging agent, a DNA repair inhibitor and a regulator or inhibitor 
of NAD+ biosynthesis.  
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4.0  UTILIZING REAL-TIME TECHNIQUES TO DETERMINE SPATIAL 
AND TEMPORAL RESOLUTION OF PARP MEDIATED ENERGY DEPLETION 
4.1 INTRODUCTION 
Given the prevalent use of DNA damaging agents in the treatment of tumors, it is critical to not 
only understand the mechanisms of DNA repair pathways that may confer resistance to 
chemotherapy by removal or repair of DNA lesions but to also understand the cellular 
consequences of incomplete or inhibited DNA repair. Inhibition of DNA repair pathways is a 
common strategy for enhancing the chemotherapeutic effect of DNA damaging agents. This is 
exemplified by the attempts of combining O6-benzyguanine with TMZ to enhance O6-
methylguanine mediated apoptosis and the current use of PARP inhibitors to inhibit BER in 
homologous recombination deficient tumors (11, 58, 59).  
 We have previously reported that the BER substrates generated by TMZ can enhance 
glioblastoma and breast cancer tumor cell death in an O6-methylguanine independent manner 
when BER is targeted through genetic manipulation. Targeting of the BER pathway is achieved 
through either overexpressing MPG or combining MPG overexpression with Polß knockdown, 
resulting in a functional Polß defect (37). The ability to initiate repair, but not complete it results 
in the accumulation of repair intermediates and is termed BER failure. We have shown that BER 
failure results in PARP hyperactivation, the depletion of cellular NAD+ and ATP and eventual 
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necrotic cell death, independent of AIF translocation to the nucleus or ADP-ribose and AMP 
mediated cell death pathways (37). This mechanistic insight has highlighted the BER pathway as 
an attractive target for inhibition in combination with TMZ or other DNA alkylating or oxidizing 
agents, and also suggests that cellular energetic pathways may prove to be valuable targets for 
inhibition in combination with alkylating agents or BER inhibitors. While the basic mechanism 
of BER failure induced cell death has been elucidated (37), the details of the PARP mediated 
energy depletion and cell death are still unclear. Understanding the metabolic pathways 
influenced by PARP hyperactivation, as well as the temporal and spatial resolution of cellular 
energy loss, will provide critical insight into not only the consequences of BER failure, providing 
potential additional targets for therapy, but could give general mechanistic clarity to any process 
resulting in PARP hyperactivation and NAD+ depletion, such as ischemia reperfusion injury after 
stroke or myocardial infarction, Parkinson’s disease or cisplatin treatment (56, 127). 
The effects on subcellular energy pools after PARP hyperactivation are controversial. 
Multiple reports suggest that the mitochondrial NAD+ pool is insensitive to depletion by PARP 
hyperactivation, suggesting that the ability to retain oxidative phosphorylation for the production 
of ATP is sufficient to promote cell survival (128, 129). David Sinclair has alternately argued 
that depletion of the mitochondrial NAD+ pool is responsible for cell death after alkylation 
damage, and protection of this subcellular pool results in rescue of PARP-mediated cell death 
(130). PARP hyperactivation and cytosolic NAD+ loss has been considered a block to glycolysis 
(131), and in fact Craig Thompson has shown that only cells relying on glycolysis are sensitive 
to alkylation mediated PARP hyperactivation and necrotic cell death (74). These conflicting 
reports highlight the need to be able to directly measure the subcellular energy pools. While 
measurement of subcellular NAD+ is difficult, ATP sensors have recently been developed that 
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are specific for subcellular pools (65). We used these ATP probes here to dissect energetic 
depletion of the mitochondria, cytosol and nucleus in live cells after DNA damage.  
The effect of PARP hyperactivation on metabolic processes such as glycolysis and 
oxidative phosphorylation is also unclear. Cytosolic NAD+ depletion has been argued to be a 
glycolytic block, and repletion of NAD+ or glycolytic products that serve as TCA cycle 
substrates, such as α-ketogluterate and pyruvate, have been shown to rescue PARP mediated cell 
death (131, 132). Other reports describe mitochondrial dysfunction that results in defective 
oxidative phosphorylation, enhanced production of reactive oxygen species and eventual loss of 
membrane potential (133).  It has been proposed that PARP hyperactivation results in complex I 
dysfunction in mouse mycocardium, potentially via depletion of NADH, a required cofactor for 
complex I function (134). Despite multiple metabolic processes being potentially affected by 
PARP hyperactivation and NAD+ depletion, it is unknown which of these metabolic defects is 
responsible for PARP mediated ATP depletion or if ATP depletion is simply a result of an effort 
to resynthesize NAD+ (100, 101). Further, it is unclear if loss of ATP from specific subcellular 
compartments after PARP hyperactivation results from defective energy production in that 
compartment, such as direct mitochondrial ATP loss via PARP mediated oxidative 
phosphorylation defects. 
Finally, it is unresolved whether NAD+ depletion alone is sufficient for the observed 
metabolic defects and ATP depletion or if there is an alternate more direct role for PARP in 
necrotic cell death, such as signaling of the PAR polymers themselves or the ADP ribosylation of 
metabolic or signaling proteins. Some studies have suggested that long complex PAR polymers 
themselves result in AIF release and caspase independent cell death after DNA damage (42); 
however, it is unclear if PAR polymers play a direct role in the BER failure phenotype given the 
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lack of observed AIF translocation. This study aims to clarify the mechanisms of PARP 
mediated energetic depletion and necrosis utilizing novel real-time live cell techniques to 
measure subcellular ATP loss and metabolic dysfunction. Here we show that mitochondrial ATP 
is lost in a similar time frame as cytosolic and nuclear ATP, within 15 minutes of the peak of 
PAR accumulation. It demonstrates that BER failure results in a PARP mediated block to 
glycolysis and identifies a novel PARP dependent, but NAD+ independent defect in 
mitochondrial respiratory capacity.  
4.2 RESULTS 
Alkylation damage results in loss of mitochondrial ATP followed by loss of cytosolic 
and nuclear ATP. 
As previously described, we have engineered a model cell line to study alkylation-
induced events utilizing low doses of alkylating agent. The LN428 glioblastoma cells 
overexpressing MPG (LN428/MPG) preferentially accumulate base excision repair intermediates 
leading to robust PARP hyperactivation and enhanced sensitivity to alkylating agents, whereas 
the LN428 parental cell line has endogenously low levels of MPG with no observable PARP 
activation after alkylation and no alkylation induced toxicity at the doses under study (Figure 
3, see chapter 3). This allows for the use of alkylation doses 50-100 fold less than commonly 
used to study the effects of PARP activation. We have previously reported that alkylation 
induced PARP hyperactivation leads to NAD+ depletion within an hour of exposure and ATP 
depletion within 2 hours of exposure, eventually resulting in necrotic cell death within 48 hours 
(37).  Using a whole cell measure of cellular ATP levels, we find that ATP levels are stable 15 
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minutes after exposure, but begin to drop 30 minutes after treatment with MNNG (Figure 10). 
This loss of ATP is approximately 15 minutes after the peak of PARP activation. 
 
 
Figure 10. Time course of global depletion of ATP after PARP hyperactivation 
Global ATP levels begin to decrease 30 minutes after DNA damage. Global ATP levels were measured by ATPlite 
assay 15 minutes after MNNG treatment at the indicated MNNG doses (left panel) or 30 minutes after MNNG 
treatment at the indicated MNNG doses (right panel) in both parental LN428 cells and LN428/MPG cells. ATP 
levels shown are the average of three independent experiments ± S.E and are reported as percent control of the 
untreated control cell line. 
*Represents statistical significance with a p < 0.05 compared to the LN428 cell line treated at the same dose. 
 
 
Despite reports attempting to determine which NAD+ compartments are critical for PARP 
mediated cell death, it has not been determined in which subcellular compartments ATP is 
depleted after alkylation induced PARP hyperactivation. Imamura et. al. recently published the 
generation and validation of FRET based ATP sensors with subcellular targeting sequences, in 
which the ε subunit of the Bacillus subtilis F0F1-ATP synthase is fused with CFP and mVenus 
resulting in a FRET signal when ATP is bound (65). Therefore, utilizing live cell imaging, loss 
of ATP after treatment can be measured as a loss of FRET signal. These constructs are fused to 
either nuclear or mitochondrial targeting sequences, allowing the visualization of ATP depletion 
in specific subcellular compartments. We have used these ATP FRET sensors to answer the 
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questions of where in the cell ATP is lost after alkylation damage and PARP hyperactivation, 
and what are the kinetics of subcellular ATP loss. An increase in CFP signal indicates a loss of 
ATP bound to the FRET sensor, thus an increase in CFP/YFP ratio above 1 indicates loss of ATP 
in relation to the baseline measurement. In the LN428 and LN428/MPG glioblastoma cells the 
subcellular FRET plasmids were transiently transfected 48 hours prior to the experiment. A ten-
minute baseline of FRET ratio was taken prior to the addition of 5µM MNNG. Surprisingly, 
mitochondrial ATP was lost most rapidly, with an observed loss of ATP beginning at 22 
minutes, followed by the cytosolic and nuclear compartments, which both begin to lose ATP at 
34 minutes after alkylation (Figure 11 and 12). In the LN428 cells, which show no visible 
PARP activation after alkylation damage, there is no change in FRET ratio at these low doses of 
alkylation (Figure 11).  
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Figure 11.  Measurement of subcellular ATP loss after PARP hyperactivation 
Depletion of ATP occurs in all subcellular compartments after DNA damage. The FRET ratio was calculated for 
either LN428/MPG cells (top panel) or LN428 cells (bottom panel) transfected with the indicated subcellular FRET 
sensor. Images were acquired every minute. A ten-minute baseline measurement period was followed with treatment 
of 5µM MNNG as indicated by the orange arrow. FRET traces shown are the mean of 7-9 cells (top panel) or 5-7 
cells (bottom panel) ± S.E. 
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Figure 12. Images of ATP FRET before and after treatment 
(A) Cytosolic ATP probe before alkylation (left) or after alkylation (right). Images shown as the ratio of CFP/YFP 
with high CFP (ATP loss) indicated as increasingly red. 
(B) Mitochondrial ATP probe before alkylation (left) or after alkylation (right). 
(C) Nuclear ATP probe before alkylation (left) or after alkylation (right). 
 
 
 
 
 
 
  58 
Alkylation induced PARP activation leads to acute inhibition of glycolysis and loss 
of mitochondrial capacity. 
The ATP generating pathways of glycolysis and mitochondrial oxidative phosphorylation 
require NAD+ and NADH cofactors. Given that PARP consumes NAD+ it serves to reason that 
NADH and other NAD+ metabolite and precursor pools will also be affected. Whole cell 
measurement of NAD+ and NADH show loss of both cofactors 30 minutes after alkylation 
(Figure 13).  
 
Figure 13. Loss of NAD+ and NADH 30 minutes after PARP hyperactivation 
Both global NAD+ and NADH are depleted after DNA damage. Global NAD+ and NADH levels were measured as 
described in materials and methods after 30 minutes of treatment with either media control (white bars) or 5µM 
MNNG (black bars). NAD+ and NADH levels shown are the average of three independent experiments ± S.E and 
are reported as percent control of the untreated cell line. 
*Represents statistical significance with a p < 0.05 
 
This data combined with the previously observed loss of ATP in both the mitochondrial and 
cytosolic compartments led us to investigate to what degree glycolysis and oxidative 
phosphorylation are compromised after alkylation treatment. In order to measure both oxidative 
phosphorylation and glycolysis concurrently in live cell culture conditions we utilized the 
Seahorse Extracellular Flux Analyzer and the standard protocol for measurement of overall 
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metabolic profiles determined by the subsequent addition of the metabolic inhibitors oligomycin, 
FCCP, 2-deoxyglucose and rotenone. Previous studies from Swanson and colleagues have 
demonstrated that PARP activation acts as a glycolytic block in mouse astrocyte cultures and that 
repletion of NAD+ can rescue glycolysis and PARP mediated cell death (48, 131). Consistent 
with these reports, one hour after alkylation treatment the LN428/MPG cell line (under 
conditions that lead to high levels of PARP activation) has basal levels of glycolysis 10 fold less 
than untreated wells, whereas the LN428 cells showed no glycolytic defect (Figure 14; bottom 
panel). In addition, the LN428/MPG cells retain their basal levels of OCR coupled to ATP 
production, but have severely reduced mitochondrial reserve capacity (calculation described in 
materials and methods), a novel mitochondrial defect not able to be observed in the set up of past 
studies that used mitochondrial extraction to measure oxidative phosphorylation (Figure 14; top 
panel). The LN428 cells (with no observable PARP activation or NAD+ depletion) do not show 
reduced glycolytic levels (Figure 14; bottom panel); however, they do have an apparent 
decrease in mitochondrial reserve capacity (Figure 14; top panel). This latter result indicates 
that mitochondrial reserve capacity is either affected by alkylation directly or that very low levels 
of PARP activation are capable of disturbing mitochondrial reserve capacity. 
 
 
 
 
 
 
 
  60 
(A) 
 
(B) 
 
Figure 14. Measurement of MNNG induced metabolic changes 
(A) MNNG induces reduction of mitochondrial reserve capacity. Seahorse measurement of the OCR metabolic 
profile were performed in the LN428 or LN428/MPG cells treated with either media control or 1 hour MNNG at 5 
µM. Bar graphs representing ATP coupled OCR and total reserve capacity are shown to the right. Data shown is the 
mean of two independent experiments ± S.E for seahorse traces or ± S.D. for calculated ATP coupled OCR and 
reserve capacity. 
*Represents statistical significance with a p < 0.05 
(B) MNNG induces loss of glycolysis in LN428/MPG cells. Seahorse measurement of the ECAR metabolic profile 
were performed in the LN428 or LN428/MPG cells treated with either media control or 1 hour MNNG at 5 µM. Bar 
graphs representing basal ECAR and oligomycin induced ECAR is shown to the right. Data shown is the mean of 
two independent experiments ± S.E for seahorse traces or ± S.D. for calculated basal ECAR and oligomycin induced 
ECAR. 
*Represents statistical significance with a p < 0.05 compared to media control for basal ECAR  
** Represents statistical significance with a p <0.05 compared to media control for oligomycin induced ECAR  
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To further elucidate the role of PARP hyperactivation on cellular metabolism, the PARP 
inhibitor, PJ34, was used. Thirty minute pretreatment and co-treatment of 2µm PJ34 with 
MNNG is capable of reducing PAR levels observed by immunoblotting for PAR and is capable 
of preventing alkylation induced cell death in a short-term cytotoxicity assay (37). The glycolytic 
defect in LN428/MPG cells is completely ameliorated by PARP inhibition (Figure 15).  
 
 
Figure 15. PARP inhibition rescues MNNG-induced glycolytic defect 
Treatment with PARP inhibitor PJ34 rescues glycolytic defect. Seahorse measurement of the ECAR metabolic 
profile were performed in LN428/MPG cells treated with either media control or 2 µM PJ34 for 30 minutes prior to 
a 1 hour treatment with either media control, PJ34, MNNG or PJ34 + MNNG . MNNG was used at a dose of 5 µM. 
Bar graphs representing basal ECAR and oligomycin induced ECAR is shown to the right. Data shown is the mean 
of two independent experiments ± S.E for seahorse traces or ± S.D. for calculated basal ECAR and oligomycin 
induced ECAR. 
*Represents statistical significance with a p < 0.05 compared to media control for basal ECAR  
†Represents statistical significance with a p < 0.05 compared to PJ34 + MNNG for basal ECAR  
** Represents statistical significance with a p <0.05 compared to media control for oligomycin induced ECAR  
††Represents statistical significance with a p <0.05 compared to PJ34 + MNNG for oligomycin induced ECAR  
 
PJ34 rescues the mitochondrial reserve defect shown in the LN428 cells, strongly suggesting that 
low levels of PARP activation influence mitochondrial capacity as opposed to direct alkylation 
damage of mitochondrial components (Figure 16). Interestingly, the large defect in 
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mitochondrial reserve capacity in LN428/MPG cells is only reversed by about 50%. Taken 
together with the LN428 data this suggests that PAR may act in a dose dependent manner on 
reserve capacity and that reserve capacity is extremely sensitive to low levels of PAR. PJ34 
(2µM) completely rescues the mitochondrial defect in the LN428 cells with low levels of PAR 
present after damage; however, in the LN428/MPG cells with high levels of PAR, PARP 
inhibition results in a 50% decrease in reserve capacity, presumably from low levels of residual 
PAR generation.  
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(A) 
 
(B) 
 
Figure 16. PARP affects mitochondrial reserve capacity in a PAR dose-dependent manner 
(A) Treatment with PARP inhibitor PJ34 reverses mitochondrial reserve capacity defect in LN428 cells. Seahorse 
measurement of the OCR metabolic profile were performed in LN428 cells treated with either media control or 2 
µM PJ34 for 30 minutes prior to treatment with either media control, PJ34, MNNG or PJ34 + MNNG for 1 hour. 
MNNG was used at a dose of 5 µM. Bar graphs representing ATP coupled OCR and total reserve capacity are 
shown to the right. Data shown is the mean of two independent experiments ± S.E for seahorse traces or ± S.D. for 
calculated ATP coupled OCR and reserve capacity. 
*Represents statistical significance with a p < 0.05 compared to media control for ATP coupled OCR  
†Represents statistical significance with a p < 0.05 compared to PJ34 + MNNG for ATP coupled OCR 
** Represents statistical significance with a p <0.05 compared to media control for OCR reserve capacity 
††Represents statistical significance with a p <0.05 compared to PJ34 + MNNG for OCR reserve capacity 
(B) Treatment with PARP inhibitor PJ34 partially reverses mitochondrial reserve capacity defect in LN482/MPG 
cells. Seahorse measurement of the OCR metabolic profile was performed in the LN428/MPG cells treated as above. 
Bar graphs representing ATP coupled OCR and total reserve capacity are shown to the right. Data shown is the 
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mean of two independent experiments ± S.E for seahorse traces or ± S.D. for calculated ATP coupled OCR and 
reserve capacity. 
*Represents statistical significance with a p < 0.05 compared to media control for OCR reserve capacity 
†Represents statistical significance with a p < 0.05 compared to PJ34 + MNNG for OCR reserve capacity 
 
 
 
However, this defect in reserve capacity does not have a strong impact on overall ATP levels 
unless reserve capacity is reduced below that of the basal level. Utilizing whole cell ATP 
measurements, PJ34 treatment is sufficient to rescue global ATP to control levels in 
LN428/MPG cells despite incomplete resolution of the spare capacity defect (Figure 17). This 
indicates that either the rescue of glycolysis is sufficient to supply 100% of the global ATP or 
that loss of spare capacity does not result in mitochondrial ATP loss unless it drops below basal 
levels (as seen in the LN428/MPG cells after MNNG treatment). Using the subcellular ATP 
FRET probes there is no detectable ATP loss in any subcellular compartment in LN428/MPG 
cells treated with PJ34 prior to MNNG, suggesting the loss of reserve capacity but maintenance 
of basal oxidative phosphorylation is sufficient to maintain mitochondrial ATP levels at least 
above the kd of the FRET probe. 
 
 
Figure 17. Incomplete rescue of mitochondrial reserve capacity does not affect ATP levels 
(A) PARP inhibition rescues global ATP loss after MNNG. Global ATP was measured via ATPlite kit in 
LN428/MPG cells either treated with media control or 2 µM PJ34 for 30 minutes prior to treatment with either 
MNNG or PJ34 + MNNG for one hour. Data shown is the mean of three independent experiments ± S.E. 
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*Represents statistical significance with a p < 0.05 compared to 0 MNNG dose 
(B) PARP inhibition reverses loss of ATP in all subcellular compartment. FRET ratio was calculated for FRET 
probes to mitochondrial, cytosolic or nuclear ATP. Cells were incubated with 2 µM PJ34 for 20 minutes prior to 
media change into imaging media containing PJ34. Images were acquired every minute. A ten-minute baseline 
measurement period was followed with treatment of MNNG to a final concentration of 5 µM . FRET traces shown 
are an average of 4-6 cells ± S.E. 
  
This PARP mediated defect in mitochondrial capacity suggests an interesting separation of 
function between NAD+ depletion dependent effects and PARP mediated effects. While a 
glycolytic block only occurs in the LN428/MPG cells with NAD+ depletion, the loss of 
mitochondrial capacity, although to different extents, is present in both the LN428 and 
LN428/MPG cell lines. PARP inhibition can reverse the effect in both cell lines indicating that 
this loss of mitochondrial capacity is PARP mediated; however, LN428 cells do not exhibit 
NAD+ loss at this dose or time point, suggesting a PARP or PAR driven mitochondrial defect 
independent of energetic depletion. 
4.3 DISCUSSION 
PARP1 plays a critical role in response to DNA damage events. In particular, PARP1 
hyperactivation by DNA damage is a prominent factor in several human disease states, such as 
ischemic injury after stroke or myocardial infarction, traumatic brain injury, Parkinson’s disease, 
meningitis and septic shock (56). In addition to its role in human disease, PARP1 hyperactivation 
is also of interest because of its involvement in the response to DNA damaging 
chemotherapeutics, such as the alkylating agent, TMZ. While PARP1 hyperactivation has been 
known to deplete cellular NAD+ and ATP levels for many years, the exact mechanism of PARP 
hyperactivation induced cell death is still a matter of debate. We have previously shown that 
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BER failure results in cell death, not through PAR mediated AIF release, but through PARP 
mediated energetic failure (37). However, the details of energetic failure on a subcellular level 
are not known. Advances in technology have allowed us to analyze the spatiotemporal kinetics 
of PARP mediated energetic depletion in live cells and has provided information about the 
process that has not been uncovered in previous studies. These novel observations on the 
subcellular consequences of PARP hyperactivation and NAD+ depletion not only further the field 
of BER inhibition and chemotherapy, but also have wide ranging implications in the above 
diseases where PARP activation plays a prominent role.  
We have seen that PARP hyperactivation rapidly lowers global ATP levels within 30 
minutes of MNNG treatment in glioblastoma cells that preferentially accumulate repair 
intermediates. Contrary to the popular hypothesis, this ATP depletion occurs in all subcellular 
ATP pools. It has been proposed that nuclear PARP activation results in cytosolic but not 
mitochondrial NAD+ depletion, a block to glycolysis and only cytosolic but not mitochondrial 
ATP loss (48, 74). Therefore, these earlier studies would suggest that cells functioning by 
glycolysis, such as rapidly proliferating tumor cells, will be sensitive to PARP hyperactivation 
and cells utilizing oxidative phosphorylation will be resistant. The results of this study suggest 
that PARP hyperactivation is more complicated than suggested by this paradigm. Nuclear PARP 
activation results in rapid depletion of mitochondrial ATP followed closely by loss of ATP in the 
cytosol and nucleus. This is a novel observation, highlighting the importance of live cell 
subcellular measurements to provide information that is overlooked by more traditional 
techniques of measurement.  
Utilizing live cell measurement of metabolic flux after DNA damage and PARP 
hyperactivation, we have been able to observe the previously reported PARP mediated glycolytic 
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block, but also a novel defect in mitochondria capacity. Without stress, oxygen consumption in 
MNNG treated and untreated cells is roughly the same after an hour; however, upon 
interrogation with metabolic inhibitors, it becomes clear that the MNNG treated cells have 
mitochondria that cannot respond to stress and lose reserve mitochondrial capacity. The control 
cells with only low levels of PARP activation after damage, due to reduced initiation of repair 
and low levels of repair intermediate accumulation, show a much milder defect in respiratory 
capacity incapable of changing subcellular or global ATP levels. An advantage to live cell 
determination of metabolic flux is the ability to modulate the system with drugs or via genetic 
manipulation, similar to those used in cytotoxicity assays. Cells treated with MNNG and PARP 
inhibitors, as analyzed with the Seahorse Extracellular Flux Analyzer, showed that both 
glycolytic and mitochondrial defects are PARP dependent. However, given the reduction of 
mitochondrial capacity in the LN428 cells, we have uncovered a novel PARP mediated but 
NAD+ independent effect on mitochondrial capacity. The nature of this mitochondrial defect is 
yet to be discovered, but presents the possibility of PAR signaling to the mitochondria as 
reported by the Dawsons or a potential direct or indirect target of PARylation in the 
mitochondria (47). Some previous studies have indicated complex 1 dysfunction after PARP 
activation (134), and it would be interesting to determine which mitochondrial components are 
affected by PARP independent of NAD+ depletion. One report has also shown PARylated 
proteins in the mitochondria after traumatic brain injury, although PARP1 is believed to be 
solely nuclear (135). The pattern and consequence of ADP ribosylation as a post translational 
modification is still very much a mystery, and understanding if these modifications can control 
mitochondrial function would be of critical interest in the field and might explain the 
significance of PARG expression in the mitochondria (136).   
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This study has uncovered a new level of information on the subcellular effects of PARP 
hyperactivaiton on metabolism and ATP pools. This data suggests that combination of metabolic 
inhibitors with treatments producing PARP hyperactivation, such as inhibition of BER along 
with TMZ, would enhance response. It also suggests that while PARP hyperactivation does 
affect oxidative phosphorylation, the overwhelming inhibition of glycolysis would make cells 
relying solely on glycolysis much more sensitive to alkylating agents than those able to use 
oxidative phosphorylation. While glioblastoma cells in culture seem capable of switching 
between energy producing sources, the hypoxic environment of the tumor may force them into 
glycolysis to support ATP levels, providing a level of selectivity for tumor cells over normal 
tissue. 
Taken together this data shows subcellular and temporal resolution of PARP mediated 
ATP depletion. Real-time live cell techniques have uncovered the predicted glycolytic block 
induced by PARP hyperactivation and cytosolic ATP depletion. However, they have also 
uncovered a novel PARP mediated mitochondrial defect, which while more subtle than the block 
to glycolysis, occurs at much lower levels of PARP activation and appears to be PAR dose-
dependent and independent of NAD+ depletion. These studies have also uncovered an 
unpredicted rapid depletion of mitochondrial ATP. This has opened a new area of investigation 
into PARP mediated control of mitochondrial function through either PAR polymer signaling or 
ADP-ribosylation of target proteins. 
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5.0  OVERCOMING TEMOZOLOMIDE RESISTANCE IN GLIOBLASTOMA 
VIA DUAL INHIBITION OF NAD+ BIOSYNTHESIS AND BASE EXCISION REPAIR 
5.1 INTRODUCTION  
Based on the previous two studies it has become apparent that BER and cellular 
energetics are linked through activation of the protein PARP.  The mechanistic link between 
these two pathways opens the possibility for enhancement of BER failure through modulation of 
cellular energetic pathways. BER failure can be induced through treatment with chemical BER 
inhibitors in combination with TMZ (30, 69). This current study proposes to exploit the above 
mechanistic studies for the benefit of cancer patients by combining inhibition of NAD+ 
biosynthesis with BER inhibition and TMZ in a proof of concept pre-clinical study. 
Glioblastoma multiforme (GBM) is a devastating form of brain cancer with a dismal 
median survival time, a high level of resistance to current therapy and common recurrence after 
treatment (137). The current standard therapy for GBM includes maximum debulking surgery, 
radiation and treatment with the monofunctional alkylating agent temozolomide (TMZ), also 
referred to as Temodar® (2). Despite the current standard treatment regimen, including the 
addition of concomitant and adjuvant TMZ, the average survival expectancy is 14.6 months and 
the overall 5-year survival rate for GBM is 9.8% (8) 4). TMZ generates a spectrum of DNA 
lesions including O6-methylguanine, N3-methyladenine and N7-methylguanine (Table 1) (61). 
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The O6-methylguanine lesion is responsible for most of the TMZ associated toxicity and is a 
substrate for direct repair by O6-methylguanine-DNA methyltransferase (MGMT) (138). In the 
absence of MGMT repair, O6-methylguanine is suggested to initiate a futile cycle of mismatch 
repair (MMR) or alternately to trigger ataxia telangiectasia and Rad3 related protein kinase 
(ATR) activation through the action of several MMR proteins (15), leading to apoptosis and cell 
death (139-141). Much of the resistance to TMZ observed clinically is due to high expression of 
MGMT (and subsequent repair of the lesion) or loss of MMR (therefore preventing the initiation 
of apoptotic signalling) (3, 17, 18). Additionally, almost all patients eventually recur with the 
disease and the large majority of recurrent tumors are resistant to chemotherapy (19, 20). There 
are currently few alternate treatment options for patients with TMZ resistant tumors and adjuvant 
chemotherapy options are an area of intense research (137). 
The N7-methylguanine and N3-methyladenine adducts make up the majority of the TMZ 
lesions and are base excision repair (BER) substrates.  However, these DNA adducts elicit little 
toxicity under current therapeutic strategies due to rapid repair by BER (13, 142). Hence, small 
molecules targeting BER have become an attractive option for enhancing TMZ toxicity 
independent of the cytotoxicity related to the O6-methylguanine DNA lesion. Repair of the 
alkylation induced DNA lesions N3-methyladenine and N7-methylguanine proceeds primarily 
through the short patch BER pathway (22). DNA polymerase ß (Polß) has been shown to be the 
rate-limiting step in BER and loss of Polß leads to increased sensitivity to the N3-methyladenine 
and N7-methylguanine lesions due to the accumulation of repair intermediates (13, 37, 83). 
Alternatively, blocking the abasic site formed during the BER process with the chemical 
inhibitor methoxyamine (MX) (also referred to as TRC102) has also been shown to enhance 
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alkylation sensitivity independently of the O6-methylguanine lesion (30-32). Thus, strategic 
targeting of BER can enhance TMZ efficacy regardless of MGMT or MMR status. 
We have recently reported that cell death due to incomplete BER is mediated through 
poly(ADP-ribose) polymerase (PARP) hyperactivation and subsequent NAD+ and ATP depletion 
(37). The PARP1 (ARTD1) and PARP2 (ARTD2) proteins (143) act as sensors of incomplete 
BER and become hyperactivated, consuming NAD+ as a substrate for poly(ADP-ribose) (PAR) 
synthesis (37). Consumption of NAD+ after DNA damage leads to ATP depletion, likely due to 
continued resynthesis of NAD+ as well as ongoing cellular utilization of NAD+ and ATP for 
metabolic functions (45, 100). Many reports on DNA-damage induced PARP hyperactivation 
suggest cell death occurs via PAR signaling and apoptosis inducing factor (AIF) translocation 
from the mitochondria to the nucleus leading to nuclear fragmentation (42, 46). Interestingly, the 
caspase-independent cell death observed after incomplete BER is independent of AIF 
translocation or PAR catabolite signaling (37). Further, alkylation hypersensitivity observed after 
incomplete BER can be rescued by supplementation with the NAD+ precursor NMN, supporting 
our conclusion that cell death after BER failure is an energy dependent phenotype (37). 
Therefore, we hypothesized that dual targeting of the NAD+ biosynthesis pathway and 
the BER pathway would greatly enhance TMZ sensitivity regardless of MGMT or MMR status. 
NAD+ can be synthesized through the de novo pathway from L-tryptophan, but in most 
mammalian cells NAD+ content is maintained through the NAD+ salvage pathways (144). 
Nicotinamide phosphoribosyl transferase (NAMPT) controls the salvage-pathway rate-limiting 
step for the biosynthesis of NAD+ from nicotinamide (145). The small molecule inhibitor FK866 
is a specific inhibitor of NAMPT with activity in the low nanomolar range that is highly effective 
in reducing cellular NAD+ levels (104). FK866 is currently in clinical trials (APO866) as a 
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monotherapy for the treatment of hematological cancers (146) and is reported to increase cell 
killing in combination with multiple cytotoxic agents (147). We report herein that combining 
FK866 with BER inhibition (using the small molecule BER inhibitor MX) potentiates TMZ 
tumor cell killing and strongly sensitizes glioma cells derived from chemotherapy resistant 
tumors. 
5.2 RESULTS 
PARP1 controls BER dependent PAR generation and cell death after alkylation 
exposure 
There are multiple PARP family members (143), of which PARP1 (ARTD1) and PARP2 
(ARTD2) have also been associated with the BER pathway (45, 49). To define the role of either 
PARP1 or PARP2 as the enzyme responsible for the increased generation of PAR after BER 
intermediate accumulation, stable PARP1 and PARP2 knockdown (KD) cell lines were 
generated via lentiviral shRNA expression in the LN428/MPG cells. PARP1-KD provides almost 
complete rescue of the MMS sensitivity and ATP depletion in the LN428/MPG/PARP1-KD cells 
(Figure 18) and reduces PAR levels as compared to the LN428/MPG cell line after 15 minutes 
of alkylation exposure as measured by quantitative PAR ELISA or immunoblotting for PAR 
(Figure 19). Whereas PARP2-KD had intermediate effects on rescue of cell survival and ATP 
levels (Figure 18). 
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Figure 18.  PARP1 and PARP2 knockdown effect on cell death and ATP 
(A) Cell viability of LN428/MPG cells or LN428/MPG cells with stable knockdown of either PARP1 or PARP2 
after 1 h MMS treatment, as measured by an MTS assay 48 hours after exposure. Plots show the % viable cells as 
compared to untreated (control) cells. Means are calculated from quadruplicate values in each experiment. Results 
indicate the mean ± S.E. of three independent experiments. 
(B) ATP levels after 0.5 mM MMS (striped bars) or 1.5 mM MMS (black bars) in LN428/MPG, 
LN428/MPG/PARP1-KD and LN428/MPG/PARP2-KD cell lines.  
 
Interestingly, PARP1-KD did not completely eliminate PAR generation, most likely representing 
PARP2-mediated PAR synthesis. Further, PARP1-KD had a significant effect on the kinetics of 
PAR catabolism, with the PAR signal remaining at the same level after 30 minutes exposure 
instead of the rapid PARG-mediated degradation observed in PARP1 proficient cells (Figure 
19). This leaves open the question of whether PARP2 generated PAR has different properties 
and consequences compared to PAR chains generated by PARP1. Taken together, we suggest 
that the energy depletion-mediated cell death observed after incomplete BER (BER inhibition) is 
largely PARP1 mediated with only a small contribution by PARP2. Given our recent 
understanding that tumor cell death after BER inhibition is an energy depletion-mediated 
process, we sought to take advantage of this observation by targeting the intersecting pathways 
of BER and NAD+ biosynthesis to enhance cell death in chemotherapy resistant tumors. 
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Figure 19. PARP1 and PARP2 knockdown effect on PAR generation 
(A) Cells were depleted of PARP1 or PARP2 via shRNA. PAR generation in LN428/MPG, 
LN428/MPG/PARP1KD and LN428/MPG/PARP2KD cells is shown before or after MMS exposure (15 and 30 
min.; 1.5 mM), as measured by quantitative ELISA (see Materials & Methods). All values are normalized to 
LN428/MPG signal at 15 min. exposure and reported as fold change PAR.  
(B) Immunoblot analysis of PAR generation after 0, 15 and 30 minutes of MMS exposure at a dose of 0.5 mM in 
LN428/MPG, LN428/MPG/PARP1-KD and LN428/MPG/PARP2-KD cell lines. All samples were the same as 
utilized in the quantitative PAR ELISA. The blot shown is a representative blot (N=3). 
 
Inhibition of NAD+ biosynthesis enhances alkylation induced cell death after 
incomplete BER 
Inhibition of NAD+ biosynthesis (24 hours) with FK866 reduces cellular NAD+ content 
to 25% of control levels in both parental and LN428/MPG tumor cells (Figure 20A). Consistent 
with previous reports in other cell types, this 24-hour window of NAD+ biosynthesis inhibition is 
not toxic when evaluated using a short-term (48 hour) cell survival assay (Figure 20B), but does 
exhibit significant toxicity in all these cells after 72 hours of FK866 treatment independent of 
BER status (Figure 20C) (104, 147). The lack of toxicity after 24 hours of FK866 treatment is 
attributed to recovery of NAD+ levels within 24 hours when cultured in normal media prior to 
assaying for cell survival (Figure 20A). Importantly, combining the non-toxic 24-hour window 
of NAD+ depletion immediately followed by a minimally toxic dose of MMS (0.5 mM) 
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dramatically sensitized glioma cells in a BER dependent manner (Figure 20D). This effect was 
dependent on the dose of FK866. 
 
 
Figure 20. Inhibitor of NAD+ biosynthesis FK866 enhances BER failure cell death 
(A) Cellular NAD+ levels in LN428 and LN428/MPG cells before exposure, after exposure to FK866 (10nM; 24 
hrs) and following an additional 24 hours of recovery from FK866 treatment.  
(B) Cytotoxicity profile of FK866. Viability of LN428 and LN428/MPG cells was measured by an MTS assay 48 
hours after FK866 (24 hrs) treatment and reported as percentage relative to vehicle control treated cells (% Control).  
(C) Cell survival assayed by MTS assay after prolonged exposure to FK866 in the LN428 (open circles) and 
LN428/MPG (closed circles) cell lines. Cells were treated with 10nM FK866 for 72 hours and cell survival was 
assayed after 48 hours of recovery.  
  76 
(D) Cell viability after FK866-mediated NAD+ depletion immediately followed by alkylation damage. LN428 and 
LN428/MPG cells were treated with FK866 (24 hours) at varying doses followed by 1 hour MMS treatment at 0.5 
mM. Cells were allowed to recover in normal media for 48 hours prior to analysis for cell viability by the MTS 
assay.  
 
Inhibition of NAD+ biosynthesis potentiates cell death by alkylating agents after 
BER inhibition 
 To test our hypothesis that NAD+ depletion would enhance BER inhibition-mediated cell 
death, we utilized methoxyamine (MX), a small molecule BER inhibitor that can potentiate 
alkylation damage-induced cell death (30-32) by covalently binding to the aldehydic form of the 
DNA abasic site formed after BER initiation (30). A 30 mM dose of MX (30 minute pre-
treatment) and co-treatment with MMS potentiates cell death 10-fold, consistent with previous 
reports in colon and ovarian carcinomas (Figure 21B; solid circle) (30, 32). This potentiation is 
dependent on MPG expression, as the initiating DNA glycosylase is required for abasic site 
formation after alkylation damage (Figure 21A; solid circle). MX inhibition of BER, in 
combination with FK866 inhibition of NAD+ biosynthesis, results in an IC50 for MMS of 
150µM, a sensitizer enhancement ratio (SER) of 3.125. This also yields a 2-fold decrease in IC50 
from either FK866 + MMS co-treatment or MX + MMS co-treatment (Figure 21B). 
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   LN428    LN428/MPG 
 
Figure 21. Dual inhibition of BER and NAD+ biosynthesis enhances alkylation sensitivity 
(A) Cell viability of LN428 cells measured by an MTS assay after treatment with MMS alone, MMS in combination 
with 30 mM MX, MMS in combination with 10nM FK866, or with the 3-drug combination of MX, FK866 and 
MMS. Drug treatments were carried out as described in the Materials and Methods section. Viable cells were 
determined and reported as percentage relative to vehicle control treated cells (% Control).  
(B) Cell viability measured by MTS assay in the LN428/MPG cells after treatment with MMS alone, MMS in 
combination with 30 mM MX, MMS in combination with 10nM FK866, or with the 3-drug combination of MX, 
FK866 and MMS. Drug treatments were carried out as described in the Materials and Methods section. Viable cells 
were determined and reported as percentage relative to vehicle control treated cells (% Control). SER was calculated 
as IC50 TMZ/ IC50 TMZ + sensitizer. 
 
Both FK866 and MX enhance ATP depletion after alkylation damage 
To further investigate the enhanced cell death observed when MX and FK866 are combined with 
alkylating agents, cellular ATP levels were measured after combination treatment. As expected 
(37), FK866 pre-treatment prior to alkylation damage resulted in lower levels of ATP two hours 
after MMS treatment compared to alkylation damage alone (Figure 22A). However, 24 hours of 
NAD+ depletion alone had no significant effect on ATP levels (Figure 22A; striped bars). 
Surprisingly, treatment with MX also induced loss of ATP beyond that observed by alkylation 
damage alone (Figure 22B). It is important to note that this enhanced ATP loss is only observed 
in the LN428/MPG cell line, supporting the notion that ATP loss after alkylation damage is 
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dependent on PARP hyperactivation (an event not seen in the LN428 cell line) (Figure 3).  This 
suggests that both inhibitors (FK866 and MX) enhance cell death when combined with 
alkylation by enhancing ATP loss in a BER and PARP dependent manner. 
 
 
 
Figure 22. Effect of FK866 and methoxyamine on ATP depletion after alkylation 
(A) Cellular ATP content two hours after 0.5mM MMS treatment (or media control) as measured by the ATP-lite 
luminescent kit. Results are reported as percent of untreated control. Cells were pre-treated for 24 hours with either 
10nM FK866 or media control.  
(B) Cellular ATP content two hours after 0.5mM MMS treatment (or media control) as measured by the ATP-lite 
luminescent kit. Results are reported as a percentage of untreated control. Cells were pre-treated for 30 minutes with 
MX or media control followed by co-treatment with MMS or media and post treatment as described in the Materials 
and Methods section.  
*Represents statistical significance with a p < 0.05. 
 
Dual inhibition of BER and NAD+ biosynthesis sensitizes chemotherapy resistant 
glioma cells to TMZ 
Given the strong potentiation of cell death with BER and NAD+ biosynthesis inhibition 
combined with TMZ in a 48-hour cytotoxicity assay, we investigated whether this three-drug 
combination could sensitize glioma cells harbouring established TMZ-resistant genotypes. TMZ 
resistance can result from either over-expression of MGMT or loss of MMR (3, 17, 18). LN428 
and LN428/MPG cells are both MMR positive and express low levels of MGMT. In a long-term 
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survival assay (allowing multiple rounds of replication required for O6-methylguanine-mediated 
cell death), LN428 cells are highly sensitive to TMZ (IC50 ≈ 15µM) (Figure 23).  
 
 
Figure 23. Sensitivity of LN428/MPG cells to TMZ in a long-term survival assay 
(A) Cell survival determined by a long-term survival assay after increasing doses of TMZ in the LN428/MPG cell 
line (open circles) compared to the LN428/MPG/MGMT cell line (closed circles). Results indicate the mean ± S.E 
of three independent experiments. 
 
To convert these cells to a TMZ-resistant phenotype, MGMT was stably over-expressed in the 
LN428/MPG cell line, resulting in resistance to TMZ in a long-term survival assay (Figure 
24A). MX, in combination with TMZ, sensitizes MPG positive cells with an IC50 of 160 µM 
TMZ (Table 3); however, combining FK866 pre-treatment with MX and TMZ results in an IC50 
of 17 µM, about a 10-fold decrease in IC50 and an sensitizer enhancement ratio (SER) value of 
15.88 (Figure 24A, Table 3). Knockdown of the MMR proteins MSH6, MLH1 and MSH2 also 
renders LN428/MPG cells resistant to TMZ (Figure 24B-D). However, the dual inhibition of 
BER and NAD+ biosynthesis can overcome the TMZ-resistance that results from MMR 
deficiency, yielding an increase in 75 µM TMZ response (Figure 24B-D).  
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Table 3. SER values of 3-drug combination in LN428/MPG/MGMT cell line  
Treatment IC50 (µM) SER50 
TMZ 270 1 
FK866 + TMZ 175 1.54 
MX + TMZ 160 1.68 
3-Drug combination 17 15.88 
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Figure 24. 3-drug combination in TMZ resistant LN428/MPG glioblastoma cells 
(A) Cell survival determined by a long-term survival assay in cells modified to overexpress MGMT. 
LN428/MPG/MGMT cells were treated with either TMZ alone for 12 days, 24 hours of 10nM FK866 followed by 
12 days of TMZ, a 30 minute pre-treatment of 10mM MX followed by MX (5mM) and TMZ co-treatment for 12 
days, or the three-drug combination (a 24 hour pre-treatment of FK866, followed by a 30 minute pre-treatment with 
MX and a 12 day co-treatment with MX and TMZ. TMZ was used at a 75 µm dose.   
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(B-D) Cell survival determined by a long-term survival assay in cells stably expressing shRNA to MLH1 (B), 
MSH2 (C) or MSH6 (D). LN428/MPG MMR knockdown cells were treated with either TMZ alone for 12 days, 24 
hours of 10nM FK866 followed by 12 days of TMZ, a 30 minute pre-treatment of 10mM MX followed by MX 
(5mM) and TMZ co-treatment for 12 days, or the three-drug combination (a 24 hour pre-treatment of FK866, 
followed by a 30 minute pre-treatment with MX and a 12 day co-treatment with MX and TMZ. TMZ was used at a 
75 µm dose. 
Results indicate the mean ± S.E of three independent experiments. 
*Represents statistical significance with a p < 0.05. 
 
To further investigate the utility of this drug combination in treating GBMs with 
endogenous or acquired resistance to TMZ, we utilized T98G cells, a glioma cell line with 
endogenous over-expression of MGMT (64) 38). T98G cells have robust expression of BER 
proteins as well as NAMPT and have approximately a 2-fold increase in the basal level of NAD+ 
as compared to the LN428 and LN428/MPG cells (Figure 25A), requiring cell line specific 
titering of FK866 dosing. Twenty-four hour exposure to FK866 with doses up to 80nM had 
minimal effect on cell viability in a long-term survival assay (Figure 25B). FK866 enhances 
TMZ toxicity in a dose dependent manner (Figure 25C), whereas MX, in combination with 
TMZ, yields a slight enhancement of TMZ toxicity (Figure 25D). Most importantly, the 
combination of FK866 and MX in combination significantly enhanced cell death in an FK866 
dose dependent manner beyond that of either combination alone (Figure 25D). All together, 
these results support our proposed strategy of dual BER and NAD+ biosynthesis inhibition to 
overcome TMZ resistance in primary or recurrent TMZ-resistant GBM and provides proof of 
principle data to validate future analysis in an in vivo preclinical model. 
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Figure 25. 3-drug combination effect on endogenously resistant T98G glioblastoma cells 
(A) Basal NAD+ content of the T98G cell line compared to basal NAD+ content of the LN428/MPG cell line. 
(B) Cell survival determined by a long-term survival assay in T98G cells after 24 hours of varying doses of FK866. 
(C) Cell survival determined by a long-term survival assay in the T98G cells after a 24 hour pre-treatment with 
varying doses of FK866 followed by a 6 hour exposure to 500 µM TMZ.  
(D) Cell survival determined by a long-term survival assay in T98G cells after treatment with either TMZ alone for 
6 hours, a 30 minute pre-treatment with 10mM MX followed by 5mM MX and TMZ co-treatment for 6 hours, or the 
three-drug combination with varying doses of FK866 as a 24 hour pre-treatment followed by a 30 minute pre-
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treatment with 10mM MX and a 6 hour co-treatment with 5mM MX and TMZ. A dose of 500µM TMZ was used in 
each treatment condition.  
Results indicate the mean ± S.E of three independent experiments. 
*Represents statistical significance with a p < 0.05 as compared to TMZ + MX. 
5.3 DISCUSSION 
This study presents a novel strategy to elicit tumor cell toxicity from the N3-
methyladenine and N7-methylguanine lesions induced by TMZ by targeting two interacting 
pathways: the BER and NAD+ biosynthesis pathways. The introduction of TMZ as a standard 
treatment for glioblastoma has resulted in a significant increase in response rate and median 
survival time over surgery and radiation therapy alone (4). However, 5-year survival rates still 
remain dismally low (8, 9), likely from inherent TMZ resistance and/or relapse with 
chemotherapy resistant tumors (19). Most of this resistance to TMZ is attributed to the loss of 
toxicity by the O6-methylguanine lesion via elevated expression of MGMT or a defect in the 
MMR pathway (18). However, more than 80% of the DNA lesions produced by TMZ are BER 
substrates, suggesting BER modulation is a promising therapeutic option (11). The explosion of 
clinical trials involving TMZ combined with PARP inhibitors and ongoing clinical trials of TMZ 
combined with MX highlights this point (33, 60). 
We have previously observed that inhibition of BER (via genetic modulation) combined 
with alkylation treatment leads to necrotic cell death resulting from PARP hyperactivation with 
concomitant NAD+ and ATP depletion (37). Given this model, we sought to enhance TMZ 
response by inhibiting both BER and NAD+ biosynthesis. This novel, combinatorial, 3-drug 
strategy realized a reduction of TMZ IC50 greater than ten fold in multiple models of TMZ 
resistant tumor cells as well as an endogenously resistant GBM cell line (T98G). The induction 
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of necrotic cell death as opposed to apoptotic cell death is a promising feature of this novel 
treatment combination, since a percentage of GBMs are also known to be resistant to apoptotic 
cell death (4), suggesting that this drug combination may be preferable over alternate 
chemotherapy options that induce apoptosis. While necrosis is primarily thought of as having a 
negative inflammatory impact on surrounding tissue, release of HMGB1 and other RAGE 
ligands after necrosis may aid in stimulation of the immune system and clearance of the tumor, 
thus potentially increasing the efficacy of this drug combination (43, 44). 
MX, in combination with TMZ, is currently in Phase I clinical trials for the treatment of a 
variety of solid tumors and appears to be well tolerated (33). FK866 (known as APO866) is also 
currently in clinical trials as a monotherapy and is well tolerated (146). The concern in 
combining BER inhibition and NAD+ biosynthesis inhibition is that the combination may 
critically lower energy levels and induce necrosis in healthy tissue. The high energy 
requirements and rapid NAD+ turnover of tumor cells may allow for selectivity for the 
FK866/MX/TMZ drug combination over normal tissue (148). Further, it has been suggested that 
NAD+ loss by PARP hyperactivation is cytotoxic by creating a glycolytic block (74, 149). Tumor 
selectivity may be realized from the reliance of glioblastomas on glycolysis for energy, whereas 
normal brain tissue exhibits higher levels of oxidative phosphorylation (150). Interestingly, in 
one report, up to 50% of GBMs tested were deficient in the NAPRT1-mediated NAD+ 
biosynthesis pathway responsible for generating NAD+ from nicotinic acid (NA) and in a 
separate report it was shown that NA supplementation can rescue the toxic effects of high dose 
FK866 on normal tissue (148, 151).  This also suggests an opportunity for a synthetic lethal 
approach using our novel 3-drug combination, in which healthy tissue is supplemented with NA 
while selectively killing tumor cells unable to utilize the NAPRT1 arm of the pathway. 
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Targeted NAD+ biosynthesis inhibition combined with BER inhibition plus TMZ gives a 
promising decrease in IC50 in resistant glioblastoma tumor cells. TMZ is also currently in clinical 
trials for the use with malignant melanoma, another chemotherapy resistant tumor with few 
treatment options (152). This drug combination may also prove to be useful in increasing 
efficacy of TMZ in melanoma and potentially in other tumor types that have shown little 
response to TMZ. For example, we have reported that genetic inhibition of BER in breast cancer 
cells shows similar sensitization, suggesting that this drug combination would also be useful for 
the treatment of triple-negative tumors (83). In conclusion, this study illustrates a novel 
therapeutic option for tumors resistant to the TMZ-induced O6-methylguanine lesion, by utilizing 
clinically available chemical inhibitors of the interacting pathways of BER and NAD+ 
biosynthesis.  
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6.0  CONCLUSION AND DISCUSSION 
6.1 MECHANISMS OF BER FAILURE AND PARP HYPERACTIVATION 
The previous chapters of this thesis have attempted to answer the question of how the inability to 
complete BER after alkylation damage results in hypersensitivity to alkylating agents and 
necrotic cell death. It had been previously shown by Sobol et. al. that Polß is the critical 
polymerase in repair of alkylation damage through BER and that functional loss of Polß through 
genetic means (and later through imbalance of the initiating glycosylase) results in alkylation 
hypersensitivity via accumulation of the 5’dRP BER intermediate (26, 38, 83). However, there 
has not been conclusive mechanistic data to determine how 5’dRP accumulation results in this 
cell death. We have previously determined that BER failure induced cell death is not apoptotic or 
autophagic (83). These studies confirm BER failure-induced cell death as necrotic. We have 
identified that the 5’dRP repair intermediate, if not removed by the lyase activity of Polß, leads 
to PARP hyperactiviation in response to failed repair and is causative of tumor cell death. Both 
PARP1 and PARP2 paralogues are implicated in response to DNA damage (41). These studies 
have confirmed that PARP1 is the primary PARP family member responsible for BER failure-
induced cell death with a minor contribution by PARP2.  
PARP hyperactivation in response to DNA damage has been shown to result in cell death 
through a number of mechanisms, and the exact mechanism of PARP-mediated cell death is still 
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hotly debated. We systematically tested all reported PARP mediated cell death pathways to 
determine which played a role in BER failure induced necrosis. Direct signaling of PAR 
polymers resulting in AIF release from the mitochondria to the nucleus as well as ADP ribose or 
AMP mediated cell death pathways were eliminated as possible BER failure modes of cell death. 
PARP utilizes NAD+ as a substrate to generate PAR polymers and upon hyperactivation PAR 
levels can increase up to 500 fold, resulting in significant depletion of NAD+, as previously 
observed by Berger et. al (41, 100, 101). After BER failure, NAD+ and ATP levels are severely 
depleted within 2 hours. Supplementation of the cell culture media with NAD+ precursors prior 
to treatment can rescue both alkylation-induced loss of ATP and cell viability. However, the 
long-term survival of these cells beyond the 48-hour assay time frame is unknown. It is possible 
that supplementation of NAD+ levels simply delays cell death beyond 48 hours as opposed to 
complete rescue of cell viability. Regardless, the ability of NAD+ precursor supplementation to 
enhance cell survival indicates that NAD+ depletion plays a critical role in BER failure induced 
cell death and supports the results that other cell death signaling events are not significant in 
influencing necrosis. 
While energetic depletion by PARP hyperactivation is a long standing observation, the 
detailed mechanism of how NAD+ depletion by PARP induces ATP depletion and necrosis is 
largely unresolved. A prevailing hypothesis suggests that PARP mediated NAD+ depletion 
occurs in the cytosol (48). Highly proliferating cells relying on glycolyisis to generate ATP can 
no longer utilize NAD+ to generate ATP and therefore ATP is depleted in the cytoplasm, 
resulting in necrosis. Whereas non-replicating cells utilizing oxidative phosphorylation to 
generate ATP are less affected by NAD+ depletion, mitochondrial ATP is not depleted and cells 
can undergo AIF release or apoptosis induced cell death (41). Our findings challenge this 
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hypothesis, at least in the context of glioblastomas, providing evidence that the glioblastoma cell 
lines we tested are capable of performing both oxidative phosphorylation and glycolysis and in 
fact are capable of up-regulating either process in the face of inhibition of the other. Importantly, 
we have shown that after BER failure and PARP hyperactivation, ATP is depleted from not only 
the cytosol, but is also rapidly depleted from the mitochondria several minutes sooner than from 
the cytosol or nucleus. Interestingly, not only is glycolytic function blocked by PARP 
hyperactivation, oxidative phosphorylation also shows a defect in oxidative capacity after an 
hour. Loss of capacity below the basal level of oxygen consumption seems to correlate with 
mitochondrial ATP loss, whereas less severe defects (seen in LN428 cells without PARP 
hyperactivation or in LN428/MPG cells treated with PARP inhibitor) do not influence 
mitochondrial or global ATP levels.  
Taken together this data suggest that the while glycolysis is most strongly affected by 
PARP hyperactivation, oxidative phosphorylation is also affected and that the inability to 
produce ATP from either pathway leads to necrotic cell death. Our data in the tested 
glioblastoma cell lines suggest that inhibition of either pathway alone is not sufficient to deplete 
global ATP levels despite defects in subcellular ATP pools, and therefore rescue of either ATP 
producing pathway would result in cell survival after PARP hyperactivation. This has interesting 
implications in relation to the Warburg hypothesis (153). While glioblastoma cell lines may be 
metabolically flexible in culture, in vivo metabolism might be tilted towards glycolytic tumors 
and oxidative normal tissue. Tumor microenvironments are known to be hypoxic, preventing 
efficient oxidative phosphorylation, and in vivo glioblastomas perform a significant amount of 
glycolysis as indicated by their ability to be seen on a PET scan (154). Given that tumors in vivo 
may have impaired ability to perform oxidative phosphorylation, the stronger inhibitory effect of 
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PARP hyperactivation on glycolysis versus oxidative phosphorylation may provide a means of 
tumor selective killing.  
The effect of PARP hyperactivation on mitochondrial capacity is especially interesting 
given that even very low levels PARP activation, as seen in cells not accumulating repair 
intermediates, results in a decrease in mitochondrial capacity but not basal levels of oxidative 
phosphorylation after treatment. Especially important is the observation that this PARP-mediated 
decrease in capacity is measurable even in the absence of significant NAD+ depletion, suggesting 
a novel PARP dependent but NAD+ independent defect in mitochondrial function. This defect 
seems to be PAR dose dependent, with high PAR levels resulting in a much more severe defect 
where, despite normal basal oxygen consumption, mitochondria appear to be unable to recover 
oxygen consumption ability after any stress (such as oligomycin injection) regardless of later 
uncoupling. Real-time measurement of metabolic function has shed a unique light on this 
process. Given that basal oxygen consumption is the same in treated and untreated cells 
regardless of PARP hyperactivation and mild decreases in capacity do not change ATP 
production, it is unlikely this phenomenon would have been observable using traditional 
metabolic measures.  
How PARP is influencing mitochondrial function independently of NAD+ or NADH 
reduction is still an open question. The possibility of alkylation damage to the mitochondria 
alone is ruled out by the rescue of the defect by PARP inhibition. Given the rapid appearance of 
the defect, within an hour of treatment, the potential of mitochondrial DNA damage resulting in 
mitochondrial protein dysfunction is unlikely. It is possible that PARP is PARylating a 
mitochondrial protein or a signaling protein upstream of mitochondrial function. Despite the 
well-established belief that PARP1 is solely nuclear, there have been reports of PARylated 
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proteins in the mitochondria after traumatic brain injury (135). Another potential scenario is that 
free PAR polymers themselves are resulting in a mitochondrial defect. The Dawson group has 
shown injection of long complex PAR polymers alone results in AIF translocation and cell death 
(42). However, given the lack of AIF translocation after BER failure, it is unclear if free PAR 
would still result in a mitochondrial defect. In line with our data, other groups have reported 
complex I dysfunction after PARP hyperactivation and reduced oxygen consumption in mouse 
cardiomyocytes after myocardial infarction (134), although it is not determined whether this is 
PARP dependent or NAD+ dependent. Determining the cause of PARP mediated mitochondrial 
dysfunction could have important implications not only in cancer treatment but more importantly 
in the rescue of normal tissue either after chemotherapy or in conditions such as ischemia 
reperfusion, myocardial infarction or Parkinson’s disease that result in PARP hyperactivation 
given the strong preference for oxidative phosphorylation in non-replicating cells such as 
neurons. 
6.2 POTENTIAL ROLE OF AMPK IN BER FAILURE 
One of the most intriguing and unexplained pieces of data to date in the lab is the observation 
that genetic manipulation resulting in BER failure (depletion of Polß or overexpression of MPG), 
does not always result in sensitivity to alkylating agents. This is observed in two pairs of cell 
lines in both the glioblastoma model cell lines and in breast cancer model cell lines. LN428 and 
MDA-MB-231 cells, with a functional Polß defect, are sensitive to alkylating agents via necrosis 
in a 48-hour toxicity assay (37, 83). T98G and MCF-7 cell lines, despite the same Polß defect, 
show no cell death in 48 hours (Figure 25). The most immediate hypothesis is a defect in PARP 
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activation in the latter cell lines; however, PAR generation in both T98G (data not shown) and 
MCF-7 (Figure 26) is strongly enhanced after alkylation treatment similar to the sensitive cell 
lines. This suggests a differential response to PARP hyperactivation on the level of cellular 
energetics. 
(A)  MDA-MB-231    MCF-7 
 
(B) 
 
Figure 26. BER failure does not always result in sensitivity to alkylating agents 
(A) Short term survival measured by MTS of MDA-MB-231 (left pane) and MCF-7 (right panel) breast cancer cells 
either proficient or deficient in Pol ß function.  
* Killing curve data courtesy of Dr. Ram Trivedi (MDA-MB-231 (83), MCF-7 unpublished) 
(B) Immunoblot of PAR in MDA-MB-231 and MCF-7 cells treated with 5µM MNNG for either 0, 15 or 30 
minutes. 
 
One possibility that could fit with the Warburg hypothesis (153) and Craig Thompson’s report 
(74) is that sensitive cell lines are primarily glycolytic and therefore are more sensitive to the 
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PARP mediated glycolytic block, whereas resistant cell lines rely more on oxidative 
phosphorylation and hence survive. Previous data from our group and the Van Houten group 
showed no consistent trend in the amount of oxidative metabolism versus glycolysis in the two 
groups of sensitive versus resistant cell lines (data not shown).  
Since there is no difference in basal metabolism, it is highly possible that the difference 
in sensitivity to PARP activation could be dependent on energetic signaling pathways. Of these, 
one of the most obvious possibilities is AMPK. In the presence of low ATP or elevated AMP, 
AMPK represses processes that utilize energy and initiates processes that restore or conserve 
ATP (155). Upon ATP depletion, AMP levels increase and bind to AMPK, inducing a 
conformational change that allows Thr-172 phosphorylation by upstream kinase LKB1 and 
activation of AMPK (156). There are reported differences in LKB1 status in MDA-MB-231 
versus MCF-7 cells. MDA-MB-231 cells have a known LKB1 mutation resulting in non-
functional LKB1, whereas MCF-7 are wild-type for LKB1 (157, 158). Overexpression of either 
wild-type LKB1 or dominant negative LKB1 in MDA-MB-231 cells was sufficient to reverse the 
BER failure induced alkylation hypersensitivity (Figure 27). So far this has only been shown in 
the breast cancer model system. While LN428 glioblastoma cells do not have a defect in LKB1 
protein expression (data not shown), it is very possible that they have other defects either in 
upstream or downstream signaling pathways that would result in the same phenotype as seen in 
MDA-MB-231 cells. Showing that AMPK related defects in both tumor type model systems are 
responsible for sensitivity to alkylating agents would significantly strengthen the hypothesis that 
LKB1/AMPK regulate sensitivity to BER failure. 
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Figure 27. LKB1 expression can rescue BER failure induced MNNG sensitivity 
Short term survival measured by MTS of MDA-MB-231 with either proficient or deficient BER and stable 
transfection of either LKB1 or LKB1 kinase dead mutant (right panel). Immunoblot of generated cell lines is shown 
in the left panel. 
*Cell line generation and validation via immunoblot courtesy of Xiao-Hong Wang 
 
The mechanism behind LKB1 mediated survival of BER failure and necrotic cell death is 
unknown. It is also appears that LKB1 mediated survival is not maintained long term. T98G cells 
with BER defects or BER inhibition are sensitive to alkylating agents in the long term, and this 
cell death is enhanced by FK866 depletion of NAD+. Whether LKB1 expression simply delays 
energetic collapse and necrosis beyond the 48-hour time point or whether it switches cells to an 
apoptotic mode of cell death after BER failure is unknown. Although it is yet to be confirmed 
whether AMPK is differentially activated between the two cell lines, there are two potential 
mechanisms for LKB1 mediated rescue or delay of BER failure induced necrosis based on the 
current literature: 1) induction of autophagy and energetic rescue or 2) modulation of energy 
producing pathways. 
 Mammalian target of rapamycin (mTOR) signaling promotes cell growth and 
proliferation processes and inhibits autophagy and other catabolic processes. AMPK suppresses 
  95 
mTOR and results in activation of autophagy (159). Autophagy is an evolutionarily conserved 
process by which cellular contents and organelles are sequestered by double membrane vesicles, 
called autophagasomes, and delivered to the lysosome for degradation and recycling of cellular 
macromolecules (160).  Autophagy is often activated in situations of energy starvation and can 
provide energy for the cell to survive by fatty acid oxidation or amino acid liberation (161). 
AMPK-mediated autophagy has been previously shown to rescue PARP activation induced cell 
death by hydrogen peroxide, reportedly through providing cell catabolites to rescue energy 
depletion by PARP (113,159). Although the initial papers reporting PARP mediated induction of 
autophagy have since been withdrawn, citing concerns on the validity of the data, another group 
has independently shown similar results with multiple DNA damaging agents, including 
alkylating agents (162). Very recently AMPK has also been shown to directly activate autophagy 
through phosphorylation of unc-51-like kinase 1 (ULK1) by both the Guan and Shaw groups 
(163, 164). Determining if autophagy induction is occurring and resulting in temporary or long-
lived rescue of ATP loss in the BER failure resistant cells (MCF7 and T98G) would be of intense 
interest. This would link BER not only with cellular NAD+ biosynthesis and metabolic pathways, 
but also with the autophagic pathway. Another interesting question is: if AMPK is indeed being 
activated by BER failure and PARP hyperactivation what is initiating this activation? While ATP 
depletion may explain activation of AMPK by changing ATP/AMP ratios, it is also possible that 
the breakdown of PAR itself creates the AMP needed to activate AMPK. PARG breakdown of 
PAR results in ADP-ribose, which can be further broken down by NUDIX enzymes to AMP and 
ribose 5-phosphate (165). The ability of PARG levels to dictate AMP levels after PARP 
hyperactivation would be a novel link between PARP and AMPK. 
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 The other potential mechanism for LKB1 and AMPK rescue of BER failure is 
enhancement of energetic pathways through AMPK. AMPK is known to enhance mitochondrial 
biogenesis and capacity (155), although given the short time frame in which energetic depletion 
occurs after PARP hyperactivation, the likelihood of AMPK mediated up-regulation of 
mitochondria content through transcription factors is small. Resistant cell line models do not 
exhibit consistently higher levels of oxidative phosphorylation on the Seahorse extracellular flux 
analyzer, making a higher basal mitochondrial content less likely. There are some indications 
that LKB1 is upstream of induction of NAMPT (166, 167). NAMPT has been shown to be 
critical in controlling survival after PARP hyperactivation by both our group and others (130).  It 
is interesting to speculate that cells lacking LKB1 may have lower NAMPT levels and therefore 
be more sensitive to BER failure induced energetic collapse compared to cells with intact LKB1 
signaling. 
Interestingly, recent papers have implicated PARP inhibition or knockdown of either 
PARP1 or PARP1 with the activation of SIRT1, potentially through increased levels of NAD+ 
(168, 169). In fact SIR2 activity has been linked to NAD/NADH ratio (170). It is possible that 
PARP hyperactivation and reduction of NAD+ could decrease SIRT family protein activity 
resulting in hyperacetylation of proteins. Pillai and colleagues have shown that SIRT3 (a 
mitochondrial protein) may be upstream of LKB1 and control down stream activation of AMPK. 
The role of SIRT family members in controlling sensitivity to BER failure would be timely and 
interesting research to pursue as a follow up to these studies. Potentially of the most interest 
would be the link between SIRT3 and complex 1 function (171). Reduction of NAD+ resulting in 
a reduction of SIRT3 deacetylation of complex 1 and loss of complex 1 function could be a 
potential explanation for mitochondrial defects seen after PARP activation. 
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6.3 THERAPEUTIC IMPLICATIONS OF THIS WORK 
The mechanistic data put forth in this thesis, explaining the mode of BER failure induced cell 
death and detailing the effects of PARP activation on metabolic processes has provided critical 
information on how targeting of the BER pathway in combination with alkylating agents may 
result in tumor cell death independent of O6-methylguanine. It has also highlighted the 
usefulness of dual targeting strategies inhibiting both BER and cellular energetic pathways that 
control PARP-mediated necrosis. We have shown in cell culture glioblastoma models that 
inhibiting BER via methoxyamine and NAD+ biosynthesis through FK866 can sensitize O6-
methylguanine resistant tumors irrespective of their mode of TMZ resistance.  
Publication from Dr. Jiang-bo Tang in the Sobol laboratory has demonstrated that 
cytotoxicity by inhibition of BER by either MX or PARP inhibitors in combination with TMZ is 
enhanced by imbalanced BER (high levels of initiation and low levels of repair by Polß)(87). 
Despite MX trapping abasic sites prior to APE1 nuclease activity and subsequent Polß gap 
tailoring, Polß expression can decrease MX + TMZ induced toxicity. This suggests that the 
presence of Polß enhances repair and reduces residency of abasic sites for modulation by 
methoxyamine (87). MPG and Polß levels varied significantly among glioblastoma cell lines and 
glioblastoma tissue (87). MPG and Polß levels may be useful in predicting which tumors would 
best respond to BER failure induced by BER inhibition and TMZ combination treatment. In a 
similar manner high MPG and low Polß levels would also enhance dual targeting of BER and 
energetic pathways, as these are the tumors most likely to have high levels of PARP activation. 
The use of methoxyamine also provides some interesting insights on the substrates of 
PARP.  Genetic loss of Polß function results in generation of the 5’dRP repair intermediate that 
acts as a substrate for PARP resulting in PARP hyperactivation, a result confirmed by the rescue 
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of BER failure by WT-Polß but not K72A-Polß, the 5’dRP lyase dead mutant. Methoxyamine, 
however, inhibits BER several steps upstream of Polß function, at the formation of the abasic site 
by MPG. Unexpectedly, this inhibition also results in enhanced ATP depletion as compared to 
alkylation alone, suggesting enhanced PARP activation by MX trapped abasic sites. 
Immunoblots of PAR after MX + MMS versus MMS alone do not show a conclusive difference 
in PAR generation in LN428/MPG cells, although using quantitative analyses (PAR ELISA), this 
may now be able to be evaluated.  
While MX is effective in enhancing BER inhibition induced ATP depletion and enhances 
cell death in combination with FK866, it may be that other BER inhibitors are better options for 
combination therapy. One important note is that inhibition of BER by PARP inhibitors would not 
be effective as a dual targeting strategy with FK866 or other inhibition of other energetic 
pathways given the dependence of energy depletion and BER failure induced necrosis on PARP 
activity. The ideal target for BER inhibition in this case would be Polß, enhancing the 
accumulation of the 5’dRP intermediate known to activate PARP. Generation of novel selective 
Polß inhibitors is an area of active research in the field (39). Of these inhibitors, those blocking 
Polß 5’dRP lyase activity would be of the most use in dual targeting strategies. Testing of a 
library of lead compounds for novel Polß 5’dRP lyase inhibitors is a project ongoing in the Sobol 
lab. Any potential Polß inhibitors found in this screen could be combined with FK866 and TMZ 
for a new dual targeting combination. 
Clearly, the next step in testing the current dual targeting strategy combining TMZ, MX 
and FK866 or for testing future dual targeting combinations will be mouse xenograft models. 
While cell culture experiments indicate efficacy of the drug combination on tumor cells, they tell 
nothing of systemic effects (damage to rapidly proliferating tissue and bone marrow is of most 
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concern) or interaction with the tumor microenvironment. Although LN428 cells are not 
tumorogenic when injected, there are glioblastoma xenograft models that can be utilized to test 
the drug combination, either through subdermal implantation or stereotactic injection of tumor 
cells into the brain. Mouse studies showing efficacy of the drug combination in arresting 
glioblastoma tumor growth or showing tumor regression without unacceptable toxicity to normal 
tissue will be critical for moving the proof of principle experiments into the clinic.   
Selective killing of tumor cells and sparing of normal tissue is a constant battle in the 
design of chemotherapeutic treatments. DNA damaging agents are used as chemotherapy based 
on the fact that tumor cells proliferate more rapidly than normal tissue, providing the first level 
of selectivity for the combination treatment. As previously mentioned, there appears to be a large 
variability in BER protein levels in tumor tissue that may enhance BER failure beyond that seen 
in normal tissue. The inherent differences in tumor metabolism versus normal tissue metabolism 
may provide a reasonable amount of tumor selectivity for the dual targeting therapy. Tumor cells 
have increased NAD+ turnover due to rapid proliferation and altered metabolism, making them 
potentially more sensitive to NAD+ depletion by PARP activation and FK866 (104). In fact this 
is the basis for the use of FK866 as a monotherapy now being tested in clinical trials against 
various cancers (146). The tendency of glioblastomas in vivo at least to rely more heavily on 
glycolysis may also enhance response to BER failure and energy depletion (172).   
Another interesting possibility for tumor specificity with this treatment would be the 
potential for targeting Rb null cells. It has been shown the Rb null cells are more susceptible to 
DNA damage induced cell death mediated by PARP hyperactivation, due to loss of cell cycle 
checkpoints (173). Up to 50% of malignant gliomas have deletion of the Rb locus (1). In this 
case, Rb status could predict glioblastomas that may be more sensitive to dual targeting by BER 
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and NAD+ biosynthesis inhibition due to checkpoint abnormalities. This genetic difference 
between tumor and normal tissue could give a greater therapeutic index in Rb null cells than in 
tumor cells without this defect. 
There is however the possibility that dual targeting strategies of BER and NAD+ 
biosynthesis in combination with TMZ will prove too toxic for normal tissue. In that case the 
dual targeting may be best suited for use in cases where it can be used to induce a synthetic lethal 
effect. In a recent report roughly 50% of glioblastomas tested had reduced levels of the NAD+ 
biosynthetic enzyme NAPRT1 (148). The Sobol lab has independently begun to analyze 
NAPRT1 levels in both adult and pediatric glioblastoma tissue slides and is currently developing 
an antibody to NAPRT1 that can be utilized for immunohistochemistry and immunoblot analysis 
of cell lines and tumor tissue. NAMPT is required to catalyze the second to last step in NAD+ 
biosynthesis from the nicotinamide salvage pathway catalyzing the production of NMN from 
nicotinamide, whereas NAPRT1 functions in an alternate route of NAD+ synthesis by catalyzing 
the eventual production of NAD+ from nicotinic acid independent from NAMPT activity (174). 
In this case it may be possible to supplement patients with nicotinic acid, also known as niacin 
and available in drug stores, in order to rescue NAD+ levels in normal tissue but not tumor tissue 
during treatment with FK866, a BER inhibitor and TMZ. This strategy has been validated as able 
to rescue normal tissue from FK866 monotherapy (175). 
A final note on the therapeutic potential of dual targeting is that this work demonstrates 
combination with NAD+ biosynthesis inhibitors, such as FK866, should enhance any treatment 
that strongly induces PARP hyperactivation. It has recently been shown that cisplatin treatment 
can result in PARP hyperactivation (127). It will be interesting moving forward to see if FK866 
or other metabolic inhibitors will enhance cisplatin treatment. While cisplatin is not generally 
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used for the treatment of glioblastoma, it is used as treatment for many other cancers such as 
bladder, ovarian and testicular cancers (176). 
6.4 SUMMARY 
In summary, this study has shown a mechanistic link between cellular energetic pathways and 
the BER pathway. Over 80% of the lesions generated by TMZ are BER substrates that elicit little 
toxicity in tumors due to robust BER repair. Given the large percentage of glioblastomas that are 
resistant to O6-methylguanine mediated cell death, finding ways to enhance cell death from the 
BER substrates N7-methylguanine and N3-methyladenine is of great importance in advancing 
glioblastoma treatment. We have linked inability to complete BER (BER failure) with activation 
of PARP and consumption of NAD+.  Further we have shown that PARP hyperactivation 
depletes not only global ATP levels, but also mitochondrial, nuclear and cytosolic ATP pools. 
We have linked this loss of subcellular ATP with inhibition of glycolysis and disruption of 
mitochondrial capacity. Using the mechanistic insights gained we have established that BER 
inhibition induced necrosis can be enhanced by addition of inhibition of the energetic pathways 
that interact with it. NAD+ biosynthesis inhibition by FK866 enhanced BER failure induced cell 
death by combining MX-induced BER inhibition with the alkylating agent TMZ. This dual 
targeting of pathways combined with alkylating agents overcame chemotherapy resistant 
glioblastoma cell survival regardless of their mode of O6-methylguanine resistance, providing 
proof of concept for further pre-clinical and clinical studies. 
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www.aacrBase excision repair (BER) protein expression is important for resistance to DNA damage–induced cytotoxi-
city. Conversely, BER imbalance [DNA polymerase β (Polβ) deficiency or repair inhibition] enhances cytotoxicity
of radiation and chemotherapeutic DNA-damaging agents. Whereas inhibition of critical steps in the BER path-
way result in the accumulation of cytotoxic DNA double-strand breaks, we report that DNA damage–induced
cytotoxicity due to deficiency in the BER protein Polβ triggers cell death dependent on poly(ADP-ribose) (PAR)
polymerase activation yet independent of PAR-mediated apoptosis-inducing factor nuclear translocation or PAR
glycohydrolase, suggesting that cytotoxicity is not from PAR or PAR catabolite signaling. Cell death is rescued
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on cellular metabolite bioavailability. We offer a mechanistic justification for the elevated alkylation-induced
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Efficacy of chemotherapy or radiation treatment is inti-
mately dependent on DNA repair capacity (1). Robust re-
pair of therapeutically induced DNA damage can provide
significant resistance, whereas tumor-specific defects in
DNA repair or inhibition of specific DNA repair proteins
can provide therapeutic advantage (2). In particular, inhi-
biting base excision repair (BER) can be an effective means
to improve response to temozolomide, radiation, bleomy-
cin, and cisplatin, among other treatments (3-10). As with
most DNA repair pathways, BER is a multistep mecha-
nism composed of >20 proteins depending on the initial
base lesion (3). However, inhibiting each step in the
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mcr.aacrjournaDownloaded from lase inhibition or loss blocks BER initiation, leading to the
accumulation of both cytotoxic (4) and mutagenic base le-
sions (5), the latter contributing to cellular dysfunction. In
this regard, the preferred option is the inhibition of BER
after repair initiation, promoting the accumulation of cy-
totoxic BER intermediates such as abasic sites and DNA
single-strand breaks by inhibiting abasic site repair with
methoxyamine and inhibiting the BER enzyme poly
(ADP-ribose) polymerase 1 (PARP1) or by loss or inhibi-
tion of DNA polymerase β (Polβ; refs. 2, 6, 7). We refer
to inhibition of the intermediate steps in BER as the
induction of “BER failure” because repair is initiated yet
is unable to be completed.
Importantly, understanding the mechanisms that are re-
sponsible for the increase in cell death due to BER inhibi-
tion or BER failure is critical in tailoring treatment as well
as designing rational adjuvant or combination treatments
that may further increase overall response. For example, in-
hibiting PARP1 has proven effective in improving temozo-
lomide-induced cell death (8). Inhibition of PARP1 results
in the accumulation of replication-mediated DNA double-
strand breaks (DSB) and the onset of apoptosis (9, 10).
This detailed understanding of the mechanism of cell
death induced by combining a DNA-damaging agent
(temozolomide) and a PARP1 inhibitor suggests that
PARP1 inhibition would be effective against many tumors
but may be ineffective against tumors that are resistant to
apoptosis (11). Further, cell death induced by PARP1 in-
hibition suggested a requirement for homologous recombi-
nation in the cellular response to the accumulated DSBs,67
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Published OnlineFirst January 12, 2010; DOI:10.1158/1541-7786.MCR-09-0411prompting preclinical and clinical trials of PARP1 inhibitors
in the treatment of homologous recombination–defective
tumors (2).
There are several BER proteins essential for the repair of
temozolomide-induced DNA lesions. Using a mouse em-
bryonic fibroblast cell model, we have shown that loss of
Polβ can significantly improve the cytotoxic effect of temo-
zolomide (12), suggesting that inhibition of Polβ may im-
prove response to temozolomide in human tumor cells.
Temozolomide is currently used in the treatment of glio-
blastoma (13), and it is therefore critical to evaluate the
role of Polβ in glioma cell response to temozolomide treat-
ment. No previous studies have investigated the role of
Polβ in the response of human glioma tumor cells to temo-
zolomide. Further, there is no mechanistic explanation for
the increase in alkylation-induced cell death observed
in cells that are deficient in Polβ beyond the evidence that
cell death in mouse cells is the result of accumulation of
unrepaired BER intermediates (7, 12).
Acute alkylation damage has been suggested to induce
cell death by multiple mechanisms, including necrosis
(14), caspase-3 and caspase-9 activation and the onset of
apoptosis (15), apoptosis-inducing factor (AIF) transloca-
tion from the mitochondria to the nucleus (16-18),
ADP-ribose–induced activation of the Ca2+ channel
TRPM2, or AMP-mediated inhibition of ATP transport
(19-21). In most, if not all, cases, cell death has been at-
tributed to the direct action of either PAR formed by
PARP1 activation or PAR catabolites that accumulate after
PAR degradation by the catabolic enzyme PAR glycohy-
drolase (PARG). Polβ-deficient mouse cells are hypersensi-
tive to the cell killing effects of alkylating agents due to
failure to repair the 5′-deoxyribose phosphate (5′-dRP)
BER intermediate (22). However, the exact downstream
signaling events and mechanism of cytotoxicity specifically
induced by the unrepaired 5′-dRP lesion remain unclear.
Previous studies in mouse cells have not been conclusive.
One report suggested that the absence of Polβ led to
damage-induced cell death via apoptosis (23), whereas a
later study proposed a necrotic form of cell death for both
wild-type (WT) and Polβ-deficient cells (24), similar to
what has been proposed as a general mechanism of alkyl-
ation-induced cell death in mouse fibroblasts (14). Howev-
er, this latter study required the use of apoptosis-deficient
cells to observe necrotic cell death (14). None of these pre-
vious studies have identified a mechanism of cell death spe-
cific to Polβ deficiency and BER failure or a failure to
repair the cytotoxic BER intermediate 5′-dRP.
The studies described herein were designed to specifical-
ly define the mechanism of cell death in human tumor cells
resulting from failure to repair the BER intermediate 5′-
dRP due to “inhibition of ” or a “deficiency in” Polβ
(BER failure). We have hypothesized that PARP1 func-
tions in BER as both a complex coordinator and a molec-
ular repair sensor. As a BER molecular sensor, we suggest
that PARP1 facilitates cell death in response to incomplete
BER or BER failure. In support of this hypothesis, we
show that a specific BER intermediate, a single-strandMol Cancer Res; 8(1) January 2010
American Asso Copyright © 2010 
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an in vivo substrate in human cells that activates PARP1
in the context of BER and that elevated cytotoxicity ob-
served in Polβ-deficient human cells is controlled by the
activation of PARP1. Further, we provide clear evidence
that following BER failure human cells die independent
of RIP1 activation or AIF translocation, thus ruling out
PAR as the cell death signal that is initiated on BER failure.
Further, we show that the observed cell death in Polβ-
deficient cells is unrelated to the accumulation of PAR cat-
abolites, such as ADP-ribose or AMP, yet is dependent on
NAD+ metabolite bioavailability or the bioenergetic capac-
ity of the cell.
This study provides mechanistic insight into why Polβ
deficiency leads to cell death, defines the mode of death,
and offers a mechanistic link between BER failure and en-
ergy metabolism—the novel finding that DNA damage–
induced cytotoxicity mediated via BER inhibition is pri-
marily dependent on cellular metabolite bioavailability. Fi-
nally, we offer a mechanistic justification for the elevated
alkylation-induced cytotoxicity of Polβ-deficient cells, sug-
gesting a linkage between DNA repair, cell survival, and
cellular bioenergetics.
Materials and Methods
Cell Culture and Cell Line Development
The cell line LN428 is an established glioblastoma-
derived cell line with mutations in p53 and deletions in
p14ARF and p16 and is WT for PTEN (25, 26). LN428
cells were kindly provided by Ian Pollack (University of
Pittsburgh, Pittsburgh, PA) and cultured in α-Eagle's
MEM supplemented with 10% heat-inactivated fetal bo-
vine serum, glutamine, antibiotic/antimycotic, and genta-
micin. MDA-MB-231 cells and derivatives were described
previously (27). Cell lines expressing human MPG (WT),
human MPG (N169D), FLAG-Polβ(WT), and FLAG-
Polβ(K72A) were developed by transfection using FuGene
6 transfection reagent (Roche Diagnostic Corp.) according
to the manufacturer's protocol. Transfected cell lines were
cultured in G418 and/or puromycin for 2 wk, and individ-
ual clones stably expressing human MPG or Polβ were se-
lected. It was recently suggested that p14ARF deficiency
results in proteosome-mediated degradation of Polβ (28).
Although LN428 cells are deficient in p14ARF (26), we
note that the expression levels of Polβ are stable. Lentiviral
particles were generated by cotransfection of plasmid
pCDF1-MCS1-EF1-copGFP (control) or pSIF-H1-
hPOLB1-copGFP (Polβ shRNA) together with pFIV-
34N and pVSV-G into 293-FT cells (29) using FuGene
6 transfection reagent. Forty-eight hours after transfection,
lentivirus-containing supernatant was collected and passed
through 0.45-μm filters to isolate the viral particles. Lenti-
viral transduction was done as described earlier (27). Brief-
ly, 6.0 × 104 cells were seeded into six-well plates 24 h
before transduction. Cells were transduced for 18 h at
32°C and cultured for 72 h at 37°C. Cells expressing
copGFP only or both copGFP and Polβ-specific shRNAMolecular Cancer Research
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Polβ-KD was confirmed by immunoblot analysis. All the
cell lines developed and used in this study are described
in Supplementary Table S1.
Chemicals and Reagents
α-Eagle's MEM was from Mediatech. RPMI 1640 and
DMEM were from Cambrex Bioscience Group and Bio-
whittaker, respectively. Fetal bovine serum, heat-inactivated
fetal bovine serum, penicillin/streptomycin/amphotericin,
glutamine, and antibiotic/antimycotic were from Invitrogen.
Temozolomide (NSC 362856; IUPAC name: 3-methyl-2-
oxo-1,3,4,5,8-pentazabicyclo[4.3.0]nona-4,6,8-triene-7-
carbooxamide; CAS number: 856622-93-1; ref. 30) was
obtained from the National Cancer Institute Developmental
Therapeutics Program. A temozolomide stock solution was
prepared in DMSO at 100 mmol/L. MMSwas from Sigma-
Aldrich. Puromycin, gentamicin, and neomycin were
purchased from Clontech Laboratories, Irvine Scientific,
and Invitrogen, respectively. PJ34 was purchased from Cal-
biochem. FK-866 {(E)-[4-(1-benzoylpiperidin-4-yl)butyl]-
3-pyridin-3-yl)acrylamide} was obtained from the National
Institute of Mental Health Chemical Synthesis and Drug
Supply Program (NIMH F-901; ref. 31). NMN was
obtained from Sigma, and NA was obtained from Fisher.
Plasmid Expression and RNA Interference Vectors
Human MPG (WT) was expressed using the plasmid
pRS1422, as described previously (27). The MPG expres-
sion plasmid (pRS1422) was then mutated at residue
N169 using the QuikChange XL Site-Directed Mutagen-
esis kit (Stratagene) to yield pIRES-Neo-MPG-N169D.
The expression plasmid for FLAG-tagged WT human Polβ
was generated by PCR amplification of the human Polβ
cDNA using a FLAG-containing forward oligonucleotide
and cloned into pENTR/D-TOPO as we described previ-
ously (27). pENTER/FLAG-Polβ(WT) was then mutated
at residue K72 as described above to yield pENTER/
FLAG-Polβ(K72A). FLAG-Polβ(WT) and FLAG-Polβ(-
K72A) were subsequently cloned into a Gateway-modified
pIRES-Puro vector by TOPO cloning, as we have de-
scribed previously (27). The FIV-based lentiviral shRNA
expression vector system specific for human Polβ was as
described previously (27) but was modified for copGFP ex-
pression (pSIF-H1-hPOLB1-copGFP). Lentiviral particles
for coexpression of PARG shRNA and TurboGFP were
prepared by transfection of four plasmids [the control plas-
mid pLK0.1-Puro-tGFP or the human PARG-specific
shRNA plasmid pLK0.1-Puro-PARGshRNA4 plus
pMD2.g(VSVG), pRSV-REV, and pMDLg/pRRE] into
293-FT cells (29, 32) using FuGene 6 transfection reagent.
Culture medium from transfected cells was collected 48 h
after transfection to isolate the viral particles, passed
through 0.45-μm filters, used immediately, or stored at
−80°C in single-use aliquots. Transduction of LN428 cells
with control lentivirus (GFP expression only) and human
PARG-specific shRNA lentivirus was completed as follows:
Briefly, 6.0 × 104 cells were seeded into six-well plates andwww.aacrjournals.org
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transduced for 18 h with virus at 32°C and cultured for
72 h at 37°C before isolation of the GFP-expressing pop-
ulation by fluorescence-activated cell sorting using the
University of Pittsburgh Cancer Institute Flow Cytometry
Facility. Cells were then cultured to expand the population
and analyzed for expression of PARG by quantitative
reverse transcription-PCR.
Quantitative Reverse Transcription-PCR Analysis
Expression of PARG and Polβ mRNA was measured by
quantitative reverse transcription-PCR using an Applied
Biosystems StepOnePlus system. Briefly, 80,000 cells were
lysed and reverse transcribed using the Applied Biosystems
Taqman Gene Expression Cells-to-CT kit. Each sample was
analyzed in triplicate and the results are an average of all
three analyses. Analysis of mRNA expression was conducted
as per the manufacturer (ΔΔCTmethod) using Applied Bio-
systems Taqman Gene Expression Assays (human Polβ:
Hs00160263_m1; human PARG: Hs00608254_m1) and
normalized to the expression of human β-actin (part
4333762T).
Cell Extract Preparation and Western Blot
Nuclear extracts were prepared and protein concentra-
tion was determined as we described previously (12).
Twenty micrograms of protein were loaded on a precast
4% to 20% NuPAGE Tris-glycine gel (Invitrogen). For
whole-cell extracts used in PAR formation assays, 3 ×
106 cells were seeded into a 100-mm cell culture dish
24 h before drug treatment. Cells were either treated with
temozolomide only or preexposed to a PARP inhibitor
(PJ34 or DR2313) followed by PARP inhibitor plus te-
mozolomide treatment. After treatment, cells were
washed twice with cold PBS, collected, and lysed with
400 μL of 2× Laemmli buffer [2% SDS, 20% glycerol,
62.5 mmol/L Tris-HCl (pH 6.8), 0.01% bromphenol
blue]. Samples were boiled for 8 min and extract from
∼1.5 × 105 cells was loaded onto each lane on a 4% to
12% precast NuPAGETris-glycine gel for immunoblot assay.
The following primary antibodies were used in immuno-
blot assays: anti-human MPG monoclonal antibody (clone
506-3D; ref. 27), anti-Polβ monoclonal antibody (clone
61; Thermo Fisher Scientific), anti-APE1 (EMD Bios-
ciences), anti–proliferating cell nuclear antigen (PCNA;
Santa Cruz Biotechnology), anti-FLAG (M2 monoclonal
antibody; Sigma-Aldrich), anti-PAR (clone 10H, kindly
provided by M. Ziegler, University of Bergen, Bergen,
Norway), anti-PARP1 (BD Pharmingen), and anti-human
HMGB1 (R&D Systems).
Cell Cytotoxicity Assay
Temozolomide-induced cytotoxicity was determined by
anMTS assay, a modifiedMTTassay as described previously
(12). Results were calculated from the average of three or
four separate experiments and are reported as the percentage
of treated cells relative to the cells without treatment (%
control). For PJ34, cells were preexposed to the inhibitorMol Cancer Res; 8(1) January 2010 69
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presence of the inhibitor for 48 h. For NA and NMN, cells
were preexposed to each for 24 h (concentrations as indi-
cated in the legend) and then treated with temozolomide
(1.0 mmol/L) in the presence of NA or NMN for 48 h.
The effect on cell growth and survival was determined by
an MTS assay, as described previously (12).HMGB1 Release Assay
Cells were pretreated with medium alone or with PARP
inhibitor (PJ34) for 30 min before cotreatment with PJ34
(2 μmol/L) and temozolomide (1.5 mmol/L) for 12 h. Cell
culture medium was then collected and passed through
0.45-μm filters. Immobilized heparin (Thermo Fisher Sci-Mol Cancer Res; 8(1) January 2010
American Asso Copyright © 2010 
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and rotated at 4°C for 2 h before centrifugation at 8,000 × g
to pull down HMGB1 bound to immobilized heparin (33).
Pellets were boiled with 100 μL of 2× Laemmli buffer, and
supernatants were used for immunoblot assay after brief
centrifugation.PAR Assay
Cells (1.5 × 106) were seeded in 100-mm dishes 24 h be-
fore treatment. For the FK-866 experiments, cells were
then incubated in the presence of FK-866 (10 nmol/L)
or DMSO for an additional 24 h. Medium was then re-
moved and replaced with fresh medium or medium sup-
plemented with PJ34 (2 μmol/L). After 30 min, cellsM
ciation for Cancer Researc
 on October 23, 2011ls.orgFIGURE 1. PARP activation due to
BER failure. A. Immunoblot of
PAR to determine activation of
PARP in the cell lines indicated
before and after exposure to
temozolomide (TMZ; 1.5 mmol/L)
for the time indicated. PARP1
and PCNA protein expression
levels are also shown. B. Top,
temozolomide-induced
cytotoxicity in LN428, LN428/
MPG, and two clones of LN428/
MPG cells complemented with
FLAG-Polβ(WT). After treatment
(48 h), viable cells were determined
using a modified MTT assay.
Plots show the % viable cells as
compared with untreated (control)
cells. Means are calculated from
quadruplicate values in each
experiment. Points, mean of three
independent experiments; bars,
SE. □, LN428;○, LN428/MPG;▴,
LN428/MPG/FLAG-Polβ(WT),
clones 1 and 6. Bottom,
immunoblot of PAR to determine
activation of PARP1 after exposure
to temozolomide (1.5 mmol/L)
for the time indicated. PCNA is
shown as a loading control.
C. Top, temozolomide-induced
cytotoxicity in LN428, LN428/
MPG, and two clones of LN428/
MPG cells complemented with
FLAG-Polβ(K72A), measured as in
B. □, LN428; ○, LN428/MPG;▴,LN428/MPG/FLAG-Polβ(K72A),
clones 5 and 16. Bottom,
immunoblot of PAR to determine
activation of PARP1 after exposure
to temozolomide (1.5 mmol/L)
for the time indicated. PCNA is
shown as a loading control.olecular Cancer Research
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placed with temozolomide for the times indicated in the
figure legends. Extracts were prepared by washing the cells
with PBS and preparing cell extract with 400 μL of 2×
Laemmli buffer. Cell extract (20 μL) was analyzed by im-
munoblot with a 4,000-fold dilution of an anti-PAR pri-
mary antibody (clone 10H) followed by a 5,000-fold
dilution of the horseradish peroxidase–conjugated second-
ary goat anti-mouse antibody.
Immunofluorescence and Confocal Microscopy
Cells were cultured on glass coverslips for 24 h before
treatment with MMS or medium control. One hour after
treatment, cells were washed and allowed to recover in me-
dium for 5 h. Cells were then fixed with 4% paraformal-
dehyde for 20 min, permeabilized with 0.5% Triton X-100
for 15 min, and blocked with 2% bovine serum albumin
for 1 h, all at room temperature. AIF was detected by in-
cubating 1 h at room temperature with an anti-AIF anti-
body (Santa Cruz Biotechnology) at 1:100 dilution
followed by goat anti-mouse Alexa Fluor 488 (Molecular
Probes) at 1:500, Alexa Fluor 647 phalloidin actin stain
at 1:250 (Molecular Probes), and 5 μmol/L DRAQ5 nu-
clear stain for 1 h at room temperature. Slides were
mounted and imaged on the Olympus FluoView 500 con-
focal microscope.
NAD+ and ATP Measurements
Cells were seeded 24 h before treatment with MMS or
medium control. NAD+: 1 h after treatment, cells were tryp-
sinized and counted and 1 × 105 cells were pelleted. NAD+
lysates were prepared and NAD+ measurements were ob-
tained using the EnzyChromNAD+/NADHAssay kit (Bio-
Assay Systems). ATP: 1 h after treatment, cells were washed
and allowed to recover in normal medium for 1 h. Cells were
then lysed and ATP content was measured by luminescent
output using the ATPlite assay kit (Perkin-Elmer).
FK-866 Cytotoxicity Assay
Cells were seeded in 96-well plates 24 h before treat-
ment. Cells were pretreated with 10 nmol/L FK-866 or
DMSO control for 24 h and then exposed to MMS for
1 h. The cells were then washed with medium and allowed
to recover for 48 h before assaying for cytotoxicity by an
MTS assay previously described (12, 27). Results shown
are the average of three independent experiments and re-
ported as percent survival of MMS-treated cells compared
with control wells.
Results
Hyperactivation of PARP due to Polβ Deficiency and
Failure to Repair the BER Intermediate 5′-dRP
BER is a finely tuned process that requires balanced
expression of several proteins to avoid accumulation of
mutagenic or cytotoxic repair intermediates (3). To under-
stand how alterations in BER enzyme activity in human
tumor cells lead to DNA damage–induced cell sensitivity,www.aacrjournals.org
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functional deficiency in Polβ by increasing expression of
N-methylpurine DNA glycosylase (MPG) and depleting
the cell of Polβ by stable lentiviral-mediated expression
of short hairpin RNA (shRNA). As we have reported, hu-
man cells with elevated expression of MPG are sensitive to
alkylation damage due to a deficiency in Polβ (27), a phe-
notype that is enhanced by Polβ knockdown (Polβ-KD).
Conversely, reexpression of Polβ eliminated the alkylation
hypersensitive phenotype (Supplementary Figs. S1 and
S2). These cells (LN428/MPG and LN428/MPG/Polβ-
KD cells) are therefore functionally deficient in Polβ and
were used to determine the mechanism that mediates the
enhanced DNA damage–induced cell death resulting from
Polβ deficiency.
The DNA binding and signaling molecules PARP1 and
PARP2 have each been implicated in BER (3). PARP1 fa-
cilitates BER complex formation, and it has been postulat-
ed that local strand break–induced activation of PARP1
and the resultant synthesis of PAR mediate recruitment
of the BER proteins XRCC1 and Polβ to stimulate
DNA repair (34). We therefore have hypothesized that
in cells that fail to complete BER (e.g., when 5′-dRP le-
sions are not repaired; herein referred to as BER failure),
PARP1 is hyperactivated and functions as a DNA damage
signaling protein that triggers cell death. To determine
whether PARP is activated by the BER intermediate (5′-
dRP) in vivo, we exposed the control (LN428) and
corresponding BER-defective cells (Polβ-deficient
LN428/MPG and LN428/MPG/Polβ-KD cells) to temo-
zolomide for up to 90 minutes. Whole-cell extracts were
probed by immunoblot for PAR accumulation following
temozolomide exposure (Fig. 1A). The level of PAR accu-
mulation was shown to correlate with the extent of the
BER defect. PARP activation was elevated in the
LN428/MPG cells (an intermediate level of sensitivity),
with the highest level of PAR observed 30minutes following
exposure to temozolomide, whereas essentially no PARP
activation was observed in the LN428 cells (Fig. 1A). In
the more sensitive cell line (LN428/MPG/Polβ-KD),
PARP activation was more robust and rapid as compared
with that of the LN428/MPG cell line (Fig. 1A), as PAR
reached its highest level at 15 minutes after exposure to te-
mozolomide. Comparable results were also observed in a
Polβ-defective breast cancer cell line, where elevated temo-
zolomide-induced PARP activation is restricted to the cells
with Polβ deficiency (Supplementary Fig. S2B and C).
Conversely, exposure to etoposide resulted in a low level of
PARP activation at all time points for all three cell lines
LN428, LN428/MPG, and LN428/MPG/Polβ-KD (Supple-
mentary Fig. S2D). Thus, PARPactivation is elevated in BER-
defective (Polβ-deficient) cells following alkylation damage.
Because the combination of alkylating agent treatment
and Polβ deficiency triggers PARP activation, we next val-
idated the significance and specificity of this finding by re-
expression of Polβ in the LN428/MPG and LN428/MPG/
Polβ-KD cells. We find that the BER-deficient phenotype
(increased cellular sensitivity to alkylating agents) observedMol Cancer Res; 8(1) January 2010 71
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cells was reversed by complementation (expression) of
FLAG-Polβ(WT) (Fig. 1B, top; Supplementary Fig. S1E)
but not the 5′-dRP lyase–deficient (K72A) mutant of Polβ
(Fig. 1C, top). Similarly, we find that complementation with
FLAG-Polβ(WT) but not with the Polβ 5′-dRP lyasemutant
eliminated the temozolomide-induced activation of PARP
observed in BER-defective cells (Fig. 1B and C, bottom).
These data therefore suggest that the Polβ-specific BER in-
termediate (5′-dRP lesion) triggers rapid and robust PARP1
activation in vivo, triggering the onset of cytotoxicity.
The correlation between PARP activation and alkylation
sensitivity prompted us to determine if inhibition of PARP
reverses the cellular hypersensitivity of Polβ-deficient hu-
man tumor cells. We inhibited activation of PARP by pre-
treatment and cotreatment with the PARP1/PARP2
inhibitors PJ34 or DR2313. Inhibition of PARP by PJ34
significantly reduced the level of temozolomide-induced
PARP activation in the Polβ-deficient cells (LN428/
MPG; Fig. 2A, lanes 3 and 4 and lanes 7 and 8). We next
assayed if PARP inhibition can rescue the alkylation-sensi-
tive phenotype of LN428/MPG cells, as determined by an
MTS assay 48 hours after temozolomide exposure. Most
importantly, we find that PARP inhibition by either
PJ34 or DR2313 treatment converted the LN428/MPG
cells from a sensitive phenotype to a resistant phenotype
(Fig. 2B; Supplementary Fig. S3A). Rescue by PARP inhi-
bition was also observed in Polβ-deficient MDA-MB-231
cells (Supplementary Fig. S3B). It remains to be deter-
mined if this resistant phenotype is long lived. In photore-
ceptor, PC12, SH-SY5Y, and HeLa cells, PARP inhibition
is cytoprotective, as we observe herein (35-37). Further
studies will determine if this resistant phenotype reportedMol Cancer Res; 8(1) January 2010
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breaks lead to the formation of DSBs and the onset of ap-
optosis after several rounds of replication (9). Regardless,
these studies support our hypothesis that PARP hyperacti-
vation mediates the alkylation-sensitive phenotype of Polβ-
deficient cells.
Unrepaired BER Intermediates (5′-dRP Lesions)
Trigger Cell Death via Energy Depletion in the Absence
of PAR or PAR Catabolite–Mediated Signaling
Several different mechanisms have been attributed to
PARP1 activation–induced cell death. We first evaluated
the involvement of caspase-dependent cell death in control
cells as compared with the corresponding Polβ-deficient
cells following temozolomide treatment. These experiments
(Supplementary Fig. S4A and B) rule out a caspase-
dependent response due to BER failure, in line with our
previous report (27). Although it has been shown that an
autophagic response contributes to temozolomide-induced
cell death in some cells (38), temozolomide hypersensitivity
of Polβ-deficient cells is not affected by the autophagy
inhibitor 3-methyladenine (Supplementary Fig. S4C). In
support of this observation, we did not observe increased
LC3 puncta in BER-defective cells following temozolomide
exposure (27).
A major mechanism that has been attributed to PARP
activation–induced cell death is direct PAR signaling to
the mitochondria, where PAR mediates translocation of
AIF from the mitochondria to the nucleus to induce
caspase-independent cell death (16-18) via a mechanism
that requires receptor (tumor necrosis factor receptor
superfamily)–interacting serine-threonine kinase 1 (RIP1)
activation (seemodel; Fig. 3A; ref. 39). RIP1 can be inhibitedFIGURE 2. PARP activation mediates cellular hypersensitivity in BER-defective cells. A. Temozolomide-induced PARP activation in LN428 and LN428/MPG
cells in the presence or absence of the PARP1/PARP2 inhibitor PJ34. Cells were pretreated with PJ34 (4 μmol/L) or vehicle control for 30 min before
exposure to temozolomide (1.5 mmol/L) plus PJ34 (2 μmol/L) for another 30 min. PCNA was used as a loading control. B. Temozolomide-induced
cytotoxicity (LN428 and LN428/MPG cell lines) in the presence (solid lines) or absence (dashed lines) of the PARP1/PARP2 inhibitor PJ34. Viable cells were
measured 48 h after exposure as in Fig. 1B. □ and▪, LN428;○ and •, LN428/MPG.Molecular Cancer Research
 ciation for Cancer Research
 on October 23, 2011ls.org
Regulation of Alkylating Agent–Induced Cell Death
Published OnlineFirst January 12, 2010; DOI:10.1158/1541-7786.MCR-09-0411by necrostatins, small-molecule inhibitors shown to inhibit
cell death (40, 41). Therefore, we investigated the role of
RIP1 in the PARP-mediated cell death we observed by in-
hibiting RIP1 with necrostatin-1 (41) and evaluating the
effect of RIP1 inhibition onDNA damage–induced cell sur-
vival in both control and Polβ-deficient cells. However,
inhibition of RIP1 did not prevent cell death in either
the parental or the Polβ-deficient cells (Supplementary
Fig. S5), suggesting but not proving that AIF translocation
may not be related to the observed cell death.
We therefore next evaluated the subcellular localization
of AIF in control and Polβ-deficient cells following expo-
sure to the alkylating agents methyl methanesulfonate
(MMS) or temozolomide as compared with vehicle (medi-
um) by immunofluorescent staining and confocal micros-www.aacrjournals.org
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immunoblot analysis (Supplementary Fig. S6). In line with
the RIP1 inhibition data above, alkylating agent treatment
of Polβ-deficient cells did not alter the subcellular localiza-
tion of AIF (Fig. 3B; Supplementary Fig. S6). All the
detectable AIF was localized to the mitochondria in both
cell lines regardless of agent or time of exposure (up to
12 hours), thus ruling out PAR as a cell death signal on
BER failure.
In the absence of a PAR-mediated cell death process
(AIF translocation), it is possible that cell death is initiated
via the rapid breakdown of PAR (see Fig. 1A) by the deg-
radative enzyme PARG and the accumulation of the PAR
catabolites ADP-ribose, ribose-5-phosphate, and/or AMP
(see model; Fig. 3A; ref. 42). ADP-ribose acts as a secondFIGURE 3. Absence of PAR or PAR catabolite–mediated cell death following BER failure. A. Model depicting the nexus of BER, the synthesis of PAR,
and the generation of PAR catabolites in response to BER failure–induced PARP1/PARP2 hyperactivation. B. Absence of mitochondria to nucleus
translocation of AIF due to BER failure as determined by confocal microscopy. BER-deficient cells (LN428/MPG) were treated with medium (left) or
1.5 mmol/L MMS (right) for 1 h and then washed and allowed to recover in medium for 5 h before fixation and staining for AIF (green), actin (red), and
nucleus (blue). C. PARG-KD prevented degradation of DNA damage–induced PAR. Left, immunoblot of PAR to determine the degradation of PAR in
LN428/MPG/PARG-KD cells following treatment with 1.5 mmol/L temozolomide. PCNA protein expression level was shown as a loading control. Right,
preventing generation of PAR catabolites from degradation of PAR via PARG-KD enhances temozolomide-induced cytotoxicity. LN428 and LN428/MPG
cells with (black columns) or without (white columns) PARG-KD were exposed to temozolomide (1 mmol/L) or vehicle control (DMSO) for 48 h. Viable
cells were determined as in Fig. 1B and reported as percentage relative to vehicle control–treated cells (% control). Columns, mean of three independent
experiments; bars, SE. D. HMGB1 released into the cell culture medium, as shown by immunoblot. LN428 and LN428/MPG cells were pretreated with
PJ34 (4 μmol/L) or vehicle control for 30 min and then exposed to temozolomide (1.5 mmol/L) with or without PJ34 (2 μmol/L) for 12 h. HMGB1 was then
captured using immobilized heparin and analyzed by immunoblot, as described in Materials and Methods.Mol Cancer Res; 8(1) January 2010 73
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Published OnlineFirst January 12, 2010; DOI:10.1158/1541-7786.MCR-09-0411messenger to activate the cation channel TRPM2 to trigger
Ca2+ influx, resulting in cell death (19, 20), or inhibits
ATP-binding cassette transporters (43), whereas elevated
AMP can block ATP transport, leading to ATP depletionMol Cancer Res; 8(1) January 2010
American Asso Copyright © 2010 
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catabolites contribute to PARP-mediated cell death in Polβ-
deficient cells, we first blocked Ca2+ influx with BAPTA-AM,
shown recently by Bentle et al. (44) and Bey et al. (45) toFIGURE 4. BER failure–induced cell death depends on NAD+ availability. A. Alkylation damage promotes NAD+ and ATP depletion in BER-defective cells.
Left, NAD+ content. Cells were treated with medium (white columns) or 0.5 mmol/L MMS (black columns) for 1 h before collection for NAD+ content
analysis via enzymatic assay as described in Materials and Methods. Right, ATP content. Cells were treated with medium (white columns), 0.5 mmol/L MMS
(gray columns), or 1.5 mmol/L MMS (black columns) for 1 h. ATP content was measured after 1-h recovery in normal medium via the luminescence
ATP assay described in Materials and Methods. NAD+ levels or ATP levels shown are the average of three independent experiments and are reported as
percent control of the untreated control cell line. B. PARG-KD does not rescue alkylation damage–induced NAD+ and ATP depletion in BER-defective
cells. Left, NAD+ content. PARG-KD cell lines were treated with medium (white columns) or 0.5 mmol/L temozolomide (black columns) for 1 h before
collection for NAD+ content analysis as described in Materials and Methods. Right, ATP content. PARG-KD cells were treated with medium (white columns),
0.5 mmol/L temozolomide (dotted columns), 1.0 mmol/L temozolomide (gray columns), or 1.5 mmol/L temozolomide (black columns) for 1 h. ATP
content was measured after 1-h recovery in normal medium via the luminescence ATP assay described in Materials and Methods. NAD+ levels or ATP
levels shown are the average of three independent experiments and are reported as percent control of the untreated control cell line. C. Bioenergetic
metabolites rescue Polβ-deficient cells from DNA damage–induced cell death. LN428 and LN428/MPG cells were pretreated with NMN, NA, or vehicle
control (medium) for 24 h and then exposed to temozolomide (1 mmol/L) in the presence or absence of NMN or NA for 48 h. Viable cells were measured
as in Fig. 1B and reported as percentage relative to vehicle control–treated cells (% control). Columns, mean of three independent experiments;
bars, SE. D. NAD+ biosynthesis inhibition augments BER failure–induced cell death. Cells were pretreated for 24 h with a nontoxic 10 nmol/L dose of FK-866
(black columns) or DMSO (white columns). Cells were then exposed to medium control or MMS (0.5 mmol/L) for 1 h. Viable cells were determined as
in Fig. 1B. Columns, mean of three independent experiments; bars, SE.Molecular Cancer Research
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Published OnlineFirst January 12, 2010; DOI:10.1158/1541-7786.MCR-09-0411abrogate PARP1 activation–induced cell death. Unlike that
observed following DNA damage from reactive oxygen spe-
cies or oxidative stress, BAPTA-AM did not prevent the
elevated damage-induced cell death in Polβ-deficient cells
(Supplementary Fig. S7). However, as there may be multi-
ple mechanisms of PAR catabolite–induced cell death, we
next knocked down expression of PARG by stable transduc-
tion of both cell lines with a lentivirus-expressing shRNA
specific to PARG. Expression of PARG mRNA is reduced
to 35% as compared with the green fluorescent protein
(GFP) control cells when determined by quantitative reverse
transcription-PCR (data not shown). Importantly, we found
no evidence for PAR-degrading activity in the cells with sta-
ble depletion of PARG (Fig. 3C, left). When exposed to an
alkylating agent, BER-deficient PARG-KD cells accumulate
significant levels of PAR with no evidence for PAR degra-
dation (Fig. 3C, left, lanes 2-4). This is in contrast to the
presence of PARG when the PAR molecule is degraded
within 60 to 90 minutes (Fig. 1, lanes 7-12). These data
show that these PARG-KD cells do not degrade PAR
and, hence, do not accumulate PAR catabolites, providing
an opportunity to determine if PAR catabolites contribute
to cell death in these cells. As shown in Fig. 3C (right),
PARG-KD did not rescue or reverse the enhanced damage-
induced cell death phenotype of Polβ-deficient (LN428/
MPG) cells. In fact, PARG-KD cells (black columns) were
more sensitive to the cell killing effect of the alkylating agent
temozolomide as compared with the PARG-expressing cells
(white columns; Fig. 3C, right). The inability of necrostatins
to abrogate the response and the lack of PAR-mediated AIF
translocation strongly suggest that PAR is not acting as a sig-
naling molecule to induce cell death, as has been suggested
(46, 47). Further, the inability of BAPTA-AM and, most im-
portantly, PARG-KD to reverse the alkylation-sensitive phe-
notype of Polβ-deficient cells also suggests that the observed
cell death is unrelated to the accumulation of PAR catabolites
such as ADP-ribose or AMP. Finally, one of the hallmarks
of caspase-independent cell death is secretion of HMGB1
into the extracellular space (48, 49). A significant level of
HMGB1 was secreted into the culture medium following ex-
posure of the BER-defective cells (LN428/MPG) to temozo-
lomide as compared with that of the control LN428 cells
(Fig. 3D). HMGB1 release was mediated through PARP
activation, likely due to PARP1 modification (49), as PARP
inhibition greatly reduced the release of HMGB1 (Fig. 3D).
It is unclear how or if HMGB1 release due to failed BER is
related to the recently reported role of HMGB1 in BER (50).
An alternate process of cell death due to PARP1 activa-
tion was originally proposed by Berger (51, 52) to involve
energy (NAD+ and ATP) depletion, in support of an earlier
observation by Jacobson and colleagues (53) showing a de-
crease in NAD+ concurrent with an increase in PAR syn-
thesis. We therefore measured NAD+ and ATP levels in the
control (LN428) and Polβ-deficient (LN428/MPG and
LN428/MPG/Polβ-KD) cells before and after exposure
to MMS or temozolomide. In line with the cytotoxicity
and PARP1 activation results described above, exposure
of Polβ-deficient cells to MMS or temozolomide led to awww.aacrjournals.org
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as the NAD+ and ATP levels in the control cells were not
affected (Fig. 4A). We next measured the effect of alkyl-
ation damage on the corresponding cells depleted of PARG
(PARG-KD). If PAR catabolites trigger cell death,
we would expect that NAD+ and ATP loss would be atten-
uated in PARG-KD cells. However, exposure of Polβ-
deficient PARG-KD cells to temozolomide led to enhanced
depletion of both NAD+ and ATP (Fig. 4B). The absence
of PAR or PAR catabolite–mediated cell death, together
with the specific loss of NAD+ and ATP (Fig. 4A) even when
the formation of PAR catabolites is prevented (Fig. 4B), sug-
gests that the BER failure response is linked to the cellular
bioenergetic capacity of the cell.
For this paradigm to hold, we hypothesized that the
availability of bioenergetic metabolites would affect the
survival of Polβ-deficient cells exposed to an alkylating
agent. In line with this hypothesis, we find that supple-
mentation of the cells with either β-nicotinamide mono-
nucleotide (NMN; ref. 54) or nicotinic acid (NA)
reversed the DNA damage–induced phenotype, rendering
the Polβ-deficient cells (black columns) completely
(NMN) or 80% (NA) resistant to the cell killing effects
of the alkylating agent as compared with the BER-profi-
cient cells (white columns; Fig. 4C). Conversely, we antic-
ipated that the hypersensitive phenotype of Polβ-deficient
cells would be exacerbated by a reduction in the cellular
level of NAD+ and related bioenergetic metabolites. We
therefore evaluated the effect of transient NAD+ deple-
tion on the observed BER failure response by pretreating
cells with FK-866, a highly specific noncompetitive small-
molecule inhibitor of nicotinamide phosphoribosyltrans-
ferase, a critical enzyme in the NAD+ biosynthetic salvage
pathway that catalyzes the synthesis of NMN (31). Most
importantly, the sensitivity of control cells to alkylation
damage was not altered by FK-866 treatment. However,
the BER-deficient cells are 9-fold more sensitive to MMS
following a nontoxic (10 nmol/L) treatment with FK-866
as compared with the untreated cells (Fig. 4D), although
PAR synthesis after the combined FK-866 + MMS treat-
ment is attenuated (Supplementary Fig. S8). These results
support our overall hypothesis that the BER failure
phenotype of Polβ-deficient cells is mediated by BER
intermediate (5′-dRP)–induced PARP1 activation and in-
duction of caspase-independent cell death that is uniquely
dependent on the availability of bioenergetic metabolites
such as NMN and NAD+.
Discussion
The requirement for BER in general and Polβ more spe-
cifically in the repair of genomic DNA base damage, par-
ticularly DNA damage induced by alkylating agents such
as the chemotherapeutic temozolomide and the SN1 and
SN2 alkylating agents N-methyl-N′-nitro-N-nitrosoguani-
dine (MNNG) and MMS, respectively (7, 12), elevates the
significance of characterizing the mechanism responsible
for Polβ deficiency–induced cell death (e.g., a failure toMol Cancer Res; 8(1) January 2010 75
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sence of Polβ). As evidenced recently by the development
of clinically significant PARP1 inhibitors, identifying BER
proteins critical for response to DNA-damaging agents (e.
g., chemotherapy) can have broad human health implica-
tions. Equally important is a clear understanding of the
mechanism(s) that contributes to the enhanced cell death
observed on DNA repair inhibition. For example, PARP1
inhibition triggers apoptosis via the accumulation of DSBs
(9, 10) and a requirement for homologous recombination
proteins such as BRCA1 and BRCA2 (2). To this end, we
have developed a unique series of genetically modified hu-
man tumor cell lines as models of Polβ deficiency that ac-
cumulate the cytotoxic BER intermediate 5′-dRP
following exposure to alkylating agents (temozolomide,
MMS, and MNNG). By directly comparing BER-defec-
tive (Polβ-deficient) and BER-competent isogenic human
cell lines, the cellular, biochemical, and signaling responses
to DNA base damage can be defined as either global (non-
specific) or BER (Polβ)–specific effects, the latter resulting
from a cellular response to the inability to complete BER,
referred to herein as BER failure. We have then used this
system to define the mechanism of cell death resulting
from Polβ loss/inhibition or BER failure and propose
and test paradigms to enhance the cell death response.
From these studies, we find that the unrepaired BER in-
termediates that accumulate on DNA-damaging agent ex-
posure when Polβ is deficient will activate PARP1, leading
to a rapid onset of PARP1-dependent, caspase-indepen-
dent cell death with little or no role for a caspase-depen-
dent or autophagy-dependent process in the response. It
remains to be determined if the BER failure–induced cell
death observed herein is dependent on extracellular signal-
regulated kinase 1/2–mediated PARP1 phosphorylation
(55) and SIRT1-regulated deacetylation of PARP1 (56)
or if the observed PARP1-induced cell death requires
BAX, calpain, and c-Jun NH2-terminal kinase activation
(57). Coincident with damage-induced necrosis in Polβ-
deficient cells is PARP1-dependent HMGB1 secretion
(49), a hallmark of caspase-independent cell death and in-
flammation signaling. HMGB1 functions in the extracellu-
lar space as a robust RAGE ligand and inflammatory
cytokine or damage-associated molecular pattern molecule
(48), suggesting that BER failure and the resulting PARP1
activation may trigger an inflammatory response in tissues
with a BER imbalance such as ulcerative colitis (58).
There are multiple PARP1 activation–induced cell death
mechanisms, as outlined in the diagram shown in Fig. 3A.
In one, it is suggested that PAR, the product of PARP1
activation, is a cell death molecule. In this process, PAR
initiates the translocation of AIF from the mitochondria
to the nucleus by a RIP1-dependent mechanism (Fig. 3A;
refs. 16-18, 39). Uniquely, PAR generated due to BER fail-
ure does not seem to trigger cell death via RIP1 activation
nor does PAR function as a signal to initiate AIF transloca-
tion. PARP1 is involved in many DNA repair processes,
including homologous recombination and nonhomologous
end joining, in response to DSBs and has a role in telomereMol Cancer Res; 8(1) January 2010
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ated via BER failure is of a unique chemical makeup as
compared with PAR generated from DSB-induced PARP1
activation. One possible explanation for the absence of a
role for AIF in this study is the concentration of DNA-dam-
aging agents used. In this report, we have used temozolo-
mide or MMS at a maximum concentration of 1.5
mmol/L or MNNG at a concentration of 5 μmol/L, result-
ing in 90% to 95% cell death in the BER-deficient cells
with little or no cell death in the control cells (Supplemen-
tary Fig. S2A). Many reports of PAR-induced AIF translo-
cation include MNNG concentrations of 100 and 500
μmol/L (35, 57, 61). Such high concentrations of DNA-
damaging gents (e.g., MNNG at 20× and 100× that used
herein) have the potential to directly induce DNA DSBs
and create overwhelming levels of both nuclear and mito-
chondrial genome damage (62) as well as the possibility of
direct protein alkylation. Regardless, it is clear that the cell
death initiated by BER failure is independent of RIP1 acti-
vation and AIF translocation, thus ruling out PAR as the
cell death signal that is initiated on BER failure.
One explanation for the absence of PAR-mediated cell
death is the rapid catabolism of PAR by PARG (42). In this
study, we find that PAR synthesized due to PARP activa-
tion is degraded within 90 minutes (Fig. 1). As summa-
rized in Fig. 3A, the breakdown products of PAR (PAR
catabolites) are also likely mediators of cell death, including
ADP-ribose (activator of the Ca2+ channel TRPM2) and
AMP (inhibitor of ATP transport; refs. 19-21). However,
PARG knockdown did not reverse the DNA damage–sen-
sitive phenotype of Polβ-deficient cells (Fig. 3C), suggest-
ing that damage-dependent cell death in Polβ-deficient
cells is not initiated by PAR catabolites. Conversely, the
PAR catabolite AMP may provide a protective phenotype
by activation of AMP kinase, induction of autophagy, and
enhanced ATP synthesis, as recently reported following re-
active oxygen species–induced DNA damage and PARP1
activation (63). Although loss of AMP kinase activation
and induction of autophagy on PARG-KD could explain,
in part, the enhanced cell death observed in the PARG-KD
cells (Fig. 3C), we suggest this is unlikely because in this
study autophagy is not involved (Supplementary Fig. S4C)
and the activation of AMP kinase, if any, does not seem to
overcome the damage-induced cell death phenotype result-
ing from BER failure in the PARG-proficient cells. Regard-
less, it is interesting to speculate that PARG may regulate
AMP kinase activation in response to reactive oxygen spe-
cies–induced PARP1 activation (63). In all, these studies
imply that the alkylation-sensitive phenotype of Polβ-defi-
cient cells is unrelated to the accumulation of PAR catabo-
lites, such as ADP-ribose or AMP, and is likely wholly
dependent on the metabolite bioavailability or bioenergetic
capacity of the cell.
The overriding response to the loss of Polβ and an in-
ability to complete BER (BER failure) is energy failure
or depletion of bioenergetic metabolites with no evidence
for cell death triggered by PAR or the PAR catabolites
ADP-ribose or AMP. The energy collapse or depletion ofMolecular Cancer Research
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levels of NMN (54) and is negatively affected by NAD+
biosynthesis inhibition (FK-866), suggesting that (a) FK-
866 (APO866) and related clinically useful NAD+ biosyn-
thesis inhibitors might be combined with temozolomide
and BER inhibitors to improve temozolomide response
and (b) any stress on or defects in the NAD+ biosynthesis
pathway such as overactivation of SIRT1 (64) or attenuat-
ing defects in nicotinamide phosphoribosyltransferase,
NMNAT1, or related NAD biosynthetic enzymes (65)
may have significant effects on cell survival following
BER failure.
Similar phenotypes (stress-induced PARP1 activation
and cell survival dependent on NAD+ metabolites) have
been observed in diverse human cell types and mamma-
lian organ systems, stressing the significance of these
findings. PARP1 activation and the resulting “NAD+ de-
pletion”–mediated or ATP depletion–mediated cell death
play critical roles in tissue injury from cerebral and myo-
cardial ischemia (66-69). Analogous to the studies
described herein, cellular protection from cerebral ische-
mia is provided by NAD+ metabolite supplementation
(70, 71). Similarly, streptozotocin-induced diabetes results
from PARP1 activation, energy imbalance, and cell death
dependent on the BER enzyme MPG (72-75). Most im-
portantly, cellular NAD+ metabolism plays an essential
role in pancreatic β-cell viability and insulin secretion
(76). With the observation that BER failure triggers
NAD+ depletion, it is interesting to speculate if overall
BER capacity controls susceptibility to ischemia or strep-
tozotocin-induced and age-related diabetes onset via neu-
ronal or β-cell death from loss of bioenergetic metabolites
after BER failure. The onset of these physiologically sig-
nificant outcomes (stroke, neurodegeneration, ischemia,
and diabetes) involves PARP1 activation, NAD+ deple-
tion, and cell death, similar to that reported here. Al-
though a portion of the environmental and endogenous
stressors that induce these phenotypes via PARP1 activa-
tion will directly induce DNA single-strand breaks, it is
reasonable to presume that a significant proportion of
cell death related to stroke, retinal degeneration, ische-
mia, and diabetes may initiate from genomic DNA
base damage, requiring repair by the BER machinery.
As such, the failure to repair the DNA damage and
the resulting accumulation of DNA repair intermediates
(BER failure) may be the trigger of PARP1 activation
and cell death.www.aacrjournals.org
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tions as a BER molecular sensor protein to induce cas-
pase-independent cell death following BER failure and
provides mechanistic insight into why Polβ deficiency
leads to cell death. Further, we show that the observed
DNA damage–dependent cell death in Polβ-deficient cells
is unrelated to the accumulation of PAR catabolites, such
as ADP-ribose or AMP, yet is dependent on NAD+ me-
tabolite bioavailability or bioenergetic capacity of the cell,
suggesting a linkage between DNA repair capacity, cell
survival, and cellular bioenergetic metabolites. Finally,
these studies have potentially important implications for
therapeutic development as it relates to a chemothera-
py-induced synthetic lethality approach to cancer therapy
involving the combination of a chemotherapeutic DNA-
damaging agent, a DNA repair inhibitor, and a regulator
or inhibitor of NAD+ biosynthesis.
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Supplemental Data include Figure S1-S8, the figure legends, Materials & Methods and Table S1. 
Materials and Methods
Chemicals and reagents
MMS, Etoposide and 3-Methyladenine were from Sigma-Aldrich. MNNG (CAS# 70-25-7; IUPAC 
1-methyl-2-nitro-1-nitrosoguanidine) was obtained from TCI America (Cat# M0527), dissolved in DMSO 
to a stock concentration of 10mM, filtered through a 0.22uM filter and stored until needed at -20˚C.
DR2313 and Z-VAD.fmk were purchased from Calbiochem. BAPTA-AM was obtained from InVitrogen 
(cat# B-1205). Necrostatin-1 was obtained from Sigma (cat# N9037).
Caspase-3 and caspase-9 activation assay
Caspase-3 and caspase-9 activation was measured using a caspase-3 and caspase-9
colorimetric activity assay kit as described earlier (1). Briefly, the assay is based on the 
spectrophotometric identification of p-nitroaniline (pNA) after cleavage of a labeled DEVD-Pna (caspase-
3) or LEHD-Pna (caspase-9) substrate.  For the caspase-3 and caspase-9 activation assay, 0.75 x106
cells were seeded in 100mm dishes. 24 hours after seeding, the cells (LN428 and LN428/MPG) were 
treated with 3.0 mM and 1.5 mM TMZ, respectively (corresponding to equitoxic dose of TMZ for each 
cell line) or media for 24 hours. Separately, cells were also treated with 60 µM ETO or media for 24 
hours. After induction of apoptosis with TMZ or ETO, the cell pellet (containing approximately 2x106
cells) was re-suspended in 1x cell lysis buffer and the supernatant (cytosolic extract) was used to 
measure caspase-3 or caspase-9 activation. Samples were mixed with assay mixture in a 96-well plate 
and incubated for 2 hours at 37˚C and absorbance was measured at 405nm. The fold increase in 
2caspase-3 or caspase-9 activation was calculated by comparing the OD from the TMZ or ETO samples 
with the OD from the untreated control samples.
Subcellular fractionation and analysis of AIF expression
Cells were seeded into 100 mm cell culture dishes at 3 X 106 cells / dish. 24 hours later, cells 
were treated with TMZ (1.5 mM) for different periods of time before washing with cold PBS and 
subjecting to subcellular fractionation, essentially as described (2). Briefly, following treatment and 
washing, cells were collected by scraping using a rubber scraper. Cells were pelleted  (400g, 5 min at 
4˚C). The cell pellet was resuspended in 1 ml of cold homogenization buffer (0.25 M Sucrose, 10 mM 
HEPES pH 7.4, 1 mM EGTA) and the cell suspension was homogenized in a 2 ml Wheaton Dounce 
Homogenizer on ice.  The homogenate was centrifuged at 1,000 x g for 15 minutes at 4˚C to obtain the 
nuclear pellet, and the supernatant was then centrifuged at 10,000 x g for 15 minutes at 4˚C to pellet
mitochondria. 
Cell cytotoxicity assay
TMZ or etoposide (ETO) induced cytotoxicity was determined by an MTS assay, a modified MTT 
assay as described previously (3). Results were calculated from the average of three or four separate 
experiments and are reported as the percentage of treated cells relative to the cells without treatment (% 
Control). For PJ34, DR2313, Z-VAD.fmk, 3-Methyladenine (3-MA), Necrostatin-1 and BAPTA-AM, cells 
were pre-exposed to those inhibitors for 30 minutes (PJ34, DR2313, Necrostatin-1 and BAPTA-AM) or 
one hour (Z-VAD.fmk and 3-MA) and were then treated with TMZ in the presence of those inhibitors for 
48 hours. The impact on cell growth and survival was determined by an MTS assay, as described 
previously (3).
3Figure Legends
Figure S1. Alkylation sensitivity mediated by a deficiency in Pol ß-mediated DNA repair 
(A) Characterization of glioma cell lines. Expression level of BER proteins including MPG, Pol ß and 
APE1 are shown for LN428 glioma cells (LN428), LN428 cells transduced by GFP expressing lentivirus
(LN428/GFP), LN428 cells transfected with plasmid pIRES.neo.MPG to over-express MPG  
(LN428/MPG), MPG over-expressing glioma cells expressing GFP (LN428/MPG/GFP) or co-expressing 
GFP and Pol ß shRNA (LN428/MPG/Polß-KD). PCNA was used as a loading control.
(B) Cell sensitivity to TMZ. Cells were cultured in 96-well plates for 24 hours prior to exposure to TMZ,
measured as in Figure 1B. [LN428, open square; LN428/MPG, open circle; LN428/MPG/Polß-KD, open 
diamond]
(C) Cell sensitivity to etoposide (ETO) exposure for 48 hours. Viable cells were measured as in (B). 
[LN428, open square; LN428/MPG, open circle; LN428/MPG/Polß-KD, open diamond]
(D) (Upper panel) Cellular cytotoxicity due to TMZ treatment in LN428 cells over-expressing either WT 
or a glycosylase activity null mutant of MPG (N169D) following 48 hours exposure to TMZ. Viable cells 
were measured as in (B). [LN428, open square; LN428/VC, filled square; LN428/MPG, open circle; 
LN428/MPG-mut, filled circle] (Lower panel) Western blots showing over-expression of mutant N169D-
MPG (lane 2) as compared to LN428 cells transfected with the vehicle control (lane 1). 
(E) (Upper panel) Cellular cytotoxicity due to TMZ treatment in LN428/MPG/Polß-KD cells 
complemented with Flag tagged WT Pol ß (clone 2 and 6) following 48 hours exposure to TMZ. Viable
cells were measured as in (B). [LN428, open square; LN428/MPG, open circle; LN428/MPG/Polß-KD, 
open diamond; LN428/MPG/Flag-Polß-WT, filled triangle; LN428/ MPG/Polß-KD /Flag-Polß-WT, filled 
triangle] (Lower panel) Over-expression of Flag tagged Pol ß (WT) in the LN428/MPG/Polß-KD cell line. 
An immunoblot from two representative clones (clone 2 and 6; lanes 4 and 5) are shown, compared to 
LN428/MPG cells (lane 1), LN428/MPG/Polß-KD cells (lane 2) and LN428/MPG/Polß-KD cells 
transfected with the vehicle control (lane 3).
4Figure S2.
(A) Hypersensitivity of Pol ß deficient cells to TMZ, MMS and MNNG. Control cells (LN428, open bars) 
were resistant to alkylating agents, while the Pol ß deficient cells (LN428/MPG, black bars) were 
significantly more sensitive. Cells were exposed to 1500µM TMZ, 1500µM MMS or 5µM MNNG for 48 
hrs. Cell survival was determined by an MTS assay, while percent survival was normalized to untreated 
control cells, as in Figure 1B. Results are reported as the mean from three independent experiments 
and error bars represent SEM.
(B) TMZ induced PARP1 activation in a breast cancer cell line (MDA-MB-231) and a cell line with both 
elevated MPG expression and reduced Pol ß level (MDA-MB-231/MPG/Pol ß KD). Cells were exposed 
to 1.5 mM TMZ for 15 or 30 min and cells without treatment were used as control (0 min). PARP1 and 
PCNA protein expression levels are also shown. 
(C) TMZ induced cytotoxicity in MDA-MB-231, MDA-MB-231/MPG and MDA-MB-231/MPG/Pol ß cells, 
measured as in Figure 1B. [MDA-MB-231, open square; MDA-MB-231/MPG,  open circle and MDA-MB-
231/MPG/Pol ß KD, open diamond]
(D) Immunoblot of PAR to determine activation of PARP1 after exposure of LN428, LN428/MPG and 
LN428/MPG/Pol ß KD cells to 50µM etoposide (ETO) for the time indicated. 
5Figure S3.
(A) TMZ induced cytotoxicity (LN428 and LN428/MPG cell lines) in the presence (solid lines) or absence 
(dashed lines) of the PARP1/PARP2 inhibitor DR2313. Viable cells were measured 48 hours after 
exposure as in Figure 1B. [LN428, open and filed square; LN428/MPG, open and filled circle]
(B) TMZ induced cytotoxicity in MDA-MB-231, MDA-MB-231/MPG and MDA-MB-231/MPG/Polß-KD cell 
lines in the presence (solid lines) or absence (dashed lines) of PJ34. Viable cells were measured 48 
hours after exposure as in Figure 1B. [MDA-MB-231, open and filed square; MDA-MB-231/MPG, open 
and filled circle; MDA-MB-231/MPG/Polß-KD, open and filled diamond]
Figure S4.
(A) TMZ-induced cytotoxicity in LN428 and LN428/MPG cells with or without 50 µM of pan caspase 
inhibitor Z-VAD.fmk. Viable cells were measured 48 hours after exposure as in Figure 1B. [LN428, open 
square; LN428 + Z-VAD.fmk, filled square; LN428/MPG, open circle; LN428/MPG + Z-VAD.fmk, filled 
circle]
(B) TMZ or ETO induced caspase-9 activation in LN428 and LN428/MPG cells 24 hours after exposure
to TMZ or ETO. 
(C) TMZ-induced cytotoxicity in LN428 and LN428/MPG cells with or without pre-treatment with the 
autophagy inhibitor 3-MA (4 mM). Viable cells were measured 48 hours after exposure as in Figure 1B. 
[LN428, open square; LN428 + 3-MA, filled square; LN428/MPG, open circle; LN428/MPG + 3-MA, filled 
circle]
6Figure S5.
Inhibition of RIP1 by necrostatin-1 does not protect cells from TMZ-induced cytotoxicity. Cells were pre-
treated with necrostatin-1 or vehicle control (DMSO) for 30 minutes and were then exposed to TMZ in 
the presence or absence of necrostatin-1 (100 μM) for 48 hours. Viable cells were measured 48 hours 
after exposure as in Figure 1B. [LN428, open square; LN428 + necrostatin-1, filled square; LN428/MPG, 
open circle; LN428/MPG + necrostatin-1, filled circle]
Figure S6.
Absence of mitochondria to nucleus translocation of AIF due to BER failure as determined by subcellular 
fractionation and immunoblot analysis. Cells were treated with 1.5 mM TMZ for times indicated in the 
figure and subjected to subcellular fractionation and immunoblot analysis. COX IV and PCNA were used 
as controls to show no cross contamination between mitochondrial and nuclear fractions. COX IV and 
PCNA were also used as loading controls to show that equal amount of mitochondrial or nuclear 
samples were loaded.
Figure S7.
Inhibition of Ca2+ influx by BAPTA.AM does not protect cells from TMZ-induced cytotoxicity. Cells were 
pre-treated with BAPTA.AM or vehicle control (DMSO) for 30 minutes and were then exposed to TMZ in 
the presence or absence of BAPTA.AM (5 mM) for 48 hours. Viable cells were determined as in Figure 
1B. Results were reported as the mean of three independent experiments ± S.E.M. [LN428, open 
square; LN428 + BAPTA.AM, filled square; LN428/MPG, open circle; LN428/MPG + BAPTA.AM, filled 
circle]
7Figure S8.
FK-866 prevents BER failure induced PAR synthesis. Cells were pretreated with FK-866 (10nM) or 
DMSO control for 24 hours prior to exposure to MMS (1.5mM). PAR synthesis at multiple time points 
post exposure was measured via immunoblot. PARP1 immunoblot is provided as loading control. 
8Table S1: Cell lines developed and used in this study
Cell Line Name Clone # Cell line Description Growth Media
LN428 - Human glioma cell line
Alpha EMEM, heat-
inactivated fetal bovine 
serum (10%), 
glutamine (2 mM), 
antibotic d antimycotic, 
gentamicin (50 µg/ml).
LN428/Pol ß KD -
LN428 cells expressing Pol ß shRNA and 
cop-GFP
LN428 cell growth 
media
LN428//MPG 7
LN428 cells modified for over-expression 
of human MPG
LN428 cell growth 
media + 600 µg/ml 
neomycin
LN428//MPG/ Pol ß KD -
LN428/MPG cells expressing Pol ß 
shRNA and cop-GFP
LN428 cell growth 
media + 600 µg/ml 
neomycin
LN428/MPG/GFP - LN428/MPG cells expressing cop-GFP
LN428 cell growth 
media + 600 µg/ml 
neomycin
LN428/VC* 1
LN428 cells transfected with vector 
control plasmid pIRES-neo
LN428 cell growth 
media + 600 µg/ml 
neomycin
LN428/MPG/VC* 2
LN428/MPG cells transfected with vector 
control plasmid pIRES-puro
LN428 cell growth 
media + 600 µg/ml 
neomycin + 0.5 µg/ml 
puromycin
LN428/MPG/Pol ß KD/VC* 3
LN428/MPG/Pol ß KD cells transfected 
with vector control plasmid pIRES-puro
LN428 cell growth 
media + 600 µg/ml 
neomycin + 0.5 µg/ml 
puromycin
LN428/MPG-N169D 11
LN428 cells modified to express 
glycosylase dead mutant (N169D) MPG 
LN428 cell growth 
media + 600 µg/ml 
neomycin
1LN428/MPG/Flag-Pol ß-
WT*
6
LN428/MPG cells expressing Flag tagged 
WT Pol ß
LN428 cell growth 
media + 600 µg/ml 
neomycin + 0.5 µg/ml 
puromycin
5LN428/MPG/Flag-Pol ß-
K72A
16
LN428/MPG cells expressing Flag tagged 
5'dRP lyase activity dead mutant (K72A) 
Pol ß
LN428 cell growth 
media + 600 µg/ml 
neomycin + 0.5 µg/ml 
puromycin
2
LN428/MPG/Pol ß KD/Flag-
Pol ß-WT*
6
LN428/MPG/Pol ß KD cells expressing 
Flag tagged WT Pol ß
LN428 cell growth 
media + 600 µg/ml 
neomycin + 0.5 µg/ml 
puromycin
LN428/PARG KD -
LN428 cells expressing PARG shRNA 
and cop-GFP
LN428 cell growth 
media + 0.5 µg/ml 
puromycin
LN428/MPG/PARG KD -
LN428/MPG cells expressing PARG 
shRNA and cop-GFP
LN428 cell growth 
media + 600 µg/ml 
neomycin + 0.5 µg/ml 
puromycin
*VC: vector control.
*WT: wild type.
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